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my p a r e n t s
"We shall not cease from exploration 
And the end of all our exploring 
Will be to arrive where we started 
And to know the place for the first time”
T S Eliot (1888-1965)
Abstract
The decision to treat cancer patients with Iressa (Gefitinib, tyrosine kinase 
inhibitor of EGFR) and Herceptin (Trastuzumab, monoclonal antibody for 
HER2) is frequently based on EGFR or HER2 receptor over-expression. 
However, even in these selective groups of patients, the response rate is poor 
and unpredictable. The underlying mechanisms contributing to drug resistance, 
as well as predicting the success of these drugs in cancer patients are still 
poorly understood. One of the reasons for poor response rates based on HER 
(ErbB) levels is that over-expression 'per se' fails to consider receptor 
activation for example through autocrine expression of one of its several 
ligands. Over-expression as a criterion for treatment fails to account for 
patients having receptor activation without up-regulation. It was hypothesized 
that using Forster Resonance Energy Transfer (FRET) to measure the 
functional status of EGFR in tumour arrays should provide more quantitative 
prognostic information than using immunohistochemistry alone. After 
validating a high throughput fluorescence lifetime microscopy (FLIM) system 
in a series of cell lines, it was shown that EGFR phosphorylation, reflected in 
high FRET efficiency, is correlated with worsening Disease Free Survival 
(DFS) in a set of head and neck tumour arrays.
The FRET methodology was applied further to assess the phosphorylation of 
HER2 and other HER family receptors in various breast cancer cell lines in 
relation to Iressa and Herceptin treatments. Monotherapy with Iressa while 
targeting EGFR and decreasing phosphorylation of HER3, induced proteolytic 
cleavage of HER4 and dimerisation between HER2 and HER4, leading to 
HER2 phosphorylation, as a result of ligand release. Therefore the activation 
of alternative pathways like HER2 and HER4 may mediate resistance to Iressa. 
It was also demonstrated that Herceptin while targeting HER2, paradoxically 
induced the phosphorylation of all HER receptors due to antagonist-induced 
ligand secretion. Therefore, it has been shown that Iressa and Herceptin 
treatment in breast cancer cells induces activation of alternative HER 
pathways, thus providing an insight into possible mechanisms of resistance for 
targeted therapies in breast cancer. The results suggest alternative treatments to
overcome resistance to these targeted therapies in patients.
FRET was also applied to assess HER2 phosphorylation in a set of HER2 
positive breast tumour arrays using automated FLIM. It was shown that FRET 
maybe used to stratify HER2 positive breast cancer patients into different 
prognostic groups. It is proposed to utilise this assay for prospective 
stratification of patients in randomised trials of EGFR and HER2 inhibition. 
The methodology shows great promise and can also be applied to assess the 
activation of other signalling pathways (e.g. PKB and MAPK) in relation to 
various cancer treatments.
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1 Introduction
1.1 Background
Cancer treatments are becoming increasingly complicated as basic science 
research has led to the introduction of new biological agents or targeted 
therapies for clinical use. These agents bring great promise to cancer patients 
since they were developed to target specific abnormal signalling pathways in 
cancers, in contrast to the conventional radiotherapy and chemotherapy which 
are non-specific and affect both cancer and normal cells. However, the 
challenge remains of how to identify appropriate patients who will benefit 
from such agents. Moreover, many questions remain unanswered, including 
the best method of using these drugs in combination with radiotherapy, 
chemotherapy and endocrine therapy; what kinds of patients should receive 
these drugs; which are the appropriate biomarkers to predict response; the 
mechanisms of primary and secondary resistance to these drugs and how to 
prevent the onset of resistance in responders.
Dysregulation of epidermal growth factor receptors (HER or ErbB) receptors 
has been implicated in various epithelial cancers (Yarden and Sliwkowski, 
2001). Drugs that target epidermal growth factor receptor family (ErbB or 
HER receptors' family) including EGFR (ErbB-1 or HER1) inhibitors and 
HER2 (ErbB2) monoclonal antibodies are among the very first generation of 
targeted therapies that were translated from basic science research into clinical 
use (Herbst, 2004). These drugs are gaining an increasingly important role in 
the treatment of various cancers, particularly the HER2 monoclonal antibody 
Herceptin (Trastuzumab) in breast cancer (Piccart-Gebhart et al., 2005; 
Romond et al., 2005)
The decision to treat cancer patients with EGFR inhibitor and HER2 
monoclonal antibody have been based on EGFR and HER2 receptor over­
expression (or gene amplification) respectively (Arteaga, 2002; Yaziji et al.,
2004). More recently, EGFR inhibitors have been given to patients without
measuring EGFR concentration since the response of EGFR inhibitors do not 
necessarily correlate with the response to the drugs (Chung et al., 2005). The 
criteria of Herceptin treatment is still currently based on HER2 over­
expression shown by immunohistochemistry (IHC) or HER2 gene 
amplification determined by fluorescence in situ hybridization (FISH) (Yaziji 
et al., 2004). However, despite the selection of these patients based on IHC and 
FISH, only about one third of these patients respond to Herceptin monotherapy 
(Vogel et al., 2002). Aside from the costs of the drugs and unpredictable 
response, up to 5-10% patients may have worsening cardiac function if given 
this drug with chemotherapy (Piccart-Gebhart et al., 2005). Therefore, to select 
the “right” patients who will benefit from this drug while sparing the “non­
responders” from potential drug-induced cardiac problems is of utmost 
importance.
The present methods to select patients for HER receptor inhibitors based on 
immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) 
measure only receptor concentration without measuring the functional status of 
the receptors. Moreover, these methods are poor predictors for response to 
targeted therapies. There is a need for a better biomarker to predict response 
than the present methods. One specific approach is to measure the 
phosphorylation status of HER receptors since a number of mechanisms other 
than over-expression of HER receptors may cause increased activation and 
phosphorylation of HER receptors, including over-expression of ligands, 
dimerisation with other HER receptors to induce potent signalling as well as 
constitutively activated mutant HER receptors (Arteaga, 2002; Dei Tos AP, 
2005). This may explain why the response to these drugs as monotherapy 
based on receptor concentration alone has been disappointing and the response 
rate rarely sustains long periods of time among the responders.
This thesis is based on a translational project that was performed using an 
interdisciplinary approach, integrating clinical oncology with cell biology, 
biophysics, chemistry as well as engineering and software interface for high 
throughput processing of the tumour samples. The project employed Forster 
Resonance Energy Transfer (FRET) (Lakowicz, 1999; Valeur, 2002) 
monitored by high throughput Fluorescence Lifetime Microscopy (FLIM) 
(Larijani, 2006) to answer some of the clinical questions regarding HER
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receptors and the targeted therapies created by the introduction of these drugs 
from basic science research into clinical use. FRET has been shown to have 
many applications including the studies of protein-protein interaction, 
activities of protein kinases as well as study of protein conformation changes 
(Calleja et al., 2007). It was postulated that FRET could be exploited to assess 
the phosphorylation status of HER receptors in tumour arrays in comparison 
with the current IHC method. Although IHC staining for phosphorylated HER 
receptors is possible, being a single antibody method the results may be 
affected by various factors including non-specific staining and its specificity 
may be affected by the usage of high antibody concentration (Dei Tos AP, 
2005). The FRET assay developed in this study uses a two-site assay 
overcomes the non-specificity problems encountered in the one-site assay used 
in immunohistochemistry.
In this thesis, FRET in combination with classical biochemistry were 
performed to assess the phosphorylation status of HER receptors in relation to 
targeted therapies in cell lines. The responses of HER receptors and 
mechanisms of resistance to EGFR and HER2 inhibitors were investigated in 
breast cell lines. In addition, a high throughput method was established in 
tumour arrays to assess phosphorylation status of EGFR and HER2 in relation 
to the prognosis of cancer patients.
In this chapter, the general aspect of tumour carcinogenesis and cellular 
signalling related to HER receptors will be discussed before an in-depth 
discussion of HER receptors and their inhibitors. The chapter will proceed to 
discuss the present methods of selection criteria for targeted therapies using 
IHC and FISH together with the principle of FRET monitored by FLIM before 
concluding with the aims and objectives of this thesis.
1.2 Carcinogenesis and cellular 
signalling
The continuous improvement in cancer treatment and the arrival of targeted 
therapies against HER receptors result from basic understanding of the cellular
20
carcinogenesis processes. To understand the importance of HER receptors and 
the targeted therapies against these receptors, one needs to put in context HER 
receptors in the overall carcinogenesis processes and cellular signalling. 
Carcinogenesis results from successive mutations in specific cellular genes, 
leading to the activation of oncogenes and inactivation of tumor suppressor 
genes. (Bertram, 2000). The mutations at the gene level may result in the over­
expression of certain proteins or reduction of inhibitory proteins and may lead 
to dysregulation in the normal cellular signalling process as well as abnormal 
proliferation of the cells (Vogt, 1993).
1.2.1 Oncogenes and tumour suppressor 
genes
Normal cells are tightly regulated for their signalling and proliferation. The 
main difference of a normal cell and a tumour cell is that the latter may 
proliferate in an uncontrolled manner, due to either mutations in and/or 
dysregulation of multiple genes (Grander, 1998) However, not all mutations 
contribute to carcinogenesis since most cells that harbour such genes are 
destined for repair or elimination (e.g. through apoptosis) (Polverini and Nor,
1999). The genes that contribute to tumourigenesis can be divided into two 
categories: oncogenes and tumour suppressor genes (King, 2000). Each gene 
in a cell contains two alleles and mutation of one of these may transform the 
normal “proto-oncogene” to an activated, transforming, dominant oncogene. 
An oncogene represents a gain-of-function mutation that may results in the 
production of a protein product that is constitutively active and not regulated in 
the normal way, resulting in tumourigenesis (King, 2000; Tannock et al.,
2005). By contrast, tumour suppressor genes are recessive and require the loss 
or the inactivation of both alleles before malignant transformation (King, 2000; 
Tannock et al., 2005). Hence a tumour suppressor gene represents a loss-of- 
function mutation. Carcinogenesis may result from either the activation of 
oncogene (s) or the inactivation of tumour suppressor gene (s) or both 
(Han ah an D, 2000).
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An oncogene activation resulting from the mutation or deregulation of a 
proto-oncogene, produces protein products leading to tumourogenesis (Vogt, 
1993). There are many ways that these oncogenes may be activated. For 
example, some retroviruses may incorporate their viral form of the oncogenes 
into the host DNA, in which regulatory viral sequences alter host gene activity 
resulting in the deregulated activity of the protein product (King, 2000). 
Chromosomal translocation may also lead to constitutive expression and 
activation of oncogenes, e.g. in Burkin’s lymphoma, the reciprocal 
translocation of chromosome 8 with chromosome 14 resulting in the myc gene 
being transcribed by the active immunoglobulin regulatory region (Taub et al., 
1982). Lastly the amplification of the genomic locus containing a proto­
oncogene can also lead to oncogene activation since multiple copies of the 
gene are produced and the encoded protein is highly expressed disrupting a 
particular regulatory balance (Tannock et al., 2005). For example HER2 gene 
amplification has been shown in human breast cancer and correlates with the 
poor prognosis in breast cancer patients (Slamon et al., 1987).
The mutations and deregulation of oncogenes act in a dominant manner and 
are associated with sporadic tumours. By contrast most inherited cancers are a 
consequence of the mutations or inactivation of tumour suppressor genes 
(King, 2000). Tumour suppressor genes are recessive at the somatic level and 
require the loss or the inactivation of both alleles before malignant 
transformation. In 1971, Knudson investigated the epidemiology of familial 
retinoblastoma (a hereditary form of retinal cancer) and found that patients 
with familial disease were more likely to develop a more severe, bilateral or 
multifocal disease at an earlier age of onset compared to sporadic cases of 
retinoblastoma (Knudson, 1971). He proposed that two mutations or two hits 
were required for retinoblastoma (Knudson’s two hit hypothesis). In familial 
cases, the first mutation is transmitted through the germline and is present in 
all cells but the tumour develops when the second mutation occurs somatically 
(Knudson, 1971; Tannock et al., 2005). In sporadic cases both mutations have 
to occur within the same somatic cell, this being more probable event may 
explain the late onset of the disease (Knudson, 1971; Tannock et al., 2005). 
His hypothesis highlights the cooperation between inherited and somatic 
mutations and deregulation in human cancers. The retinoblastoma gene Rb is
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the tumour suppressor gene implicated in retinoblastoma and loss of 
retinoblastoma gene Rb is a frequent event in human cancers, including breast 
cancers (Lee et al., 1988). Other tumour suppressor genes that are involved in 
human carcinogenesis include p53 gene (Vousden and Prives, 2005), PTEN 
(Depowski et al., 2001; McMenamin et al., 1999) and BRCA1 and BRCA2 
genes (Suthers, 2007). The p53 gene is the gene most frequently altered in 
human cancers and loss of p53 activity appears to be important for malignant 
progression (Vousden and Prives, 2005). Loss of pTEN is associated with poor 
prognosis and outcomes for several cancers including breast cancer and 
prostate cancers (Depowski et al., 2001; McMenamin et al., 1999). Mutations 
of BRCA1 and BRCA2 are associated with increased risk of cancers (Chen 
and Parmigiani, 2007), with the cumulative lifetime risk in developing breast 
cancer being 50-60% and the equivalent risk of ovarian cancer is 20-40% 
(Suthers, 2007).
The oncogenes and tumour suppressor genes can generate carcinogenesis on 
their owns. However, more commonly synergism occurs between cooperating 
oncogenes and tumour suppressor genes, e.g. APC, K-ras and p53 mutations in 
colon carcinogenesis (King, 2000). Therefore, oncogenes and tumour 
suppressor genes cooperate in carcinogenesis (Grander, 1998).
1.2.2 Cellular signalling
Tumour oncogenes and tumour suppressor genes may result in the over­
expression of certain proteins or reduction in the expression of others and thus 
may lead to dysregulation of the normal cellular signalling process with 
consequent abnormal cellular proliferation (Grander, 1998). For example, 
EGFR gene amplification may lead to over-expression of EGFR and ligand- 
independent cellular dysregulation and proliferation (Chung et al., 2006; 
Nicholson et al., 2001). Cellular signalling is normally a well-regulated 
process through an elaborate network of intracellular signals transmitted by 
changes in the protein phosphorylation of the receptors (King, 2000). The 
regulation is typically controlled by growth factors which are secreted
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polypeptides that trigger cascades of signalling processes within cells via their 
interaction with specific transmembrane receptor tyrosine kinases (RTKs) 
(Blume-Jensen and Hunter, 2001). There have been a large number of growth 
factors or ligands identified with diverse functions including cell growth, 
proliferation, differentiation, survival and metabolism although only a few has 
been associated with carcinogenesis (Tannock et al., 2005). These growth 
factors have variable specificities for these RTKs receptors in different cells 
and thus create diverse signalling processes between them (Robinson et al.,
2000). They are usually small monomeric (single chain) polypeptides (e.g. 
EGF) although they can exist as dimeric polypeptides (e.g. PDGF) (Tannock et 
al., 2005). They interact with specific domains of the RTKs in the extracellular 
domain to cause intracellular signalling (Cho et al., 2003; Franklin et al., 
2004).
Receptor protein tyrosine kinases (RTKs)
HER receptors belong to the receptor protein tyrosine kinases (RTKs) which 
represent a large family of molecules (Yarden and Sliwkowski, 2001). More 
than 60 of them have been identified and they are also subdivided into 
different families according to the their distinct structural components (van der 
Geer et al., 1994). Most of the RTKs consist of extracellular domains which 
are connected to the intracellular (cytoplasmic) domains by single short 
hydrophobic helix transmembrane components (Robinson et al., 2000). The 
cytoplasmic domain is comprised of regulatory sequences and a conserved 
kinase domain. The kinase domain is capable of phosphorylating tyrosine 
residues of a protein by catalysing the transfer of a phosphate group from 
adenosine trisphosphate (ATP) onto the protein substrate. The regulatory 
sequences contain sites of tyrosine phosphorylation and usually regulate 
catalytic activities as well as signal transmission (Robinson et al., 2000). 
Without the growth factor, the intracellular kinase domain is usually inactive 
and is held in a repressed conformation by intramolecular interactions. Upon 
the binding of growth factor or ligand, the extracellular domain undergoes 
conformational changes that facilitate dimerisation between the receptors (Cho 
et al., 2003). The dimerisation of two receptors bring their catalytic domains
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together, resulting in intermolecular transphosphorylation of tyrosine residues 
within the catalytic domain and in the noncatalytic regulatory sequences of the 
cytoplasmic domain (Schlessinger, 2002). The phosphorylation of key residues 
within the kinase activation loop induces the alignment of the catalytic site and 
allows access to ATP and protein substrates (Robinson et al., 2000). The 
phosphorylation of tyrosine residues in non-catalytic regions creates docking 
sites for downstream signalling molecules that are essential for signal 
transduction.
Carcinogenesis may result from abnormal RTKs which are ligand 
independent and deregulated with increased catalytic activity. For example, the 
amplification of HER2 oncogene results in the over-expression of HER2 RTKs 
(Slamon et al., 1987) that increase the concentration of active dimers in 
generating continuous and uncontrolled cellular signalling.
Formation of protein complexes and activation of downstream pathways
Upon ligand binding, a network of downstream signalling pathways of RTKs 
is created through interaction of specific proteins (Tannock et al., 2005) 
(Figure 1.1). The activation of RTKs creates a number of docking sites for 
cytoplasmic proteins including those that contain SH2 (Src homology 2), PTB 
(phosphotyrosine binding domain), SH3 (Src homology 3) and PH (Pleckstrin 
homology) domain (Figure 1.1) (Tannock et al., 2005). These proteins mediate 
the formation of signalling complexes following the activation of receptor 
tyrosine kinases. Different SH2 domains recognise specific tyrosine 
phosphorylated motifs in the non-catalytic regions (Songyang et al., 1993). 
The PTB domains recognise phosphotyrosine in a specific sequence motif 
where amino acids on the amino terminal side of the tyrosine are critical for 
binding specificity (van der Geer and Pawson, 1995). SH3 can bind to proline 
rich motifs in target proteins and the interaction is not dependent on changes 
induced by phosphorylation. They function in the assembly of multiprotein 
complexes, and as regulatory domains in intramolecular interaction. A number 
of PH domains interact specifically with membrane phosphoinositides and 
recognise specific phosphoinositides such as PtdIns(3,4,5)P3 that are 
transiently produced following growth factor receptor activation (Bazley and 
Gullick, 2005).
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The activated RTKs may associate with phospholipase C (PLCy) via the SH2 
domain, hydrolysing phosphatidyl inositol (PIP2) into inositol triphosphate 
(IP3) and diacylglycerol (DAG) (Figure 1.1) (Tannock et al., 2005). Many 
activated growth factor receptors also result in the activation of PI-3 kinases, 
comprises a catalytic subunit pi 10 and a regulatory subunit p85, leading to the 
activation of PKB and PDK1 via PH domain, the refined mechanisms of which 
have recently been proposed by Calleja et al (2007) (Calleja et al., 2007).
The binding of growth factors to RTKs results in the phosphorylation of the 
intracellular domain on tyrosine residues, which are targets of the adaptor 
proteins (Figure 1.1) (Tannock et al., 2005). The adaptor proteins (e.g. growth 
factor receptor bound-2, grb2) are composed entirely of SH2 and SH3 domains 
without catalytic activity (Bazley and Gullick, 2005). They however interact 
with signalling enzymes which do not contain SH2 domains, thereby coupling 
them to tyrosine kinase signalling complex (Pawson and Scott, 1997). Each of 
these adaptor molecules has a different capacity to form protein complexes due 
to binding specificities of its SH2 and SH3 domains, resulting in an organised 
network of protein-protein interactions within the extensive intracellular 
signalling network (Tannock et al., 2005). The adaptor protein grb2 plays an 
important role in the activation of the small GTPase protein, Ras. The Ras 
protein is a central transducer of growth factor receptor signals and it is a 
membrane-associated molecule that is activated when bound to the guanine 
nucleotide GTP (Downward, 2006). The SH2 domain of grb2 associates with 
the some of the receptors when activated while the SH3 domains are bound to 
SOS (Son-of-Sevenless), which is a guanine nucleotide exchange protein that 
activates Ras (Figure 1.1) (Bazley and Gullick, 2005). The small GTPase Ras 
cycles between the inactive GDP bound state and the active GTP bound state 
and Ras is activated when SOS promotes the exchange of GDP for GTP 
(Downward, 2006). The activation of Ras leads to the downstream signalling 
including activation of the extracellular signal regulated kinase 1 and 2 
(ERK1/2) (mitogen activated protein kinase MAPK signalling pathways) 
(Figure 1.1).
The formation of protein complexes and activation of downstream pathways 
described above is common to a large family of RTKs and its dysregulation 
may lead to carcinogenesis processes. HER receptors are among the most
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important RTKS implicated for human carcinogenesis (Nicholson et al., 2001) 
and the specific details of HER receptors will be described in the next section.
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Figure 1.1: Receptor protein tyrosine kinases and recruitment of cytoplasmic 
signalling molecules. See list of abbreviations. Figure taken from Tannock et al 2005.
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1.3 HER (ErbB) family
The epidermal growth factor (HER or ErbB) family comprises four receptors: 
EGFR (also known as HER1 or ErbBl), HER2 (ErbB2), HER3 (ErbB3) and 
HER4 (ErbB4) (Bazley and Gullick, 2005). ErbB receptors were originally 
named because of their close homology to the erythroblastoma viral oncogene 
protein sequences, v-erbB (Downward et al., 1984). These receptors belong to 
subclass I of the superfamily of RTKs which are transmembrane receptors with 
an intrinsic ability to phosphorylate their tyrosine residues in the cytoplasmic 
domains to transduce signals (Citri and Yarden, 2006). However, HER2 and 
HER3 are not autonomous since HER2 has no known ligand and the kinase 
activity of HER3 is defective (Yarden and Sliwkowski, 2001). These two 
receptors can form heterodimeric complexes with each other as well as other 
HER receptors to generate potent signals (Olayioye et al., 2000).
A number of ligands can activate HER receptors (see table below). These 
ligands include epidermal growth factor (EGF), amphiregulin (AR), 
transforming growth factor-a (TGFa) for EGFR; betacellulin (BTC), heparin- 
binding EGF (HB-EGF) and epiregulin (EPR) for EGFR and HER4; 
neuregulin (NRG) 1-4 (also called heregulin or neu differentiation factor) for 
HER3 and HER4 (NRG-1 and NRG-2 bind to HER3 and HER4 but NRG-3 
and NRG-4 bind to HER4 only) (Olayioye et al., 2000) (Figure 1.2A). 
However, no direct ligand for HER2 has been identified.
HER receptors Ligands
EGFR - EGF, AR, TGFa
- BTC, HB-EGF and EPR (co-ligands with HER4)
HER2 - No direct ligand
HER3 - NRG (heregulin) 1-2 (co-ligands with HER4)
HER4 - NRG (heregulin) 1-4 (co-ligands with HER3);
- BTC, HB-EGF and EPR (co-ligands with EGFR)
The ligands determine which receptor dimers are formed and thus influence 
the activation of various signalling pathways (Beerli and Hynes, 1996). The 
HER receptors are able to dimerise (homodimerisation) or interact with 
different receptors (heterodimerisation) upon ligand binding (Bennasroune et 
al., 2004). The homo- or hetero-dimerisation of the receptors results in the 
activation of the intrinsic tyrosine kinase domain and autophosphorylation of 
specific tyrosine residues in the C-terminus. Depending on the pattern of 
phosphorylated tyrosine residues in the C-terminus, different subsets of SH2- 
and PTB-binding signalling molecules are recruited to the activated receptors 
(Figure 1.2B). The specific characteristics of each HER receptor will be 
discussed below.
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Figure 1.2: A, HER (ErbB) receptors and their ligands. B, Specific phosphoty­
rosine residues and binding sites of signalling molecules to the cytoplasmic 
domains of HER receptors. For E rbB l, the sites for the Src kinase are in black, 
including Y845 in the kinase domain (indicated by asterick) (Figures taken 
from Olayioye et al 2000)
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EGFR
EGFR was the first receptor discovered and was originally known as the 
Epidermal Growth Factor Receptor (Downward et al., 1984). It is now also 
known as HER1 or ErbBl. Upon ligand binding it can form either EGFR 
homodimers or can dimerise with other HER receptors. Compared to other 
HER receptors it has the most signalling molecules recruited to the 
phosphorylated receptor upon activation (Olayioye et al., 2000) (Figure 1.2B). 
It also has the highest percentage of tyrosine residues with more than one 
binding partner (Schulze et al., 2005). The binding of Grb2 and She to EGFR 
(Figure 1.2B) is responsible for the recruitment of Ras and activation of the 
MAPK cascade. The recruitment of the ubiquitin ligase Cbl to Tyr 1045 (see 
Figure 1.2B) would commit the receptor to internalisation and recycling and 
therefore negatively regulate EGFR signalling. In fact it is the only HER 
receptor with a binding site for Cbl and this explains why it is the only HER 
receptor with a ligand-dependent down-regulation mechanism whereas other 
HER receptors (HER2-HER4) show impaired ligand-induced rapid 
internalisation, downregulation and degradation (Baulida et al., 1996). No 
direct binding site for PI3K is present on EGFR and therefore it cannot activate 
PI3K-PKB pathway directly but it couples to the Ras-MAPK pathway as well 
as to the Ras-PI3K-PKB pathway (Citri and Yarden, 2006).
HER2
Ligand induced HER receptor dimerisation follows a strict hierarchy and 
HER2 has been shown to be the preferred dimerisation partner (Graus-Porta et 
al., 1997). Using intracellular expression of specific antibodies (scFVO to 
down regulate surface EGFR and HER2), Graues-Porta et al 1997 showed that 
HER3 and HER4 preferentially dimerised with HER2 upon heregulin 
stimulation and would only dimerise with EGFR when HER2 was not 
available partner (Graus-Porta et al., 1997). In addition, they showed that EGF 
and betacellulin induced HER3 activation was dramatically impaired in the 
absence of HER2, suggesting that HER2 mediates lateral transmission between 
other HER receptors. They also showed that HER2 enhanced and prolonged 
MAPK signalling in response to various ligands. Over-expression of HER2
may cause ligand independent activation as well as activation of EGFR 
(Worthylake et al., 1999). HER2 containing dimers have defective endocytosis 
and enhanced recycling properties (Lenferink et al., 1998; Sorkin et al., 1993).
HER3
HER3 is kinase defective but it can form functional dimers with other HER 
receptors. Upon dimerisation and tyrosine phosphorylation of its cytoplasmic 
domain, HER3 can recruit PI3K to six distinct sites (Y1035, 1178, 1203/05, 
1241, 1257 and 1270) and She to one site (Figure 1.2B). Together with HER2 
it can generate downstream signalling both through the Ras-Erk pathway for 
proliferation, and through the PI3K-PKB pathway for survival (Citri et al., 
2003). Wallasch et al (1995) showed that the tyrosine phosphorylation of 
HER2 and HER3 receptors upon heregulin stimulation did not occur when the 
kinase-inactive HER2 mutation was co-expressed with HER3 in cells; whereas 
HER2/HER3 transphosphorylation was stimulated by heregulin when HER2 
was coexpressed with the kinase-inactive HER3 receptor mutant (Wallasch et 
al., 1995). Therefore, activation of the signalling potential of the HER2/HER3 
dimer upon heregulin stimulation is due to unidirectional transphosphorylation 
of HER3 by the HER2 kinase.
HER4
HER4 shares recognition and signalling features with EGFR, including 
common ligands (betacellulin, HB-EGF and epiregulin) and an ability to 
recruit GRB2, She and STAT5 (Citri and Yarden, 2006). An isoform of HER4 
(CYT-1) can also activate PI3K (Elenius et al., 1999). Moreover, it has been 
shown that proteolytic cleavage of HER4 occurs in cells at a low basal level 
and can be increased by TPA, heregulin, or other growth factors that bind 
HER4 (Zhou and Carpenter, 2000) (Figure 1.3). The ectodomain cleavage of 
HER4 is mediated by tumour necrosis factor-<*=-converting enzyme (TACE), a 
transmembrane metalloprotease. Proteolysis produces a membrane-anchored 
fragment (80 kD) which consists of the entire cytoplasmic and transmembrane 
domain (Carpenter, 2003; Vecchi and Carpenter, 1997). The m80 HER4 
fragment from ectodomain cleavage was found to associate with full length 
HER2 (Cheng et al., 2003). In addition, the transmembrane m80 was found to
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be cleaved by y-secretase and the soluble fraction (S80) was found to be 
associated with STAT5A as well as translocated to the nucleus to influence 
transcription (Ni et al., 2001; Williams et al., 2004). The growth factor- 
dependent HER4 cleavage seems to involve endocytosis while TPA-dependent 
cleavage does not (Figure 1.3) (Carpenter, 2003).
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Figure 1.3: Proteolytic cleavage pathway for HER4 (ErbB4). The ectodomain cleavage of HER4 can occur upon TPA treatment 
or growth factors that bind to HER4.This process is mediated by TACE, producing a membrane-anchored fragment, m80, consisting of 
entire cytoplasmic and transmembrane domain.The transmembrane m80 was then cleaved again by gamma-secretase (PS-1). Growth 
factor-dependent HER4 cleavage seems to invlove endocytosis, while TPA-dependent HER4 cleavage does not although either route 
produces m80 which is found in the nucleus (Figure taken from Carpenter et al 2003).
1.4 HER receptors and cancers
Dysregulation of HER receptors is implicated in various epithelial cancers, 
the mechanisms of which include over-expression of receptor ligands, receptor 
over-expression (e.g. due to gene amplification) and activating mutations 
(Mendelsohn and Baselga, 2006). These mechanisms are discussed below.
Over-expression of ligands
Over-expression of ligands has been implicated in both the prognosis and 
progression of various cancers. The most important of which is TGF-a which 
has been implicated in prostate, pancreas, lung, ovary, colon cancers (Salomon 
et al., 1995; Scher et al., 1995; Yamanaka et al., 1993). It is also implicated in 
the prognosis of head and neck cancers (HNSCC) (Endo et al., 2000; Rubin 
Grandis et al., 1996; Todd et al., 1989). Using gene expression patterns from 
60 HNSCC samples assayed on cDNA microarrays to allow categorisation of 
HNSCC tumors into different subtypes, Chung et al (1994) showed that the 
worst outcome of all the subtypes was the group that were characterised by the 
high expression of TGFa (Chung et al., 2004), confirming the prognostic role 
of TGF-a in HNSCC.
Over-expression or gene amplification of HER receptors
Over-expression of various HER receptors has been implicated in various 
cancers (Salomon et al., 1995; Yarden and Sliwkowski, 2001). EGFR over­
expression was found to be a strong prognostic indicator for head and neck 
cancer, ovarian, cervical, bladder and oesophageal cancer; a moderate 
prognostic marker for gastric, breast, endometrial and colorectal carcinoma but 
a weak prognostic marker for non-small cell lung carcinoma (Nicholson et al., 
2001). For head and neck cancer, several studies have shown a correlation of 
over-expressed EGFR with overall survival (OS), disease-free survival (DFS), 
increased loco-regional recurrence and decreased sensitivity to radiation 
treatment in these patients (Ang et al., 2002; Dassonville et al., 1993; Gupta et 
al., 2002; Sheridan et al., 1997). Gene amplification of EGFR was also shown
to be associated with prognosis of head and neck cancer (Chung et al., 2006). 
The amplification of HER2 was first shown to be a significant predictor for 
both overall survival and time to relapse in breast cancer patients (Slamon et 
al., 1987). The protein expression of HER2 was also found to correlate with 
the prognosis of breast cancer patients (Hartmann et al., 1994; Marks et al., 
1994; Rosen et al., 1995; Ross and Fletcher, 1999).
Mutation of HER receptors
Several mutations involving HER receptors have been reported. One of the 
commonest mutations in EGFR is the deletion of a section of the extracellular 
domain resulting in a constitutively active receptor, e.g. in glioblastoma 
(Moscatello et al., 1995) although the mutation is rare in breast cancers and 
other cancers (Rae, Scheys et al. 2004). Mutations of EGFR, either small, in­
frame deletions or amino acid substitutions (including L858R) clustered 
around the ATP-binding pocket of the tyrosine kinase domain, have been 
detected in human lung cancer (Lynch et al., 2004). They seem to increase the 
kinase activity and predict a dramatic response to Iressa (Lynch et al., 2004). 
The mutations are associated with bronchioloalveolar pathology that arise in 
non-smoker, and in individuals of East Asian descent (Paez et al., 2004). 
However, EGFR kinase domain mutations rarely present in other types of 
cancers although they have been reported in a few cancer types including small 
cell lung cancer, ovarian, oesophageal and pancreatic carcinoma (Kwak et al., 
2006; Okamoto et al., 2006; Schilder et al., 2005). In head and neck cancer, 
where the majority of patients have over-expression of EGFR most Caucasian 
patients do not have the mutations seen in non-small cell lung cancer, except in 
a small proportion of patients from certain ethnic origins (Loeffler-Ragg et al., 
2006). Furthermore, the activating mutations in EGFR exons are also 
uncommon in sporadic breast cancer (Generali et al., 2007). HER2 mutation 
(including a G776YVMA insertion in exon 20) has also been found in lung 
cancer, resulting in constitutive activation of HER2 and EGFR. The mutations 
rendered the cells resistant to EGFR tyrosine kinase inhibitors but the cells 
remained sensitive to HER2 inhibitors (Wang et al., 2006). However, the 
HER2 kinase domain mutations are only found in a small proportion of
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patients in gastric carcinoma, colorectal and breast cancer (5% or less) (Lee et 
al., 2006).
1.5 HER receptors and targeted 
therapies
Since over-expression of ligands as well as the HER receptors are implicated 
in the carcinogenesis, various targeted therapies against these HER receptors 
are increasingly used in various cancers. These include inhibitors of EGFR and 
HER2 receptors and the mechanisms of these drugs and their clinical use will 
be discussed in this section.
In order to understand how these inhibitors work on EGFR and HER2 
receptors, the crystal structure of HER receptors needs to be discussed. HER 
receptors comprise an extracellular domain, transmembrane region, a small 
intracellular juxtamembrane domain preceding a cytoplasmic protein tyrosine 
kinase domain, and a C-terminal tail, on which the phosphotyrosine-binding 
molecules are recruited (Cho et al., 2003). The extracellular region of about 
630 amino acids, consists of four subdomains: I, II, HI and IV (Cho et al., 
2003) (Figure 1.4a). The subdomains I (LI) and HI (L3) are leucine-rich 
repeats and subdomains II (CR1 or SI) and IV (CR2 or S2) are laminin-like, 
cysteine-rich domains. The crystal structure revealed that ligands bind to 
domain I and HI. Domain H mediates inter-receptor dimerisation via its long- 
finger-like projection although it is in intramolecular contact with domain IV 
when the receptors are not activated. The unliganded receptors exist in an 
autoinhibited (‘closed’) form but become ‘open’ upon ligand stimulation when 
domains I and HI are brought close together, breaking the domain n  and IV 
interaction and allowing domain n  to participate in dimerisation of the 
receptors. The only exception is HER2 receptor since its extracellular domain 
is always in the ‘open’ conformation with the projection of domain II ready for 
dimerisation even when monomeric (Figure 1.4a) (Franklin et al., 2004). This 
fixed ‘open’ conformation of HER2 in the absence of ligand binding 
(mimicking the ligand-bound form in the EGFR structure) may account for
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why it is the preferred dimerisation partner for other HER receptors (Cho et al.,
2003).
EGFR inhibitors
The two principal classes of EGFR inhibitors are monoclonal antibodies that 
bind to the extracellular domain (e.g. Cetuximab) and quinazoline small 
molecular inhibitors of the intracellular kinase domain (e.g. Gefitinib and 
Erlotinib) (Mendelsohn and Baselga, 2003).
Cetuximab is a human-murine monoclonal antibody to EGFR. Cetuximab has 
been most extensively investigated compared to other existing anti-EGFR 
monoclonal antibodies. For EGFR to change its conformation resulting in the 
extension of the dimerisation arm of domain n, ligand must engage sites on 
both domain I and III for high affinity binding (Mendelsohn and Baselga, 
2006). Cetuximab binds to extracellular domain III of EGFR occluding the 
ligand binding on this domain and prevents the receptor from adopting the 
conformation required for dimerisation. Therefore it blocks activation of 
receptor tyrosine kinase by the ligands. Cetuximab has been used in cancers of 
colon and head and neck. It has been shown to have a modest activity in 
chemotherapy refractory colon carcinoma that express EGFR with a partial 
response rate of 9% (Saltz et al., 2004). In a randomised trial, 329 patients 
were assigned to either Cetuximab monotherapy or Cetuximab in combination 
with chemotherapy for treatment of EGFR expressing metastatic colon 
carcinoma that are refractory to standard Irinotecan (topoisomerase-1 inhibitor) 
chemotherapy (Cunningham et al., 2004). The response rate for Cetuximab 
monotherapy was 10% and that of the combination therapy was 23%. In head 
and neck cancer, a phase III trial which randomly assigned 424 head and neck 
cancer patients to receive either radiation therapy alone or radiation with 
concurrent Cetuximab showed that Cetuximab nearly doubled the median 
survival in these patients (Bonner et al., 2006). Cetuximab is now licensed for 
treatment of colon carcinoma and head and neck cancer.
Gefitinib (ZD 1839, Iressa) and Erlotinib (Tarceva) are reversible tyrosine 
kinase inhibitors of EGFR. These low molecular weight inhibitors act 
intracellularly by competing with ATP for binding to the tyrosine kinase 
domain of EGFR and thus inhibiting the enzymatic activity (Mendelsohn and
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Baselga, 2006). It has been shown that these inhibitors may induce inactive 
EGFR homodimers and EGFR/HER2 dimers and thus prevent EGFR mediated 
transactivation of EGFR and HER2 activities (Arteaga et al., 1997; Geyer, 
2006; Lichtner et al., 2001). It has also been shown that they inhibit PI3K and 
PKB pathways via inhibition of EGFR/HER3 (Engelman et al., 2005). 
Moreover, they are also effective in HER2 over-expressing breast cancer cells 
through the inhibition of EGFR mediated lateral heterodimerisation (Anderson 
et al., 2001; Anido et al., 2003; Moulder et al., 2001). Both Iressa and Tarceva 
have been used in non-small cell lung carcinoma (NSCLC) with some modest 
response. Patients with advanced stage NSCLC, who had progressed on first- 
line or second chemotherapy were randomised to either Tarceva or placebo 
(Shepherd et al., 2005). NSCLC patients who received Tarceva had a 
statistically significant increase in overall survival by 2 months compared to 
those who received placebo alone although the response rate was only 8.9%. 
Iressa has also been used in NSCLC patients with a similar response rate to 
Tarceva but the difference in overall survival compared to placebo was not 
statistically significant (Fukuoka et al., 2003; Kris et al., 2003). Some of these 
patients have mutations around the ATP-binding pocket of tyrosine kinase 
domain which render these patients highly sensitive to Iressa (Lynch et al.,
2004). Iressa has been tested in a phase II trial in head and neck cancer 
(HNSCC) and the response rate was about 10% (Cohen et al., 2003).
HER2 inhibitors
The drugs that target HER2 are a monoclonal antibody that binds to HER2 in 
the extracellular domain, Trastuzumab (Herceptin); inhibitor of HER2 
dimerisation that also acts extracellularly, Pertuzumab; and the small 
molecular inhibitor targeting the tyrosine kinase activities of EGFR and HER2, 
Lapatinib.
Herceptin binds to the juxtamembrane region of HER2 of domain IV (Cho et 
al., 2003) (Figure 1.4b). There have been several proposals of mechanisms of 
Herceptin to explain its clinical benefits but the precise mechanisms of action 
are still not known. The current proposed primary mechanisms of action for 
HER2 include HER2 receptor downregulation and inhibition of aberrant 
receptor tyrosine kinase activity (Cuello et al., 2001; Sliwkowski et al., 1999).
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There was also suggestion of immune mediated mechanisms from the 
interaction of Herceptin’s human Fc region with immune effector cells, 
resulting in the stimulation of natural killer cells and activation of antibody- 
dependent cellular cytotoxicity (Clynes et al., 2000; Cooley et al., 1999). More 
recently it was shown that Herceptin increased PTEN membrane localization 
and phosphatase activity by reducing PTEN tyrosine phosphorylation via Src 
inhibition (Nagata et al., 2004). Moreover, PTEN deficiency is predictive for 
Herceptin resistance (Nagata et al., 2004). Other proposed mechanisms include 
inhibition of basal and activated HER2 ectodomain cleavage in breast cancer 
cells (Molina et al., 2001), and increased p27Kipl levels and interaction with 
CDK2, resulting in decreased CDK2 activity (Lane et al., 2001). Unlike 
Pertuzumab, Herceptin does not prevent dimerisation of other receptors with 
HER2 (Agus et al., 2002). Herceptin was first shown to increase an objective 
response, longer time to disease-free progression and longer survival for 
metastatic breast cancer patients where tumours over-express HER2 receptors 
(Slamon et al., 2001). More recently however, Herceptin has been given as an 
adjuvant treatment in non-metastatic HER2 positive breast cancer patients 
since several trials have shown an improvement of disease-free survival and 
overall survival for Herceptin given to this group of patients in the early course 
of the disease before any sign of recurrence (Piccart-Gebhart et al., 2005; 
Romond et al., 2005; Smith et al., 2007).
Pertuzumab binds to different epitopes in the extracellular domain of HER2 
from Herceptin. It binds near the centre of domain II, preventing HER2 
receptor dimerisation with other HER receptors and thus blocking the 
signalling from dimerisation (Franklin et al., 2004). It has been shown to 
prevent dimerisation of HER2/HER3, which was not the case in Herceptin 
(Agus et al., 2002). This may explain why it may be effective against cancers 
that may not over-express HER2 (Agus et al., 2002). HER2 undergoes 
proteolytic cleavage upon activation by 4-aminophenylmercuric acetate 
(APMA), a well-known matrix metalloprotease activator, resulting in the 
release of the extracellular domain and the production of a truncated 
membrane-bound fragment, p95 (Molina et al., 2001). Herceptin inhibits basal 
and induced HER2 cleavage and prevention of the production of an active 
truncated HER2 fragment (Molina et al., 2001). Pertuzumab however does not
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inhibit this proteolytic cleavage of HER2. Pertuzumab had been used in 
ovarian carcinoma and prostate carcinoma, with no clinical significant activity 
as a single agent in hormone-resistant prostate cancer (Agus et al., 2007; de 
Bono et al., 2007) and a response rate of 4.3% in heavily treated advanced 
ovarian carcinoma patients (Gordon et al., 2006).
Lapatinib is a potent dual tyrosine kinase inhibitor of EGFR and HER2. 
Unlike other reversible 4-anilinoquinazoline inhibitors of EGFR like Iressa and 
Erlotinib (Tarceva), Lapatinib is bound to an inactive-like conformation of 
EGFR and HER2, reducing the rate of inhibitor dissociation from the 
intracellular domains of these receptors, so that the autophosphorylation of 
these receptors recovers very slowly in tumour cells after treatment (Wood et 
al., 2004). Lapatinib was found to reduce growth of human breast cancer 
xenografts in athymic mice and the combination of Lapatinib and Herceptin 
was synergistic in exerting anti-proliferative effects in HER2-over-expressing 
cell lines (Konecny et al., 2006). Moreover, it retained significant in vitro 
activity against breast cell lines treated in long-term Herceptin-containing 
culture medium, providing a rationale of its use in patients who are clinically 
resistant to Herceptin. In a randomised trial, women with advanced HER2- 
positive breast cancer women who had progressed on chemotherapy and 
Herceptin, were randomly assigned to either Capecitabine (oral 5-FU 
chemotherapy) alone or Capecitabine with Lapatinib and the results showed 
that combination of Lapatinib and Capecitabin increased median time to 
progression in these patients (Geyer et al., 2006).
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Herceptin Fab
Figure 1.4: Crystal structure of HER2 receptor. A, Four domains of HER 2 receptors. B, Herceptin’s binding 
site on HER2 receptor (Figures taken from Cho et al 2003).
1.6 Current methods of assessing  
HER receptors: IHC and FISH
In the previous section, the mechanisms of action and clinical use of various 
EGFR and HER2 inhibitors were discussed. These drugs have been used with 
increased frequencies in cancer patients over the past decade. As discussed 
previously, the decision to treat cancer patients with these targeted therapies, 
e.g. Iressa (Gefitinib) and Herceptin (Trastuzumab) have been based on EGFR 
(HER1) and HER2 receptor over-expression (or gene amplification) 
respectively. More recently, EGFR inhibitors have been given to patients 
without measuring EGFR concentration since the response of EGFR inhibitors 
does not necessarily correlate with the response to the drugs or survival 
(Chung et al., 2005; Perez-Soler et al., 2004). The criteria of Herceptin 
treatment is still currently based on HER2 over-expression shown by 
immunohistochemistry (IHC) or HER2 gene amplification determined by 
fluorescence in situ hybridization (FISH). In this section, the discussion will be 
based on these two present methods in terms of their scoring systems and their 
cut-off points.
1.6.1 Immunohistochemistry (IHC)
Immunohistochemistry is a relatively quick and simple technique to localize 
proteins in cells of a tissue section by exploiting the principle of antibodies 
binding specifically to antigens. It is used widely in histopathology 
departments for the diagnosis and treatment decisions in cancer. It has the 
benefit of preserving the cellular morphology and tissue integrity of the 
tumours (Dei Tos AP, 2005). It usually involves the staining of the tissue 
samples with appropriate antibodies to detect specific antigens and the 
antibody-antigen interaction can then be visualised by a variety of methods. 
For example, an antibody may be conjugated to an enzyme, such as peroxidase 
(Press et al., 1994), that can catalyse a colour-producing reaction or
alternatively an antibody can be tagged to a flurophore, such as rhodamine. 
The antibodies used for specific detection may be either polyclonal or 
monoclonal. The monoclonal antibodies are considered to have greater 
specificities since polyclonal antibodies are a heterogeneous mix of antibodies 
that recognise several epitopes.
Both direct and indirect methods can be used in IHC. The direct method 
utilises only one labelled antibody reacting directly with the antigen in tissue 
section (Ramos-Vara, 2005). However, this method may have low sensitivity 
due to little signal amplification and it is not used widely compared to the 
indirect method. In the indirect method, the unlabelled primary antibodies 
recognise a specific antigen of interest while the labelled secondary antibodies 
react with the primary antibodies (Ramos-Vara, 2005). The secondary 
antibodies recognise immunoglobulins of a particular species and are 
conjugated to a reporter or fluorophore (Press et al., 1994). For example, a 
biotinylated secondary antibody may be coupled with streptavidin-horseradish 
peroxidase which reacts with 3,3’-Diaminobenzidine (DAB) to produce a 
brown staining (Walker, 2006). The indirect method has greater sensitivity 
since the signal may be amplified through several secondary antibody 
reactions with different antigenic sites on the primary antibody (Ramos-Vara, 
2005).
1.6.1.1 EGFR scoring by IHC
The EGFR IHC scoring is based on the assessment of proportion of positively 
stained tumour cells as well as the intensity of the observed staining using an 
antibody detecting EGFR antigen. IHC has been used in many studies to 
measure EGFR expression and many investigators have developed various 
algorithms to score them by either proportion of staining or intensity of 
staining or a combination of both methods, resulting in a variety of scoring 
systems (Chung et al., 2005; Cunningham et al., 2004; Hirsch et al., 2003; 
Kersemaekers et al., 1999). An example of a scoring system is illustrated in the 
table below and Figure 1.5 (Chung et al., 2005):
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Score Criteria
0 No membranous staining in any of the tumor cells
1+ Membranous staining in less than 10% of the tumor cells with 
any intensity or in less than 30% of the tumor cells with weak 
intensity
2+ Staining in 10% to 30% of the tumor cells with moderate to 
strong intensity or staining in 30% to 50% of the tumor cells 
with weak to moderate intensity
3+ Staining in more than 30% of the tumor cells with strong 
intensity or more than 50% of the tumor cells with any 
intensity
The scoring systems are not strictly quantitative despite the numerical scoring 
being assigned to them since the assessment of the intensity and the actual 
percentage of staining may represent only a rough estimate by the scorers and 
such visual interpretation of the stained samples may be subjective and may 
vary between individuals (Walker, 2006). In addition, the choice of antibodies 
and IHC protocol is not consistent and may cause variation in the sensitivity to 
detect EGFR expression (Dei Tos AP, 2005). Therefore, current EGFR 
scorings by IHC for epithelial cancers may vary between laboratories. The 
variation may be partially controlled by using a panel of tissue control slides 
and consensus scoring system by several observers (Adams et al., 1999). 
However, a standardised scoring system is urgently needed to allow direct 
comparison between studies and laboratories (Adams et al., 1999; Dei Tos AP, 
2005).
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Figure 1.5: EGFR scoring by immunohistochemistry in colorectal carci­
noma. A, 0. B, 1+. C, 2+. D, 3+ (Figure taken from Chung et al 2005)
1.6.1.2 HER2 scoring by IHC
Like EGFR scoring, assessment of HER2 over-expression by IHC has also 
produced variable results between laboratories due to non-standardised 
procedures (the antigen-retrieval process, usage of antibodies) or different 
scoring systems. For antigen-retrieval processes, the solution used (e.g. citrate 
buffer or EDTA and their pH), the duration of heating and antigen-retrieval 
may all affect the detection of the HER2 antigen by IHC (Yaziji et al., 2004). 
The other major variable is the anti-HER2 used for IHC staining. For example, 
in a study by Mitchell et al (1999), R60 (rabbit polyclonal antibody) uniformly 
stained cell membranes in paraffin-embedded tissue sections of breast cancers 
containing two to five copies of HER2 gene. However, 4D5 (monoclonal 
antibody to HER2) stained the majority of these sections with more than 5 
copies of the gene and lastly TA-1, another anti-HER2 antibody failed to stain 
even cells with more than five copies of the gene (Mitchell and Press, 1999). 
The HercepTest (Dako, Carpinteria, CA) using A0485 antibody was proposed 
as the standardised IHC method to overcome the problems between inter-lab 
variations. The scoring system uses the intensity of HER2 staining as its basis 
(Vincent-Salomon et al., 2003):
Scoring Criteria
0+ Absence of membranous staining,
1+ > 10% stained cells with a weak staining intensity
2+ > 10% stained cells with moderate staining intensity
3+ > 10% stained cells with a strong intensity
The College of American Pathologists (CAP) also issued its own guideline 
and a tumour is considered to be HER2 over-expressed if it scored 2+ or 3+ 
using the Herceptest reporting system or if > 60% cells had a moderate or 
strong membranous staining (Fitzgibbons et al., 2000). Beside the variability 
from the IHC procedures, the question also arises as to whether HER2 protein
may still be intact after fixation and being made into paraffin sections and this 
will be discussed in greater details in Chapter 6.
1.6.2 Fluorescence In Situ Hybridization 
(FISH)
Fluorescence in situ hybridization (FISH) has been used to detect HER2 
amplification for selecting breast cancer patients for Herceptin treatment 
(Wolff et al., 2007). It is a cytogenetic technique which detects and localises 
specific DNA sequences on chromosomes using complementary probe 
sequences (Fan et al., 1990). The procedures involve constructing a 
fluorescence probe that hybridizes specifically to its target on the 
chromosomes before adding it to a sample DNA (Fan et al., 1990). The sample 
is denatured to separate the complementary strands within the DNA double 
helix structure. The fluorescence probe hybridises with the sample DNA at the 
target sites as it re-anneals back into the double helix. The fluorescence probe 
signal is visualised through a fluorescence microscope and the sample DNA 
can then be scored for the presence or absence of the signal. FISH has been 
used in many other applications in addition to detection of HER2 gene 
amplification, e.g. to diagnose specific chromosomal abnormalities in genetic 
counselling (Fan et al., 1990).
Fluorescence in situ hybridization (FISH) can directly detect amplification of 
HER2 genes within the cells and this may be assessed by various methods, 
including INFORM assay (commercial kit from Oncor Inc, Gaithersburg- 
Maryland, USA) or PathVysion assay, the HER2 DNA probe kit from Vysis 
(Wang et al., 2000). In the INFORM assay, the cells were counted for HER2 
gene signal in each specimen (Wang et al., 2000). Gene amplification is 
considered when there are more than four HER2 gene copies per nucleus. For 
PathVysion, the cells are counted for both HER2 gene and chromosome 17 
centromere (Wang et al., 2000). The result is reported as the ratio of the 
average number of the HER2 gene to that of the chromosome 17 centromere. 
When the specimens with a signal ratio of less than 2 they are considered as 
“non-amplified” and when the signal is 2 or greater, they are classified as
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“amplified” (Wang et al., 2000). The difference of HER2 gene amplification 
by FISH from HER2 expression determined by IHC methods will be discussed 
in the next section.
1.6.3 IHC versus FISH in HER2 
assessm ent
As discussed in the background (Section 1.1), the current criteria to choose 
breast cancer patients for Herceptin treatment is based on either HER2 over­
expression by IHC or HER2 gene amplification by FISH (Wolff et al., 2007). 
The usage of IHC versus FISH for testing HER2 levels is however the subject 
of debate (Seelig, 1999; Wiley and Diaz, 2004). Although both methods are 
supposed to measure HER2 level, the two methods are essentially different 
with IHC measuring its protein level and FISH, the gene level. The gene 
amplification of HER2 is supposed to be the surrogate marker for protein 
expression of HER2, but this difference of measuring gene level or protein 
level may produce disparity between the two methods (Wang et al., 2000). For 
example, IHC 2+ patients have been found to contain significant amount of 
FISH negative patients (Kakar et al., 2000) and patients with polysomy of 
chromosome 17 may also produce high HER2 over-expression detection from 
IHC without true HER2 gene amplification (Salido et al., 2005). When the two 
methods are discordant, e.g. IHC-positive/FISH-negative or IHC- 
negative/FISH-positive, it may cause problems in decision-making for 
Herceptin treatment. Gene amplification of HER2 was first shown to correlate 
with relapse and survival of breast cancer patients in 1987 (Slamon et al., 
1987). Initially assessment of HER2 gene amplification was found to be 
superior to IHC (Pauletti et al., 2000). However, FISH is more expensive and 
labour-intensive than IHC. In addition, there is a lack of clinical data regarding 
negative gene amplification and response to Herceptin; Herceptin acts at the 
protein level and not gene level. IHC assesses HER2 at the protein level and 
therefore it is potentially more directly relevant for assessment of patients for 
Herceptin treatment. However, HER2 assessment by IHC has produced
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variable results, e.g. HercepTest (Dako, Carpinteria, CA) (Section 1.6.1.2) for 
IHC was found to have high false-positive results (Kakar et al., 2000). The 
discrepancy of IHC methods may be due to the choice of antibody, technical 
procedures, tissue fixation, cut-off levels and subjective interpretation and 
analysis between assessors and centres (Yaziji et al., 2004). Although the two 
methods may be discordant in their results, one study showed a close 
correlation of the two methods if quality control and quality assurance was in 
place (Yaziji et al., 2004). This particular study recommended IHC to be used 
first and then to perform FISH for intermediate over-expression of HER2.
Determining a cut-off point for high HER2 concentration is also problematic 
for both IHC and FISH. In IHC, there is a problem of using the criteria either 
based on the intensity of the membranous staining or the percentage of stained 
cells. One study recommended reporting IHC-HER2 as a continuous variable 
and selecting patients for Herceptin based on high percentage of positive 
tumour cells (Vincent-Salomon et al., 2003). In FISH, the choice of using 
different FISH ratios to classify “amplification of HER2” (see Section 1.6.2) 
affects whether it correlated with shorter survival (Kakar et al., 2000). The 
recent American Society of Clinical Oncology (ASCO) / College of American 
Pathologists (CAP) defined HER2 positive or negative based on either IHC 
(see Section 1.6.1.2) or FISH (gene copies or FISH ratio, see Section 1.6.2):
HER2 status IHC or FISH criteria
HER2 positive - IHC 3+ (Uniform, intense membranous staining of > 
30% of invasive tumour cells)
- FISH > 6 HER2 gene copies per nucleus or
- FISH ratio > 2.2 (the ratio of HER2 gene signals to 
chromosome 17 signals)
HER2
negative
-IHC 0-1+
- FISH < 4 HER2 gene copies per nucleus
- FISH ratio <1.8
Equivocal
HER2
-IHC 2+
- FISH 4-6 gene copies per nucleus
- FISH ratio 1.8-2.2
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The panel recommended extra testing for equivocal cases: IHC 2+ to have 
FISH test and FISH equivocal cases, to either retest or count additional 
cells or test with IHC. Nevertheless, not all centres adopt the 
recommendations, especially those centres outside the USA since they may 
use their own HER2 systems, creating variability in the definition of HER2 
status between centres.
Therefore, the current methods using IHC and FISH to select patients for 
Herceptin have a variable scoring systems and cut-off points which are not 
standardised between centres; a tumour that is “HER2 positive” may be 
negative under the criteria used by another centre and this may cause 
problems in patient selection for Herceptin treatment. However, more 
important and urgent issues are how these tests that are supposed to select 
correct patients for targeted therapies for Herceptin perform as predictive 
markers for such therapies. These issues will be discussed in the next 
section.
1.7 HER receptor concentration and 
response to targeted therapies
Increasingly targeted therapies have been used in all types of cancers. 
Although the EGFR and HER2 inhibitors are meant to target the over­
expression of receptors, the response to these drugs has been disappointing 
based on receptor concentration criteria monitored by IHC or FISH.
The two phase II head and neck cancer trials revealed a relatively low 
response rate (around 10%) of patients to Cetuximab despite the fact that the 
majority of the patients had a 2 to 3+ staining for EGFR (Baselga et al., 2005; 
Herbst et al., 2005). Iressa had a similar low response rate of about 10% in 
head and neck cancer (Cohen et al., 2003). In non-small cell lung carcinoma, a 
similar poor response rate was noted for Iressa (Fukuoka et al., 2003; Kris et 
al., 2003) unless the patients had mutations around the ATP-binding pocket of 
the tyrosine kinase domain which rendered these patients highly sensitive to 
Iressa (Lynch et al., 2004; Paez et al., 2004). However, these mutations are
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associated with brochioloalveolar pathology that arise in non-smokers, and in 
individuals of East Asian descent (Lynch et al., 2004; Paez et al., 2004). EGFR 
kinase domain mutations are rarely present in other types of cancers. In head 
and neck cancer, where the majority of patients have over-expression of EGFR 
most Caucasian patients do not have these mutations seen in non-small cell 
lung cancer, except in a small proportion of patients from certain ethnic origin 
(Loeffler-Ragg et al., 2006). In two colon cancer two trials the relationship 
between the expression of EGFR and response rate to Cetuximab was 
examined and a relationship was not found (Cunningham et al., 2004; Saltz et 
al., 2004). In fact another trial has reported objective responses to Cetuximab 
in chemotherapy-refractory colorectal cancer even when EGFR expression was 
not detected by IHC (Chung et al., 2005). When the tyrosine kinase inhibitors 
of EGFR were first used, they were given to patients with over-expression of 
EGFR. However, it was found that the EGFR level does not necessarily predict 
the response to targeted therapy (Parra et al., 2004) and now they may be 
administered to patients irrespective of EGFR expression (Shepherd et al.,
2005).
Chung et al (2004) found, by molecular classification of HNSCC using 
patterns of gene expression, that the poorest outcome group was the group with 
tumours characterised by the high expression of TGF-°c with evidence of 
activation of EGFR pathway (Chung et al., 2004). In addition, another study 
has shown that it is the over-expression of multiple receptors, mainly EGFR, 
with other HER receptors (HER2-4) that correlates more with metastatic 
disease (Bei et al., 2004). Based upon our understanding of the behaviour of 
these receptors, these studies indicate that not only is the actual level of EGFR 
expression important, but specifically the activation/phosphorylation state of 
these receptors.
Despite the selection of HER2 positive breast cancer patients based on IHC 
and FISH, only about one third of these patients respond to Herceptin given as 
monotherapy (Vogel et al., 2002). It was also shown that non-HER2 over­
expressing tumours may also respond to Herceptin through its activation via 
heregulin over-expression (Arteaga, 2006; Menendez et al., 2006). One of the 
reasons accounting for poor predictive value using receptor concentration is 
that over-expression per se fails to consider receptor activation e.g. through
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autocrine expression of one of the several ligands. In addition, over-expression 
as a criterion for treatment fails to account for patients having receptor 
activation without up-regulation through other HER receptors since it is the 
preferred dimerisation partner for other HER receptors (Graus-Porta et al., 
1997). Therefore, it may be assumed that some patients without HER2 over­
expression may have a highly active HER2 receptor and may also benefit from 
HER2 inhibitors like Herceptin. Therefore, like EGFR inhibitors, it is assumed 
that assessing HER2 phosphorylation may be a better predictor for response to 
Herceptin treatment.
In summary, this section discussed the poor relation between the expression 
of EGFR and HER2 receptors and the response to targeted therapies. It is 
therefore of critical importance to determine how EGFR and HER2 activation 
status, rather than concentration, track with response to these and related 
EGFR and HER2-directed treatments. The next section will discuss various 
methods that can be used to assess the phosphorylation status of HER 
receptors.
1.8 A ssessm ent of HER receptor 
phosphorylation status
To assess phosphorylation status of HER receptors, various methods can be 
used, including IHC, eTag or FRET methods. IHC that is currently used to 
determine the expression of HER receptors (Section 1.6.1) may also be used to 
monitor the phosphorylation status of HER receptors in tumours. However, 
using IHC methods to detect phoshorylated HER receptors will have the same 
limitations relating to EGFR and HER2 scorings by IHC (Section 1.6.1.1 and 
1.6.1.2). And not being a two-site assay, it specificity may be influenced by 
background staining and high antibody concentration and thus it is difficult to 
be optimise quantitatively to obtain reliable results. Using eTag reporters 
(fluorescence molecules) conjugated to different HER antibodies, the eTag 
assay platform have been shown to be potentially useful in assessing HER 
activation and dimerisation (Chan-Hui et al., 2004). The amount of released
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eTag reporter is said to be proportional to HER concentration. The problem 
with such assays is that it depends on fluorescence intensity which may be 
influenced by multiple factors including dye concentration, background 
fluorescence, photo-bleaching, and concentration of antibodies conjugated to 
fluorescence reporters. Moreover, it does not provide any spatial data which is 
of critical importance when assessing HER receptors in the tumours. A more 
quantitative method would be required that is not affected by the problems 
encountered in IHC and eTag.
FRET is measured by variation in the changes of lifetime and is independent 
of dye concentration and fluorescence intensity (Larijani, 2006). It was 
proposed that FRET may provide spatial data about the interaction between the 
HER antibodies and may be used to assess phosphorylation status of HER 
receptors as well as dimerisation of HER receptors. For these reasons, FRET 
was chosen to assess HER receptor activation in relation to cancer treatments 
in this thesis. The principle of FRET will be discussed below.
1.9 Principles of Forster Resonance 
Energy Transfer
In this thesis, Forster Resonance Energy Transfer (FRET) monitored by 
Fluorescence Lifetime Imaging Microscopy (FLIM) was exploited to assess 
the phosphorylation of various HER receptors. Since the thesis aims to present 
a translational project, using FRET as a tool to assess HER receptor activation 
in cells and tumour arrays, in-depth discussion on the photophysics of the 
flurophores, mathematic calculations of FRET and physics of FLIM 
instruments will not be given here and may be obtained from other sources 
(Lakowicz, 1999; Larijani, 2006; Valeur, 2002). The relevant details of FRET 
and principles relevant to the project will be described below.
1.9.1 Fluorescence
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When the electrons of the molecules of a fluorophore are excited to a higher 
energy state, the absorbed energy can be released by the emission of a photon 
(radiative) before returning to the ground state, resulting in two types of 
luminescence: fluorescence and phosphorescence (Larijani, 2006).
Fluorescence occurs when there is immediate release of energy (between the 
states of the same spin state of the electrons, e.g. SI to SO) through the 
emission of a photon (Figure 1.6). If the spin states of the initial and final 
energy levels of the electrons are different (e.g. from T1 to SO), the emission of 
the photon is called phosphorescence (Figure 1.6). Fluorescence is statistically 
much more likely to happen than phosphorescence and the lifetimes of 
fluorescent states are very short (1-10 nanoseconds) and phosphorescence 
greater (1 x 10'4 seconds to minutes or even hours). The two processes may be 
illustrated using the Jablonski diagram (Figure 1.6). However, not all the 
excited electrons of the fluorescent molecules return to the ground state via 
luminescence since many other non-radiative competing processes may occur. 
These include internal conversion to the ground state (a non-radiative 
transition between energy states of the same spin state, e.g. via heat);
intersystem crossing to triplet state (a non-radiative transition between
different spin states where energy may be dissipated); collisional quenching 
(when the excited state fluorophore is deactivated upon contact with other 
molecules or the quencher) (Lakowicz, 1999; Larijani, 2006) and resonance 
energy transfer (RET or Forster resonance energy transfer, FRET). These 
radiative decay and non-radiative decay processes compete to depopulate the 
molecules in the excited state.
Fluorescence lifetime of a fluorophore is defined as the mean time the 
electrons of fluorescent molecules spend in the excited state before coming 
back to ground state or the probability of the molecule existing in the excited 
state. Fluorescence lifetime is thus affected by the rate of various radiative and 
non-radiative processes. Measuring the lifetime of a fluorescence probe may 
inform on the local environment of the molecule since the local environment 
may change the rate of non-radiative decay (Lakowicz, 1999; Valeur, 2002). 
Therefore fluorescence has been exploited to investigate structure and the 
dynamics of molecules in their microenvironment since the emission of
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fluorescence molecules is sensitive to physical and chemical parameters such 
as pH, pressure, viscosity, electric potential, quenchers, temperature and ions 
(Larijani, 2006). Forster resonance energy transfer is one of the photophysical 
processes that are responsible for the de-excitation of fluorescent molecules 
and has been used as a reporter of molecular environment (Larijani, 2006). In 
this thesis FRET has been exploited to answer some important clinical 
questions regarding HER receptors and cancer treatment. The following 
sections will focus on various methods of FRET measurement and its 
application.
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Figure 1.6: Jebloski diagram (Figure taken from http://www.shsu.edu/-chemistry/chemiluminescence/JABLONSKI.html, by Dr. 
Thomas G. Chasteen at Sam Houston State University, Huntsville, Texas).
1.9.2 Fdrster Resonance Energy 
Transfer
FRET is a process whereby the energy of an excited donor fluorophore is 
transferred to an acceptor fluorophore without emission of a photon (non- 
radiatively) (Lakowicz, 1999; Valeur, 2002). It was first proposed by Forster 
that the transfer occurs due to the dipole-dipole resonance interaction between 
the donor and acceptor fluorophores (Forster, 1948). The process is distance 
dependent (Stryer and Haugland, 1967), typically occurs with the distance 
between the two fluorophores of less than 10 nm and when the emission 
spectrum of the donor fluorophore overlaps with the absorption spectrum of 
the acceptor fluorophore. It was shown that the spatial proximity relationship 
of two fluorescence-labelled molecules may be determined in biological 
samples and therefore establishes FRET as a “spectroscopic ruler” (Stryer and 
Haugland, 1967).
FRET efficiency is the probability of the occurrence of energy transfer per 
donor excitation event (Yasuda, 2006) and this efficiency depends on the 
distance between the two fluorophores:
E = Ro6/ (Ro6 + r6) (Equation 1)
Where r (nm) is the distance between the two fluorophores and Ro is the 
Forster distance (the distance between the two fluorophores that gives 50% 
FRET efficiency). Therefore, FRET efficiency is inversely proportional to the 
sixth power of the distance between the donor and acceptor fluorophores.
Reported Forster distance Ro may typically range between 1-7 nm (10-70 A) 
but up to 12 nm may be measured (Wu and Brand, 1994). The Ro may be 
affected by various parameters given by the equation below:
Ro = [k2 x J  (A,) x nA x Q]m  x 9.7 x 102 (Equation 2)
Where K2 is the relative orientation of the transition dipoles of the flurophores, 
J {X) is the overlap integral between the donor emission and acceptor 
absorption spectra, n is the index of refraction of the medium and Q is the 
quantum yield of the donor. From the equation it can be determined that the 
energy transfer rate depends on three parameters: (1) the overlap of the donor 
emission and acceptor absorption spectra; (2) the relative-orientation of the 
donor absorption and acceptor transitions moments; and (3) the refractive 
index (Jares-Erijman and Jovin, 2003). These factors as well as the distance r 
between the two fluorophores will influence FRET efficiency from the donor 
to the acceptor fluorophores.
1.9.3 Methods to measure FRET
FRET may be quantified and monitored by both steady-state and time- 
resolved methods (Wu and Brand, 1994). The steady-state methods include 
intensity-based measurements like ratiometric imaging and donor 
dequenching; and the time-resolved methods are comprised of fluorescence 
lifetime imaging microscopy (FLIM) and anisotropy imaging.
In the steady-state measurement, the fluorescence sample is illuminated 
continuously and the emission of photons is measured. The steady state is 
reached immediately when the sample is first exposed to light. The intensity of 
the fluorescence is measured and this depends on the concentration of the 
probe. The time-resolved measurements are used to measure intensity decays 
or anisotropy decays. For this type of measurement, the sample is exposed to a 
short pulse of light and the decays are recorded with a high-speed detection 
system.
The detection of FRET using intensity-based methods and time-resolved 
FLIM methods will be discussed in this section. Since anisotropy imaging is 
not used in this thesis, the details of anisotropy will not be explained in this 
section and may be obtained elsewhere (Lakowicz, 1999; Valeur, 2002).
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1.9.3.1 Intensity-based m ethods
In the intensity-based methods (steady-state measurement), FRET is 
quantified using intensities of donor and acceptor fluorescence, and typically 
involving the decrease in donor fluorescence and increases in the acceptor 
fluorescence. FRET based on intensity-based methods can have many pitfalls 
including the insensitivity, high background and the signal is dependent on the 
concentration of the fluorophores (Parsons et al., 2004). Ratiometric imaging 
and donor quenching methods are two examples of intensity-based 
measurement and will be discussed below.
Ratiometric imaging
In this method, the donor fluorophore is selectively excited and the ratio of 
acceptor emission Ia and donor emission Id is used to measure relative FRET 
efficiency ( I a /I d )  (Parsons et al., 2004). The donor and acceptor fluorescence 
can be separated by appropriate dichroic filters that detect the donor and 
acceptor fluorescence at different wavelengths. However, the excitation source 
may directly excite the acceptor and therefore the emission of the acceptor may 
not be due to the transfer of energy from the donor fluorophore (Lakowicz, 
1999). In addition, the donor fluorescence may bleed through into the acceptor 
detection channels and make the FRET efficiency difficult to measure (Parsons 
et al., 2004). For the method to be reliable, the donor and acceptor 
stoichiometry needs to remain constant (Lakowicz, 1999). Otherwise 
correction for the spectral bleed through needs to be done.
Donor dequenching (acceptor photobleaching)
In this method, donor fluorescence is measured quantitatively while the 
acceptor fluorophore is photobleached selectively (Parsons et al., 2004). As a 
result, the donor is no longer quenched by the acceptor i.e. donor dequenching 
and the intensity of the donor increases (Lakowicz, 1999). FRET efficiency 
can be obtained using the equation below:
E  =  1 -  Id / I d a
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Where Id  is the donor fluorescence intensity and I d a  is the donor fluorescence 
intensity after acceptor photobleaching (Parsons et al., 2004). The method may 
be used reliably when the bleed-through of the acceptor into the donor channel 
is negligible. It also does not depend on the relative concentration of the donor 
and acceptor fluorophores (Parsons et al., 2004).
1.9.3.2 Fluorescence lifetime imaging
microscopy (FLIM)
FLIM is a time-resolved method and it may be monitored by either time- 
domain or frequency-domain measurements. FLIM measures fluorescence 
lifetime as a readout for FRET efficiency. Unlike the steady state methods 
where the intensity of the fluorophore may change in a way that is difficult to 
quantitate, a key advantage of using time-resolved method is that Fluorescence 
lifetime is relatively independent of fluorophore concentration, light scattering 
and the excitation intensity (Larijani, 2006). Therefore FLIM using either 
time-domain or frequency-domain measurements may be exploited to measure 
quantitatively the environmental factors that affect the excited state in fixed 
and live cells (Larijani, 2006).
Time-domain method
In the time-domain method, the fluorescence sample is excited with a short 
pulse of light (usually in the orders of tens to hundreds of picoseconds), 
producing a population of fluorophores in the excited-state, which will relax to 
the ground-state by emitting photons. The resulting emission decay in intensity 
may be reconstructed using various methods including multiple time gating 
method or time correlated single photon counting (TCSPC). The most common 
method is TCSPC and in this method the time delay between the emitted 
photon and the excitation pulse is recorded (Alcor D, 2007). An entire decay 
curve is built by plotting the number of photons versus delay time. The 
excitation profile needs to be measured so that a deconvolution may be done to 
separate the excitation pulse from the emission profile. The fluorescence 
lifetime of the fluorophore may be determined by fitting the decay curves
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(Figure 1.7A) (Lakowicz, 1999). Recent advances have also enabled the use of 
multi-photon or confocal laser scanning microscopes to measure FRET, 
yielding highly improved spatial resolution, controlled depth of field and the 
potential to generate a three-dimensional reconstruction of FRET signals 
within a cell by acquiring multiple optical sections (Calleja et al., 2007; 
Parsons et al., 2004).
Frequency domain method
FRET data presented in this thesis is measured by frequency-domain FLIM. 
The fluorescence sample is excited by a continuous wave laser in a frequency- 
domain method as opposed to a pulsed laser in the time-domain method. The 
light source is modulated via an acousto-optical modulator and the sample is 
excited by a sinusoidally modulated light (Larijani, 2006). The emitted light 
appears as a sine wave but it is demodulated and phase-shifted from the 
excited light due to Stokes shift (with a lower energy) (Figure 1.7B). The 
phase shift and demodulation are used to obtain the lifetimes x of the 
fluorophore from the equations below:
cox = Tan (O)
cox = V 1/M2 - 1
where co is the angular modulation frequency (co = 27tf), f is the modulation 
frequency, O is the phase difference and M is the demodulation. To obtain the 
maximum sensitivity, the angular modulation frequency should be roughly the 
inverse of the lifetime obtained. Therefore, the typical modulation frequencies 
are between 20 to 200 MHz since the lifetimes are usually between 1-10 ns. 
The FLIM instrument used in Cell Biophysics Lab uses a single modulation 
frequency of 80 MHz and the range of lifetime detected is between 1.5 ns to 
2.6 ns.
The frequency-domain method is more rapid than the time-resolved method 
in detecting the lifetime of fluorescence although it is not the best tool to 
directly measure multiple exponential decays (Larijani, 2006). However, 
multiple-frequency FLIM instruments may be used to detect multiple
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exponential decays that may arise due to heterogeneity of the local 
environment of the fluorophore (Larijani, 2006).
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Figure 1.7: A, Time-domain method. B, Frequency-domain method
(Figures taken from Olympus microscope website)
65
1.9.4 Application of FRET
FRET may be used to detect changes or interaction of intra- and inter- 
molecular distances in the 1-10 nm range and is therefore capable of resolving 
molecular interactions and conformations with a spatial resolution (Jares- 
Erijman and Jovin, 2003). It has been used to detect protein-protein interaction 
(e.g. Grb2 with EGFR) (Sorkin et al., 2000), protein-lipid interaction (e.g. 
PITP and phospholipids PI) (Larijani et al., 2003), conformational change of a 
protein (e.g. PKB conformation change) (Calleja et al., 2007), study of the 
activities of protein kinases (Miyawaki, 2003; Yasuda, 2006), dimerisation of 
receptors (e.g. CXCR4 receptor dimerisation) (Toth et al., 2004), high 
throughput screening (Mere et al., 1999) and many other applications. In this 
thesis, FRET was exploited to assess the phosphorylation status of HER 
receptors in relation to cancer prognosis and treatments.
1.10 Aims, strategy and objectives
1.10.1 Aims
As discussed in Section 1.8, there is a lack of relationship between EGFR 
expression and response to EGFR inhibitors. There is a need for a quantitative 
method to assess the activation and phosphorylation of HER receptors since 
this may prove to be a better predictive marker for cancer prognosis and 
response to these inhibitors. The overall aim of this thesis was to establish a 
methodology whereby phosphorylation of HER receptors may be assessed by 
FRET monitored by high throughput FLIM and to apply such methodology to 
formalin-fixed, paraffin-embedded cancer tissues in relation to prognosis and 
treatments of various cancers. The ultimate long-term goal is to develop a 
validated methodology using various assays to assess activation of a whole
range of other pathways like PKB and MAPK activation in a high throughput 
manner in relation to cancer prognosis and treatments.
1.10.2 Strategy
To assess HER receptor activation state by FRET, a pair of anti-non- 
phosphoHER and anti-phosphoHER antibodies may be employed and 
conjugated to Cy3b and Cy5 respectively. The strategy is illustrated in Figure 
1.8 using EGFR as an example. The hypothesis was that when EGFR was not 
phosphorylated, only EGFR-Cy3b would bind to the tyrosine kinase domain of 
EGFR. However, when the EGFR was phosphorylated, either from the 
autocrine loop (basal condition) or from exogenous ligand stimulation (e.g. by 
adding EGF), there would be autophosphorylation of the tyrosine residues of 
the C-terminal of EGFR resulting in the binding of pEGFR-Cy5 to the 
phosphotyrosine sites. This would bring the two conjugated antibodies into 
proximity, resulting in the quenching of the donor EGFR-Cy3b and a decrease 
in the lifetime of donor EGFR-Cy3b. Therefore, it was hypothesized that the 
decrease of lifetime could be used as a reporter of EGFR phosphorylation.
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Figure 1.8: Strategy to assess EGFR phosphorylation by FRET.
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1.10.3 Objectives
In this thesis, one of the first objectives was to develop an assay that can 
assess HER receptor phosphorylation by FRET monitored by high throughput 
FLIM using the strategy outlined in Section 1.10.2. EGFR pathway was 
chosen to be the one of the main and first HER pathways to be assessed by 
FRET since EGFR over-expression was found to be a strong prognostic 
indicator for a variety of cancers including head and neck cancer, ovarian, 
cervical, bladder and oesophageal cancer and EGFR inhibitors are now used in 
many of these cancers (Nicholson et al., 2001). A431 was chosen as the test 
cell line to establish the assay, because of its high EGF receptor expression and 
its extensive use for nearly 20 years in the analysis of EGFR function. The 
FRET assay to assess EGFR phosphorylation was also tested in other cell lines 
with less EGFR receptors to assess the robustness of the methodology. The 
assay was established first in various cell lines so that it could be applied for 
use in paraffin-embedded tumour tissue. Since majority of head and neck 
tumours express or over-express EGFR, the established methodology from cell 
lines was applied to an archive of formalin-fixed and paraffin-embedded head 
and neck tumour arrays as a test of principle. The EGFR phosphorylation 
determined by FRET was correlated with survival data of head and neck 
patients to assess the prognostic value of FRET assay. In addition, the 
prognostic value of FRET was compared with conventional IHC in the head 
and neck arrays.
The other main HER pathways to be chosen for assessment by FRET in this 
thesis is HER2 since it has been shown to be the preferred dimerisation partner 
(Graus-Porta et al., 1997) as well as a strong prognostic factor for breast cancer 
(Hartmann et al., 1994; Marks et al., 1994; Rosen et al., 1995; Ross and 
Fletcher, 1999). Therefore, one of the objectives of this thesis was to establish 
an assay to assess HER2 phosphorylation by FRET in cell lines and breast 
tumour arrays.
Both EGFR and HER2 play in role in the prognosis of breast cancers and thus 
both EGFR and HER2 inhibitors (alone or combination) have been used in
breast cancer patients (Geyer et al., 2006; Piccart-Gebhart et al., 2005; 
Polychronis et al., 2005; Romond et al., 2005; Smith et al., 2007). The 
intention was that the FRET will eventually be applied to prospective trials of 
HER receptor inhibitors in breast cancer patients (e.g. adjuvant Herceptin and 
Lapatinib trials (Geyer et al., 2006; Piccart-Gebhart et al., 2005; Romond et 
al., 2005; Smith et al., 2007)). Therefore, it was essential to first assess the 
responses of HER receptors in relation to EGFR and HER2 inhibitors in breast 
cell lines. Moreover, the mechanisms of action and resistance to these drugs 
are still poorly understood. Since FRET can be used to assess the 
phosphorylation status in vivo, it was used to monitor HER receptors’ 
responses to these drugs in combination with classical biochemical analysis. 
The results from cell lines are also essential before such assay may be applied 
to prospective trials to assess responses of HER receptors by FRET in relation 
to HER receptor inhibitors.
It is often assumed that the phosphorylated antigens (including that of HER 
receptors) may survive the conventional IHC procedures for the tumours to be 
fixed and made into paraffin sections. However, if this was not the case, FRET 
could not have been used to assess the phosphorylation of these HER 
receptors. Therefore one of the objectives of the thesis was to investigate 
whether phosphorylated antigens may survive the conventional IHC 
procedures as well as the best way to fix and preserve the phosphorylated 
antigens. These results will be useful in providing guidelines for tumour 
fixation procedures of tumour samples used for FRET experiments in 
prospective trials. To assess the best way to preserve phosphorylated antigens 
(using HER2 phosphorylated antigens as a reporter), the MDAMB-453 breast 
tumours were grown in xenograft model. The tumours were fixed with either 
formalin or liquid nitrogen after varying the durations of delay in fixation. 
These tumours were subsequently assessed for their HER2 phosphorylation 
status using both conventional IHC and FRET.
Other than the potential problems with preservation of phosphorylated 
antigens, the optimisation of the established HER2 FRET assay from cell lines 
was necessary in archives of human breast tumour arrays before it may be 
applied to prospective trials. This would identify the difficulties of using such 
methodology in breast tumour arrays and to solve all the potential problems
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before applying the assay to prospective trials. For this purpose, the established 
HER2 FRET methodology was applied to assess HER2 phosphorylation in 
archives of HER2 positive breast tumour arrays as well as mixed HER2 breast 
tumour arrays (consisting of both HER2 positive and HER2 negative cases).
In summary, the work of this thesis had the following objectives:
- First, the establishment of an assay that can assess EGFR 
phosphorylation by FRET monitored by high throughput FLIM.
- Second, the establishment of an assay that can assess HER2 
phosphorylation by FRET in cell lines, and to assess the responses of 
HER receptors in relation to EGFR and HER2 inhibitors in breast cell 
lines.
- Third, the assessment of the best way to preserve phosphorylated 
antigens in xenograft breast tumours.
- Fourth, the establishment of HER2 phosphorylation by FRET in breast 
tumour arrays.
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2 M aterials and M ethods
2.1 Materials
2.1.1 Mammalian Cell lines
A431, COS-7, MCF-7, SKBR3, MDMB-231 and MDAMB-453 cells were 
provided by the cell services at Cancer Research UK London Research 
Institute (CR-UK LRI) and MCF-12F cells were obtained from American Type 
Culture Collection (ATCC), USA.
2.1.2 Mice for xenograft work
Nude mice and Severe Combined Immune Deficiency (SCID) mice were 
obtained from Transgenic Lab at Cancer Research UK London Research 
Institute.
2.1.3 Tissue microarrays (TMAs)
Tissue arrays were prepared from formalin-fixed, paraffin-embedded tumour 
blocks derived by surgical resection from the Pathology Department, John 
Radcliffe Hospital, Oxford. Quality control for tumour specimens was 
undertaken and all slides were examined by at least one specialist consultant 
pathologist. It was not possible for each core to be uniformly involved by the 
tumour and naturally there was variation between the individual cores with the 
percentage of the tumour. The tonsil sections were provided as a reference 
point for slide orientation and contain heterogeneous tissues including 
squamous tissue, lymphoid and vascular tissues as well as supporting stromal
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tissues. 500 p.m cores were taken and transferred to an 8 x 15 core recipient 
array block using a Beecher Instruments Manual Tissue Arrayer-1 (Beecher 
Instruments Incorporated, Sun Prairie, WI). 5 pm sections were cut from each 
array block and made into slides which were stored at 4 0 C.
The work was carried out with the approval of the Oxford Ethics Committee. 
For head and neck tumour arrays, 133 consecutive cases from the Ear Nose 
Throat department, Radcliffe Infirmary, Oxford, were analysed. Surgical 
approach was the primary approach always in these patients unless they were 
not encompassable in an appropriate surgical field. If, after primary surgery, 
margins were positive then radiotherapy was given to the patients. No 
chemotherapy was given to these patients. No primary radiotherapy cases are 
included here and patients who had previously been treated for HNSCC were 
also excluded. Two sets of breast arrays were used, one with a mixture of 
HER2 positive and HER2 negative cases (n=115) and the other set with only 
HER2 positive cases (n=55). All patients had conventional treatment including 
surgery, radiotherapy, chemotherapy and hormonal therapy according to their 
TNM staging and guidelines from medical oncology department at the 
University of Oxford.
2.1.4 Antibodies
Name Species Application Source
Anti-EGFR, F4 
(recognizing 
intracellular 
residues 985-996)
Mouse WB 1: 10000 Cancer Research 
UK
Anti-
phosphotyrosine,
FB2
Mouse WB 1:500 Cancer Research 
UK
Anti-EGFR
(Tyr845)
Rabbit WB 1:1000 Cell Signalling
Anti-HER2 Rabbit WB 1:1000 Cell Signalling
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(intracellular) IP 1:100
Anti-
phosphoHER2
(Tyrl248)
Rabbit WB 1:1000 Cell Signalling
Anti-
phosphoHER2 
(Tyr1221/1222)
Rabbit WB 1:1000 Cell Signalling
Anti-HER3
(monoclonal)
Mouse WB 1:100 Sigma
Anti-
phosphoHER3 
(Tyr1289)
Rabbit WB 1:1000 Cell signalling
Anti-HER4 83B10 
(intracellular)
Rabbit WB 1:1000 Cell signalling
Anti-HER4 111B2 
(intracellular)
Rabbit WB 1:1000 Cell signalling
Anti-HER4 (C- 
terminus)
Rabbit IP 1:25 Santa Cruz
Anti-
phosphoHER4
(Tyrl284)
Rabbit WB 1:1000 Cell signalling
Anti-
phosphotyrosine
(p-TyrlOO)
Mouse WB 1:2000 Cell signalling
Anti-Akt (PKB) Rabbit WB 1:1000 Cell signalling
Anti-phosphoPKB
(Thr308)
Rabbit WB 1:1000 Cell signalling
Anti-phosphoPKB
(Ser473)
Rabbit WB 1:1000 Cell signalling
Anti-p44/42 MAP 
Kinase
Rabbit WB 1:1000 Cell signalling
Antiphospho- 
p44/42 MAP
Rabbit WB 1:1000 Cell signalling
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Kinase
(Thr202/Tyr204)
Anti-beta actin Mouse WB 1:20000 Sigma
Anti-pTEN Rabbit WB 1:2000 Santa Cruz
Anti-Human IgG Mouse WB 1:5000 Sigma
HRP-conjugated 
anti-mouse whole 
IgG
Sheep WB 1:10000 (F4 
and FB2); 1:2000 
(for others)
Amersham (GE 
healthcare UK 
Limited)
HRP-conjugated 
anti-rabbit IgG
Goat WB 1:2000 Amersham (GE 
Healthcare UK 
Limited)
Anti-human TGF- 
a
Goat WB 1:2000 
(0.05 pg/ml)
Cell viability 
1:40
(1 pg/ml)
Sigma
Anti-heregulin-a
(Ab-1)
Goat WB 1:10000 
(0.1 pg/ml)
Cell viability 
1:100 (10 (ig/ml)
Calbiochem
Anti-heregulin-1
precursor
Rabbit (human 
and mouse 
cross­
reactivity)
WB 1:10000 
(0.05 |Xg/ml)
Upstate
Anti-betacellulin Mouse WB 1:10000 
Cell viability 
1:25 (0.02 g/ml)
Sigma
2.1.5 Growth factors
Name Species Dose Source
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Epidermal Growth Factor (EGF) Mouse 50-100 ng/ml Sigma
Transforming Growth Factor-a 
(TGF-a)
Human 100 ng/ml
Heregulin p* Human 100 ng/ml
Heregulin pi* Human 100 ng/ml
Betacellulin Human 20 ng/ml
* Heregulin p: Recombinant EGF domain of heregulin P3 (amino acid 
residues 178-241) of neuregulin 1 gene (Sigma product information), 
f  Heregulin pi: Recombinant EGF domain of heregulin p i (amino acids 176 
to 246) of neuregulin 1 gene (Sigma product information).
2.1.6 Inhibitors and drags
Generic name Trade name Typical
dose
Company
4-(3-Chloroanilino)-
6,7-
dimethoxyquinazoline
AG 1478; 
Tryphostin AG 
1478
3 pM Calbiochem
Gefitinib (ZD 1839) Iressa 1 pM Astrazeneca
Trastuzumab Herceptin 40 pg/ml Roche
TNF-a Protease 
Inhibitor-1 (TACE 
inhibitor)
TAPI-1 100 pM Calbiochem
2.1.7 Solutions
PBS: 130.37 mM NaCl, 3.19 Mm KCL, 9.6 mM Na2HP04, 1.75 mM KH2P04, 
1.1 mM CaCU, ImM MgCl2, pH 7.2
PBST: 0.2 % (v/v) Tween 20 (polyoxyethylene-sorbitan monolaurate) in PBS
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Trypsin / versene: 0.05 % (w/v) trypsin, 0.02 % (w/v) EDTA, 27 Mm NaCl, 
1.62 mM Na2 HP04, 0.3 mM KH2P04, 0.0003% (v/v) phenol red 
Cell lysis buffer: 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 100 mM NaF, 10 
Mm Na2P2C>7 , 10 mM EDTA, supplemented with 1% (v/v) Triton X-100 and 1 
protease inhibitor cocktail tablet per 10 ml of cell lysis buffer 
4xSDS sample buffer: 250 mM Tris-Cl (pH 6.8), 20 % (w/v) glycerol, 4 % 
(w/v) SDS, 0.01 % (w/v) Bromophenol Blue, 50 mM p-mercaptoethanol 
8 % (v/v) SDS polyacrylamide resolving gel: 8 % (v/v) acrylamide mix, 
0.375 M Tris pH 8.8, 0.1 % (w/v) SDS, 0.1 % (w/v) ammonium persulfate, 
0.06 % (v/v) TEMED
5 % (v/v) SDS polyacrylamide stacking gel: 5 % (v/v) acrylamide mix, 
0.126 M Tris pH 6.8, 0.1 % (w/v) SDS, 0.1 % (w/v) ammonium persulfate, 0.1 
% (v/v) TEMED
Tris-glycine electrophoresis buffer: 25 mM Tris, 250 mM glycine, 0.1 % 
(w/v) SDS, pH 8.3
Tris-glycine transfer buffer: 24 mM Tris, 192 mM glycine, 20% (v/v) 
methanol
Stripping buffer: 500 mM glycine -  acetic acid, pH 2.5
Ponceau S: 5% acetic acid (v/v), 2% Ponceau S (w/v) in water
Coumassie Blue stain: 40% (v/v) methanol, 10 % (v/v|) glacial acetic acid,
0.04 % (w/v) Coumassie Brilliant Blue R-250
4% PFA (paraformaldehyde): 8g PFA in 200 ml PBS
0.2% (v/v) Triton X-100: 50 pi of Triton X-100 in 25 ml PBS)
1 mg/ml Sodium borohydrate: 0.05g sodium borohydrate in 50 ml PBS 
1% (w/v) BSA (Bovine Albumin): 0.5g in 50 ml PBS 
Reaction buffer (for protein tyrosine phosphatase YOP): 50 mM Tris- 
HCL, 150 mM NaCl, 5 mM DTT, 2.5 mM Na2EDTA, 100 pg/ml BSA 
Mowiol: 10% (v/v) Mowiol, 25% glycerol, 100 Mm Tris-HCl, pH 8.5 
OCT™: Polyvinyl alcohol (<11 %), Carbowax (<5%), non-reactive
ingredients (> 85%)
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2.1.8 Reagents
Application Reagents Source
Cell culture Foetal Bovine Serum Bioclear
Dulbecco’s Modified 
Eagle Medium (DMEM)
Cancer Research UK
Trypsin / versene
Cell lysis Protease inhibitor 
cocktail tablets
Roche
Triton X-100
(t-Octylphenoxypoly-
ethoxyethanol
Sigma
Protein assay Bio-Rad Protein Assay Biorad
SDS-PAGE Acryl/Bis 30 % (v/v) Amresco
Tris, Ammonium 
Persulfate, TEMED
Sigma
RPN 800 Molecular 
Weight Markers
Amersham
4-12 % pre-cast gels Invitrogen
NuPAGE MOPS SDS 
running buffer x20
Western blotting Immobile® IM-P PVDF 
membrane
Millipore
ECL Western Blotting 
Detector System
Amersham
30 % solution Bovine 
Albumin
Sigma
Ponceau S solution
Medical X-Ray film AGFA
RPN800 Full range 
Rainbow Molecular 
Weight markers
GE healthcare
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FRET Cy3b GE Healthcare
Cy5 GE Healthcare
DMF
(N,N-
Dimethylformamide)
Sigma
4%PFA
(paraformaldehyde)
Sigma
Triton X-100
(t-Octylphenoxypoly-
ethoxyethanol)
Sigma
Sodium borohydrate Sigma
BSA (Bovine Albumin) Sigma
p-Nitrophenyl Phosphate Calbiochem
Protein Tyrosine 
Phosphatase, YOP 
(Yersinia enterocolitica)
Calbiochem
Cell viability Trypan Blue (Vi- 
CELL™ Reagent Pak)
Beckman Coulter
DMSO
(Dimethylsulfoxid 99.8% 
Methyl sufoxide 99.8%)
Aldrich
Liquid nitrogen 
fixation
OCT Sakura
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2.2 Methods
2.2.1 Mammalian cell culture
A431, MCF-7, SKBR3, MDAMB-453 were routinely cultured as monolayers 
in Dulbecco’s modified eagle’s medium (DMEM) supplemented with 7.5 % 
(v/v) foetal bovine serum (FBS) at 37°C CO2  humidified atmosphere. The cells 
were obtained from Cancer Research UK cell services and were split before 
they were confluent. The cells were grown to a maximum of 30 passages 
before being discarded and new cells would be obtained from cell services. 
When splitting the cells, the cells were washed once with PBS to get rid of the 
dead cells and to clear the serum which contained inhibitors that would 
otherwise suppress trypsin. The cells were then incubated with 2 ml of 
trypsin/versene in a 10-cm plate for a maximum of few minutes before the 
trypsination was inhibited by adding 8 ml of 10% FBS. Following splitting the 
new cells were seeded at 1:10 - 1:20 dilution for MCF-7, SKBR3 and 
MDAMB-453 and 1:20 to 1: 40 dilution for A431 cells (since these cells have 
a faster proliferation rate).
2.2.2 Determination of protein 
concentration
Bio-Rad’s protein assay (based on the Bradford’s dye-binding procedure) was 
used to determine the protein concentration (Bradford 1976) before sample 
loading for SDS polyacrylamide gel eletrophoresis. Near confluent cells were 
first washed with cold PBS (4°C) before adding lysis buffer (Section 2.1.7) for 
10 minutes at 4°C. The total protein concentration of the cell lysate was 
determined using the Coomassie Brilliant Blue G-250 dye that binds to 
basic/aromatic acid residues and changes its colour in response to various
concentrations of the protein. Bovine serum albumin (BSA) was used as a
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standard and a stock solution of 10 pg / pi was diluted with dHaO (0.2, 0.5, 
1.0, 1.5, 2.0, 3.0, 4.0 pg / pi) to produce a standard curve. The dye Reagent 
was first diluted with water (1:5 ratio) and 500 pi of this was transferred into 
each reaction vial. 2 pi of each standard solution or each cell lysate was mixed 
with 500 pi of diluted dye Reagent. After 10 minutes of incubation, a duplicate 
of each condition (200 pi) was loaded into a 96-well microtitre plate. The 
absorbance of the dye-protein complex was measured at 585 nm in a 
SpectraMax plate-reader from Molecular Devices and the protein 
concentration of the cell lysate was determined from the BSA standard curve 
(using lysis buffer as the blank measurement).
2.2.3 Immunoprecipitation
All experiments were performed using Protein G Agarose beads (Roche) 
which were washed with PBS for three times before each experiment to get rid 
of the storage ethanol. The cells were grown to near confluency before being 
lysed with lysis buffer (Section 2.1.7) on ice. The cell lysate was centrifuged 
for 5 minutes at, a speed of 20817 ref (14000 rpm) in a 5417R centrifuge (from 
Eppendorf) before transferring the supernatant to a new reaction vial. The 
supemanatant was presorbed with beads for 2 hours at 4°C. The mixture of cell 
lysate and beads was then centrifuged for 5 minutes at a speed of 20817 ref 
(14000 rpm) before transferring the supernatant to another new reaction vial. 
The antibodies anti-HER4 (concentration 1:100, C-terminal; Santa Cruz) or 
anti-HER2 (concentration 1:100, intracellular; Cell signalling) were added to 
the supernatant and were incubated overnight at 4°C. The next day, the 
immune-complex was collected by the addition of new beads and further 
incubation for 2 hours at 4°C. The beads were washed thoroughly with lysis 
buffer before boiling with 1 x SDS. 40 pi was loaded in each lane in SDS- 
PAGE for western blot analysis.
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2.2.4 SDS polyacrylamide gel 
electrophoresis (SDS-PAGE)
Following protein determination by Bradford Assay, the cell lysate was 
mixed with 4X SDS (with a reducing agent, p-mercaptoethanol). The SDS and 
cell lysate mixture was boiled for 10 minutes at 95°C to dissociate the protein 
into their individual polypeptide subunits. Equal amounts of protein based on a 
Bradford Assay were then loaded onto an SDS-PAGE gel. In the first half of 
my PhD, the SDS polyacrylamide resolving and stacking gels (Section 2.1.7) 
were routinely made and SDS-PAGE was performed in a Tris-glycine 
electrophoresis buffer using a Biorad Mini Trans Blot electrophoresis cell. 
However, to improve the resolution, pre-cast gels were subsequently used to 
perform SDS-PAGE with lx NuPAGE MOPS SDS running buffer and 
Invitrogen Novex Mini-Cell. The gels which contained separated polypeptides 
with the molecular marker were transferred onto the PVDF membrane for 
western blot analysis.
2.2.5 Protein transfer
Using the Biorad Trans-Blot Semi-Dry Transfer apparatus, the separated 
polypeptides and the molecular markers on the gel were transferred to 
Immobilon™-P PVDF membranes. For each gel, a PVDF membrane was 
initially equilibrated with methanol and two sets of Whatman paper (3mm, 4 
pieces in each set) were immersed in Tris-glycine buffer before protein 
transfer. The gel was placed on top of the soaked PVDF membrane and both 
were then sandwiched between the two sets of Whatman papers. The transfer 
was performed using the Transfer apparatus at 12 V for 2 hours at room 
temperature. The membrane was then used for western blot analysis. To check 
for efficient protein transfer, the membrane was stained with Ponceau S 
solution and de-stained with water before western blot analysis.
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2.2.6 Western blot analysis
After transfer, the PVDF membrane was washed with PBS first at room 
temperature for 5 minutes. The membrane was then incubated for 1 hour at 
room temperature or overnight at 4 0 C with blocking buffer, 3% (v/v) BSA in 
PBS supplemented with 0.2% Tween-20 (PBST). Following blocking, the 
membranes were incubated with the appropriate primary antibody for 2 hours 
at room temperature, followed by four washes (15 minutes each) with PBST 
containing 1% (w/v) low fat milk powder. The membranes were then 
incubated with the appropriate HRP-conjugated secondary antibody (section 
2.1.4) in PBST (containing 5% (w/v) low fat milk powder) for 1 hour at room 
temperature and another four washes with PBST (15 minutes each) containing 
1% (w/v) low fat miik powder. The membranes were then washed twice with 
PBST and once with PBS before incubation with a 1:1 mixture of the 
Amersham ECL reagents for 2 minutes. The membranes were then put in 
Kodak BioMax MS cassette and exposed to photographic AGFA Cronex 5 
Medical X-Ray Film for variable durations before being developed using an 
IGP Compact 2 Developer. All the western blot experiments were repeated at 
least three times and represented blots were shown in the results’ section.
Western blot for experiments on growth factor stimulation and drug 
treatment in cell lines
The cells were grown to 80% -100% confluent in a 6-well cell culture plate 
after seeding 30,000 cells per well. The cells were grown for at least 24 hours 
before treated with drugs, e.g. 3 flM AG 1478, 1 pM Iressa and 40 |ig/ml 
Herceptin for different durations according to the experiments (unless 
indicated otherwise, these will be the doses used for these drugs). The dosage 
for TAPI inhibitor, TAPI-1 was 100 jiM. For growth factor experiments, the 
cells were treated with 50 ng/ml EGF, lOOng/ml heregulin p (P3 of NRG1, 
Section 2.1.5) and lOOng/ml heregulin-pi (Pi of NRG1, Section 2.1.5) for 10 
minutes following serum starvation of 16 hours. The cells were then obtained 
after 30-minute treatment with lysis buffer (Tris HC1, 20 mM; NaCl, 150 mM; 
NaF 100 mM; Na4 ? 2 0 7  10 mM; EDTA 10 mM with 1% Triton and protease
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inhibitor cocktail-Roche) and centrifuged at 4°C to remove of the insoluble cell 
pellets. Polyacrylamide gel electrophoresis was carried out employing 10 pg of 
protein in each lane. Western blots were performed using primary antibodies 
mentioned above. A dilution of 1:1000 was used for the primary antibodies 
unless otherwise indicated in Section 2.1.4. Antibodies were incubated 
overnight at 4°C. They were detected using horseradish peroxidase-linked 
secondary antibody (a dilution of 1:2000 sheep anti-rabbit IgG) and visualized 
with an enhanced chemiluminescent (ECL) system (Amersham).
2.2.7 Cell viability
To test cell viability, cells were grown in 24-well plates after seeding 
approximately 15,000 cells per well. The cells were left to grow for at least 24 
hours before treatment with either 40 pg/ml Herceptin or 1 pM Iressa. For the 
Iressa experiments, a DMSO control (1:1000) was also performed. On the day 
of the experiment, the cells were trypsinised and diluted with PBS. The viable 
cells were counted in cell viability analyzer (Vi-cell ™ XR, Beckman Coulter) 
using Trypan Blue to stain the dead cells. The viable cells for each condition 
were compared with the control.
2.2.8 Xenograft experiments
MDAMB-453 (2.5-5xl06) and SKBR3 cells (5-10xl06 cells) both in 100 |il 
serum-free medium were bilaterally injected subcutaneously into the flanks of 
SCID mice (n=2 for each cell type). SKBR3 cells were not tumourigenic in 
SCID mice but xenograft tumours were successfully grown in the bilateral 
flanks of the two SCID mice using MDAMB-453 cells. These two mice were 
killed using C02 chamber after two months when the tumours grew to about 
lcm3. Only xenograft tumours from one mouse were used for tissue fixation 
experiments with either formalin (NBF) or liquid nitrogen.
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The largest tumour measuring 1.1 cm was cut into three parts. One part was 
fixed immediately with formalin (NBP), one was left in the pot for 1 hour at 
27° C before fixation with NBP, one was left in the pot for 1 hour at 4 0 C 
before fixation with NBP. The tumours fixed with formalin were processed 
and embedded into paraffin block before being sectioned and made into slides 
by the staff at the Experimental Pathology Department.
The second tumour measuring 0.8 cm was cut into two parts. One part was 
frozen within 15 minutes with liquid nitrogen and the other part was left in 
20% sucrose/PBS solution (cryopretection solution) for 24 hours before 
fixation with liquid nitrogen. To prevent damage to the tumour tissues from 
sudden freezing by liquid nitrogen, the following steps were used in 
Experimental Pathology Department. The tumours were first immersed in OCT 
solution (Section 2.1.7) contained in an aluminium foil mould. The mould 
containing tumour tissues and OCT was then submerged for 5-10 seconds in 
thawing isopentane when it was semi-liquid and having first frozen by liquid 
nitrogen. OCT would crack if the mould was submerged in isopentane for a 
significant amount of time (instead of 5-10 seconds). The frozen tumour 
tissues in OCT were transferred immediately to -  70 °C for storage or to 
cryostat at -  20 °C for sectioning.
2.2.9 Antigen retrieval
Antigen retrieval was applied to cells fixed with 4% PFA or paraffin- 
embedded xenograft tumour slides or tissue microarrays (TMA) to recover the 
buried epitopes. Before the antigen retrieval, tumour slides or TMAs were de­
waxed in Xylene and rehydrated through graded alcohols to water. For the 
cells fixed with 4% PFA, this additional step was not required. For antigen 
retrieval, 0.01M of citrate buffer (pH 6) was heated in an 800-watt microwave 
oven at full power for 4 minutes. The samples were then placed in the buffer 
and heated in the microwave for a further 4 minutes at full power. The citrate 
buffer was then topped up and microwave heated again for 4 minutes. The 
citrate solution and sections were then allowed to cool for 10 minutes before
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handling. For IHC anti-pHER2 staining and HER2 FRET experiment, the New 
England Biolabs’ protocol was used. This procedure is similar to the antigen 
retrieval process using citrate buffer, except that the tissue slides were brought 
to boiling in 1 mM EDTA pH8, followed by 15 minutes at a sub-boiling 
temperature.
2.2.10 Immunohistochemistry (IHC)
As discussed in the Introduction, the IHC scoring may vary depending on 
different laboratories and countries as well as the antibodies and the epitopes 
used. The scoring systems for TMAs in the histopathology department at the 
University of Oxford were previously validated by the department and they are 
based on either intensity or /and percentage of cell staining.
Intensity is scored as either 0 (negative staining); 1+ (weak intensity); 2+ 
(moderate intensity); or 3+ (strong intensity). Percentage of staining is scored 
as either 0 (negative staining); 1+ (1-10% staining); 2+ (11-50% staining); 3+ 
(51-80%) or 4+ (81-100%). These scoring systems are shown in the table 
below:
Scoring Intensity Percentage of staining
0 Negative staining Negative staining
1+ Weak intensity 1-10% staining
2+ Moderate intensity 11-50% staining
3+ Strong intensity 31-80% staining
4+ 81-100% staining
The score from intensity may be multiplied by the score from percentage of 
staining to give an overall score. The exact criteria may vary depending on 
antibodies used and may depend on the detected epitopes and tumours as well 
as locations of staining (membranous versus cytosolic versus nuclear).
For EGFR scoring reported in this study, F4 (anti-EGFR) antibody was used 
and intensity of the membranous staining (based on University of Oxford
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histopathology department as classified above) is used. For HER2 scoring, 
HercepTest (DAKO) using A0485 (anti-HER2) antibody was used to screen 
for HER2 positivity (2+ and 3+) in breast tumour arrays. The scoring system 
of HercepTest based on intensity of anti-HER2 staining is illustrated in 
Introduction.
5 pm sections of TMAs were dewaxed in Xylene and rehydrated through 
graded alcohols to water. High temperature antigen retrieval was performed in 
0.01 M citrate buffer pH 6 heated for 1 minute in a microwaveable pressure 
cooker. The sections were then cooled and washed in water. Following 
peroxidase block, sections were protein blocked for 15 minutes in 2.5% normal 
horse serum. The primary monoclonal antibody F4 (anti-EGFR) was incubated 
on the sections for 1 hour at room temperature with an antibody concentration 
of 10 pg/ml and then washed twice in PBS. The primary antibody was 
visualised using an HRP Vectorlabs Immpress Mouse Kit (Vector 
Laboratories, Burlingam, CA) and the sections were developed with 
diaminobenzidine (DAB). After washing in water, sections were mounted on 
cover slips with aqueous mounting medium.
2.2.11 FRET monitored by frequency- 
domain FLIM
FRET involves the transfer of energy from an excited donor molecule to a 
nearby (1-10 nm) spectrally overlapping acceptor. As discussed in the 
Introduction, various methods may be used to quantify FRET including FLIM 
used in this thesis. FRET can be quantified by measuring fluorescence lifetime 
of the donor, which is reduced as energy is non-radiatively transferred via a 
dipole-dipole interaction. Spatial aspects of fluorescence lifetime may be 
assessed by using FLIM (Larijani et al., 2003). In this thesis, the donor Cy3b 
lifetime variations were monitored in the frequency (phase) domain where the 
excitation light was sinusoidally modulated at 80.224 MHz to excite the 
sample. The emitted light oscillated at the same modulation frequency but with 
a phase shift and a decrease in amplitude (demodulation). Determining these
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two parameters permitted measurement of phase (xp) and modulation depth 
(Tm) of the fluorescence. The average lifetime, <T>, is the average of phase 
shift and relative modulation depth (xm + xp) / 2 of the emitted fluorescence 
signal. The efficiency of FRET can be mapped in a single cell by determining 
the excited state lifetime of the donor fluorophore at each pixel of the image. 
FRET efficiency is calculated as E = 1 -  [<Xd/a > /< X d > ]  x 100, where <Xd/a>  is 
the lifetime map of the donor in the presence of the acceptor, and <X d> is the 
average lifetime of the donor in the absence of the acceptor (Larijani et al., 
2003; Wu and Brand, 1994).
2.2.11.1 Frequency-domain FLIM system  and 
set-up
The single frequency-domain FLIM used in this thesis at the Cell Biophysics 
Laboratory, consisted of several key components connected to an inverted 
microscope (Carl Zeiss Ltd) mounted on a 2xlm optical table (Technical 
Manufacturing Corporation) (Figure 2.1). The key components were:
(a) Light source. The light source was from Argon/Krpton monochromatic 
laser (Innova Spectrum 70C, Coherent UK Ltd) which was tuneable to select 
an appropriate wavelength for the excitation (e.g. 488 nm for GFP and 514 nm 
for Cy3b).
(b) Standing-wave acousto-optic modulator (SW-AOM; Intra-Action 
Corporation). The light source was sinusoidally modulated with SW-AOM at a 
modulation frequency of 80 MHz. Since the FLIM used was a single frequency 
set-up, the modulation frequency of 80 MHz was not changed and the 
maximum sensitivity of lifetime it could detect is around 2 ns (explanation in 
Section 1.9.3.2). Therefore, it was optimal for GFP (488 nm) or Cy3b (514 
nm) since their lifetimes are around 2 ns in cells. The room temperature was 
kept close to 18° C to prevent thermal phase drift in AOM, which was essential 
for phase coherence between the fluorescent signal and the modulated gain of
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the detector. With the help of an array of mirrors, the modulated light source 
was directed to an iris diaphragm to selectively isolate the central (zero-order) 
beam from the higher-ordered diffracted beams. The modulated central light 
beam was further directed into a multi-mode fibre light scrambler (a 1.5-metre 
step index silica fibre, 1-mm core, numerical aperture 0.37; Technical video 
Ltd) that disrupted the coherence of the laser light by vibrating the fibres at 
frequencies of around 100 Hz. This resulted in a randomly moving speckled 
illumination of the specimen and was subsequently integrated during detection.
(c) Frequency synthesisers (2023 Marconi). The AOM was driven by a 
frequency synthesiser (slave) to a resonance frequency of about 40.112 MHz 
and this produced the intensity oscillations in the laser light beam at 80.224 
MHz (twice the driving frequency). The master frequency synthesiser driving 
the micro-channel plate (MCP) and the image intensifier head was set at 
80.224 MHz which was the value that exactly double that driving the AOM 
(40.112 MHz).
(d) Phase-sensitive detection system. The resulting fluorescence was separated 
using a combination of dichroic beam splitter (Q565 LP; CHROMA 
technology Corp.) and narrow band emitter filter (BP 610/75; Delta Lys and 
Optik). The fluorescence was imaged onto the photocathode of the image 
intensifier head (Hamamatsu C5825) which then focused the photoelectrons 
ejected from the photocathode onto the face of a MCP. An intensified light 
image was generated when the electron image at the output of the MCP hit the 
phosphor screen. The effective gain of the image intensifier was modulated at 
a frequency equal to that of the SW-AOM (80 MHz) for homodyne detection. 
The outputs from the two synthesisers were used to provide sinusoidal voltages 
sources for modulating both the excitation laser light via the SW-AOM and the 
gain of the image intensifier unit. The amplified image was then projected 
from the phosphor screen of the MCP onto the chip of a charged-coupled 
device (CCD) camera (Quantix, Photometries). Two-by-two binning for cell 
experiments and three-by-three binning for tumour arrays were typically set as 
the readout of the CCD. The gain was adjusted according to the fluorescence 
intensity of the sample and it was usually set either two or three.
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(e) Other components. 100-W Mercury arc lamp (Carl Zeiss Ltd) was used as a 
source of illumination for acceptor fluorophores and to bleach the acceptors as 
required. A variable density filter wheel was used to select the intensity of the 
excitation light.
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Figure 2.1: Simplified schematic diagram of frequency-domain FLIM 
at the Cell Biophysics Lab.
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2.2.11.2 Im age acquisition and d a ta  analysis
All images (a cycle of 16 phase-dependent images) were taken using a Zeiss 
Plan-APOCHROMAT x 100/1.4 NA phase 3-oil objective for cell experiments 
and using x 10/0.5 NA phase 1 objective for TMAs experiments. Before 
proceeding to obtain the lifetimes of donor Cy3b, a reference image (a cycle of 
16 phase-dependent images, each separated by 22.5°C) using a scattering foil 
was first obtained. Before taking images of the foil, the intensity of the 514 nm 
laser line was reduced to minimum using the variable density filter wheel. The 
reference measurement taken with this scattering foil was used to determine 
the phase setting at which the maximum intensity was reached in the image 
series. This was used to calibrate the phase of the master frequency synthesizer 
that must be set at a maximum in order to acquire a phase-dependent FLIM 
data. The phase value was set to zero degree on the master frequency 
synthesizer and another cycle of 16 phase images from the foil was taken and 
saved as a zero lifetime reference. This procedure was repeated every hour to 
ensure that the phase of the master frequency synthesizer remained at zero 
during the experiments. The reference measurement from foil also revealed a 
modulation value, indicating the modulation of the excitation laser source. The 
modulation value was approx 0.50 for the experiments done in this thesis. In 
addition, an arbitrary value of intensity (which is saturated at a value of 4095 
counts) may be obtained with the scattering foil. If the intensity of the 
scattering foil was low (less than 1000 counts) or the modulation value was not 
near 0.50, it was due to the misalignment of the laser. The FLIM therefore 
needed to be optimised and aligned using the scattering foil before performing 
any experiments. In addition, when the wavelength of the tunable laser source 
was changed (between 488 nm and 514 nm), it was also essential to check that 
the laser alignment by assessing the modulation and intensity values of the 
scattering foil.
To obtain the lifetimes of donor Cy3b in cells or tumour cores, the intensity 
of the excitation light was restored to a maximum using the variable density 
filter wheel and the Cy3 filter set (excitation, HQ 545/30 band pass filter,
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dichroic mirror, Q565 long pass; emission, HQ610/751 band pass filter; 
Chroma) was moved into excitation path. Two contiguous series of 16 phase- 
dependent images (one forward and one reverse cycle, 45 degree phase- 
stepped) and a background image from the samples were taken. The exposure 
time of the acquisition was chosen depending on the fluorescence intensity and 
may vary from 50 to 1000 ms. To acquire acceptor images, the laser source 
was switched to 100-W mercury arc lamp using a rotating mirror and the Cy5 
filter set (excitation, HQ620/60 band pass filter; dichroic mirror, Q660 long 
pass; emission, HQ 700/75 band pass filter; Chroma) was set in the detection 
path.
Using these images from acquisition and the zero lifetime reference from the 
foil, the donor lifetimes (phase xp and modulation xm parameters) were 
obtained using IPLab Spectrum software (version 3.1.2c Scanalytics, Inc.) 
based on Fourier transformation. An average of the lifetime phase and 
modulation is calculated for each pixel ([xp + xm]/2) although these 
independent parameters cannot be averaged if the Tp and xm do not have close 
values (Alcor D, 2007). To help visualization, the average lifetime map may be 
represented with pseudo-colour scale (higher lifetimes in blue and shorter 
lifetimes in red). However, since the pseudo-colour scale may differ for each 
set of experiments, it is essential to consider the values of the lifetimes in each 
experiment. Previously, the determination of the correct thresholding and the 
average lifetime map was done by the operator manually. In collaboration with 
Pierre Leboucher at College de France, an automatic analysis of the data was 
implemented, resulting in an increased speed in the non-biased data analysis 
and improved reproducibility of the results (Alcor D, 2007).
2.2.11.3 Choice of fluorophores and conjugation 
of fluorophores to  antibodies
As discussed in the Introduction, FRET efficiency depends on several 
parameters including the quantum yield of fluorescence of the donor and the 
overlap between the emission spectra of the donor and the absorption spectra
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of the acceptor (Section 1.9.2). Therefore, a suitable pair of donor and acceptor 
fluorophores needed to be chosen for FRET experiments. The FLIM 
instrument used in Cell Biophysics Lab uses a modulation frequency of 80 
MHz and the maximum sensitivity of lifetime to be detected is around 2 ns 
(explanation Section 1.9.3.2). Cy3b was chosen as a donor fluorophore 
because of its near 2 ns lifetime as well as being a fluorophore that has high 
quantum yield (source from GE healthcare, formerly Amersham). Cy5 was 
chosen as the appropriate acceptor for Cy3b since the emission spectrum of 
Cy3b overlaps with the absorption spectrum of Cy5, which makes FRET 
possible between the pair. Both Cy3b and Cy5 have good photo-stability and 
therefore they are a suitable pair of fluorophores for FRET experiments.
F4 (anti-EGFR or anti-ErbB-1), anti-HER2 (anti-ErbB-2) and anti-HER4 
(ErbB-4) were conjugated to Cy3b (donor fluorophore) and FB2 (anti- 
phosphotyrosine), anti-phospho-HER2 and pTyr-100 (anti-phosphotyrosine) 
were conjugated to Cy5 (acceptor fluorophore). The resulting pairs of F4-Cy3b 
/ FB2-Cy5, HER2-Cy3b / pHER2-Cy5, HER4-Cy3b / pTyr-Cy5 were used to 
assess EGFR and HER2 phosphorylation as well as HER4 proteolytic cleavage 
respectively. 100 j l l I  of N, N-Dimethylformamide (DMF) was added to 1 mg 
Cy3b to make a 10 mg/ml stock solution (15 mM). The stock 10 mg/ml Cy3b 
was diluted in DMF 10 fold to 1 mg/ml (1.5 mM). 50 pi of Cy3b / DMF from 
a stock of 1 mg/ml was added drop by drop into 450 pi anti HER receptor 
antibody / 50 pi Bicine (1M, pH 8) with continuous stirring. The final 
concentration of conjugated anti-HER receptor antibodies with Cy3b was 
approximately 100 pg/ml (150 pM). The solution was stirred in the dark for 2 
hours. To conjugate FB2, anti-HER2 and anti-pTyr-100 with Cy5, 20 pi of 
DMF was added to a Cy5 vial. Cy5 dye in DMF was then added drop by drop 
to 450 pi antibodies (FB2, anti-HER2 and anti-pTyr-100) / 50 pi Bicine (1M, 
pH 8) while stirring. The solution was stirred in the dark for 2 hours. The 
conjugated antibodies were separated from free dyes by column 
chromatography (desalting column, Bio-Rad). The matrix of the column 
excluded solutes greater than 6000 Daltons (i.e. conjugated antibodies with 
Cye dyes) and retained the smaller contaminants (free dyes). The column was 
first washed and equilibrated with 3 x 5 ml PBS before the loading. The
94
labelled antibody and unconjugated Cy3 were eluted with PBS. The labelled 
antibody was collected and the dye/protein ratio was measured by UV/visible 
spectroscopy: detection of the antibodies’ concentrations at 280 nm; F4-Cy3b, 
HER2-Cy3b and HER4-Cy3b at 561 nm; and FB2-Cy5, pHER2-Cy5 and 
pTyr-Cy5 at 650 nm wavelength. An example is given in Figure 2.2. The D/P 
ratios (aiming for 1-2) were calculated using the protocols provided by GE 
Healthcare (formerly Amersham Biosciences) for Cy™3B and Cy5 mono­
reactive dyes:
D/P = [(Absorption Amax) x (Antibody Extinction Coefficient)] / [(A2 8 0  -  
correction factor x Amax) x (Cy Dye Extinction Coefficient)]
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Figure 2.2: Dye/protein ratios (D/P) of F4-Cy3b and FB2-Cy5 were determined by UV spectroscopy.
50ul of F4-Cy3b was put in a cuvette and the absorbance of F4 was determined at 280 nm wavelength, and Cy3b 
at 561 nm by the UV spectroscopy. For FB2-Cy5,the absorbance of FB2 was determined at 280 nm and that of Cy5 
at 650 nm by the UV spectroscopy. PBS solution was used as "blank" before measuring D/P ratios of F4-Cy3b and 
FB2-Cy5.The D/P ratios were then calculated by the formulas supplied by GE Healthcare (see text for details).
2.2.11.4 In-sltu FRET experim ents
Cells were grown in 24-well plates with cover slips after seeding 
approximately 15,000 cells per well for A431 cells and 30,000 cells per well 
for breast cell lines (SKBR3, MCF-7 and MDAMB-453). The cells were left to 
grow for at least 24 hours before treated with drugs, 3 pM AG 1478, 1 pM 
Iressa and 40 pg/ml Herceptin (unless indicated, otherwise this will be the 
doses used for these drugs). For growth factor experiments, the cells were 
treated with 50 ng/ml EGF, 100 ng/ml heregulin p and 100 ng/ml heregulin-pi 
for 10 minutes following serum starvation of 16 hours. Following stimulation, 
the cells were fixed with 4% PFA at room temp for 10 minutes. 500 pi of 0.2 
% (v/v) Triton X-100 was added in the well for 5 minutes to make the cell 
membrane permeable. This is followed by incubation with 1 mg/ml fresh 
sodium borohydrate in PBS for 10 minutes to quench the background 
fluorescence. The cells were then blocked with 1% w/v BSA in PBS for 1 
hour. The cells were incubated and labelled with conjugated donor antibodies 
(e.g. F4-Cy3b, HER2-Cy3b or HER4-Cy3b) for 2 hours. For cells that required 
detection with the acceptor fluorophores, further incubation with conjugated 
acceptor antibodies (e.g. FB2-Cy5, pHER2-Cy5 or pTyr-Cy5) was done for 2- 
4 hours. The cover slips were mounted on the slide with Mowiol mounting 
medium containing 2.5% (w/v) 1,4-diazabicyclo (2.2.2) octane as an anti-fade. 
The slides were left at 37°C incubator for 1 hour and then left at room 
temperature overnight prior to image acquisition.
For phosphatase experiments, the protein tyrosine phosphatase from Yersinia 
enterocolitica (YOP), 50 units of phosphatase in 50 pi reaction buffer (50mM 
Tris-HCL, pH 7.2, 150 mM NaCl, 5mM DTT, 2.5 Mm Na2 EDTA, and 100 
pg/ml BSA as recommended by Calbiochem) was used for each coverslip on 
the laboratory film (Parafilm “M”) after fixing with 4% PFA. The rest of the 
procedures are the same as above.
2.2.11.5 FRET Data Interpretation and 
S tatistical analysis
For FRET experiment, at least three to five measurements of lifetimes from 
single cell(s) were obtained from each condition and the results were 
represented in either two-dimensional (2-D) histograms or scatter diagrams.
Two-dimensional histograms
The two-dimensional histograms showed both the phase (tp) and modulation 
(Tm) measurements for lifetimes for all recorded pixels and they quantified the 
reduction of the phase and modulation lifetimes of donor Cy3b when there was 
FRET. The error bars represent the standard deviations from all the 
measurements (n > 3 or 5).
Scatter diagrams of average lifetimes of donor
An average lifetime was obtained from the average of phase and modulation 
components of the lifetimes and the distribution of average lifetimes of donor 
fluorophore (e.g. EGFR-Cy3b) from each condition was shown as scatter 
diagrams. The basal condition was defined as the basal phosphorylation of the 
HER receptor, indicated by the decrease of lifetime of the donor in the 
presence of the acceptor without growth factor stimulation or drug treatment. 
The basal phosphorylation was due to autocrine ligand release of the cancer 
cells (Van de Vijver et al., 1991). The enhanced decrease in the average 
lifetime indicated further phosphorylation of the receptor due to its 
dimerisation with its partners. The medians of these measurements were 
displayed in the scatter diagram. Mann-Witney test was used to compare the 
medians of the average lifetimes between the basal condition and those 
stimulated with ligands or treated with drugs.
2.2.11.6 FRET experim ent for tissu e  
m icroarrays (TMAs)
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To label the tumour arrays with conjugated donor antibodies (F4-Cy3b, 
HER2-Cy3b), the arrays were immersed with 0.2 % (v/v) Triton X-100 for 5 
minutes to permeabilise the membrane. This was followed by incubation with 
1 mg/ml fresh sodium borohydrate / PBS for 10 minutes to quench background 
fluorescence. 1 % w/v BSA in PBS was used for blocking. The tumour arrays 
were incubated with the donor (either F4-Cy3b or HER2-Cy3b) for 2 hours 
and the acceptor (either FB2-Cy5 or pHER2-Cy5) for 2 hours. The arrays were 
then mounted on a glass cover with Mowiol mounting medium containing 
2.5% (w/v) 1,4-diazabicyclo (2.2.2) octane.
Automation of frequency-domain FLIM and high throughput processing 
for TMAs
The advantage of frequency-domain FLIM is its speed in acquiring images 
compared to time-domain FLIM. The frequency-domain FLIM was 
programmed by our consultant engineer Pierre Leboucher (College de France, 
Paris) and my primary supervisor Banafshe Larijani to process the TMAs and 
to analyse the data in a high throughput manner. This was achieved by writing 
a special script (“APierre”) in the computer so that the motorized stage driver 
unit (x,y,z) which controlled the stage of the inverted microscope would be 
automated. Before processing the tumour arrays, the tumour cores were first 
mapped in IPLab Spectrum (Signal Analytics). The stage was first initialized 
and the first cell (in this case, first tumour core) was selected. The motorized 
stage driver unit needed to be set at zero value for this first cell by pressing 
“perform stage” on this first cell. The other tumour cores could then be 
mapped and the mapping of the tumour cores on the slide was named and 
saved in the slide mapping file. Following the mapping of the tumour cores, 
the processing of the tumour array was done automatically by “APierre” script 
after selecting the saved file. To analyse the data automatically, a copy of the 
foil from the experiment was saved in the desktop of the computer. The file
(containing the list of data to be analysed) in IPLab was first opened. The data
«
to be analysed was put in the same named folder and the data was analysed 
under “script automation 01.00” by pressing “run script”. This automation of 
the data analysis listed all the parameters of lifetimes (phase, modulation and 
average) and the intensity of the donor fluorophore as well as number of pixels
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and bad data analysed in an excel sheet which could then be exported into 
other files.
The automation of frequency-domain FLIM is essential if the FRET 
methodology is going to be applied for wide clinical use for. The first proof of 
principle for the automated high throughput FLIM was done in HNSCC 
tumour arrays described in chapter 3. However, the automation of FLIM as 
well as the analysis of the data at cell biophysics Lab are continuously being 
improved and upgraded by Pierre Leboucher and Banafshe Larijani.
HNSCC tumour arrays
HNSCC tumour arrays were labelled with donor F4-Cy3b and acceptor FB2- 
Cy5 to assess EGFR phosphorylation of the tumour cores. Using the 
automated FLIM system, each tumour core was mapped according to the 
position on the arrays. All images (a cycle of 16 phase-dependent images) of 
the tumour cores were taken using a Zeiss Plan-APOCHROMAT xlO / 0.5 NA 
phase 1. The readout of the CCD was set for three-by-three binning and the 
gain was set at two. Images from each tumour core were acquired 
automatically from the arrays according to their positioning. The phase, 
modulation and average lifetimes of each tumour core were calculated 
automatically and the average FRET efficiency for each tumour core was 
obtained. Average FRET efficiency for each tumour core was correlated with 
survival data. A pilot study was first carried out to assess the first set of arrays 
with the automated system. To validate the pilot study, a new set of arrays 
were prepared with new antibodies and fluorophores and the arrays were 
processed with automated FLIM. In the validation study, the system was 
programmed to run two loops so that two lifetime measurements were taken 
from each tumour core (n = 2, i.e. 574 tumour cores in total). However, in any 
one array a patient would have a duplicate sample, so for each patient the final 
lifetime represents an average of four measurements. In total 1114 tumour core 
recordings were made and analysed in the validation study.
To obtain the EGFR status by FLIM, the donor intensity was calculated. For 
each tumour core, images were acquired and an intensity distribution 
histogram was plotted using Matlab version 7 and the median of the intensity 
distribution was calculated by Matlab 7. This median was normalised to the
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background intensity. The average of two median intensity values from the 
two tumour cores of the same patient was used in each array. Thereafter these 
values were used to correlate with immunohistochemistry stains and average 
FRET efficiency.
Breast tumour arrays
The breast tumour arrays were labelled with donor HER2-Cy3b and pHER2- 
Cy5 to assess HER2 phosphorylation of the tumour cores. The tumour cores 
were mapped and processed automatically like HNSCC tumour arrays. In 
HNSCC tumour arrays the signal-to-noise ratio was not a problem when 
assessing EGFR phosphorylation in these tumour cores since almost all 
HNSCC tumours contain high EGFR. The problem only arrived when a 
particular tumour core contained very little tumour tissue or contained mostly 
stromal tissue. In breast cancer, less than a third of the breast tumours over­
express HER2. Assessing HER2 phosphorylation was a problem for some of 
the breast tumour cores with low HER2 expression and for tumour cores with 
very little tumour tissues since inadequate signal-to-noise ratio was reached for 
some of the tumour cores. These specific problems were encountered and the 
details are described in Chapter 5.
Statistical analysis for TMAs
Disease-free Survival (DFS) is defined as the length of time after treatment 
during which no cancer is found and overall survival (OS) is a defined period 
of time that the subjects in a study have survived since diagnosis or treatment. 
All statistical analyses were done using Graphpad Prisms 3cx (Macintosh 
Version) except the univariate and multivariate analysis for prognostic factors 
which were done using ‘R’ (see below). The Kaplan-Meier survival curves 
were used to compare between the groups and a log-rank test was used to 
assess the hazard ratios. For the univariate and multivariate analysis of the 
prognostic factors, the data was analysed by fitting cox proportional hazard 
models to the data, using top 10% FRET efficiency as the group indicator with 
a common baseline hazard function, and including immunohistochemistry, 
UICC tumour stage, grade, necrosis, age and sex variously as covariates. To 
fit the models, the 'coxph' function was used from the 'survival' package within
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R. R is a language and environment for statistical computing and is available 
as Free Software under the terms of the Free Software Foundation's GNU 
General Public License in source code form.
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3 A ssess in g  EGFR activation and 
phosphorylation s ta te  in c e lls  and 
head and neck  tumour arrays
3.1 Introduction
As discussed in the Introduction, the current methods of measuring EGFR 
levels including immunohistochemistry (IHC) cannot be unequivocally 
endorsed as predictive of patient prognosis or response to treatment (Arteaga, 
2002). Therefore there is a need for a quantitative method to be set up to 
measure EGFR and its activation status. To achieve this, Forster Resonance 
Energy Transfer (FRET) monitored by Fluorescence Lifetime Imaging 
Microscopy (FLIM) was exploited as a reporter for EGFR (ErbBl or HER1) 
phosphorylation and as a molecular prognostic tool to identify HNSCC 
patients who show over-expression and/or phosphorylation of the EGFR. To 
establish an assay to assess EGFR phosphorylation, a suitable pair of donor 
(Cy3b) and acceptor fluorophores (Cy5) were conjugated to F4 (anti-EGFR 
cytoplasmic domain antibody) and to FB2 (anti-phosphotyrosine antibody) 
respectively to monitor FRET between the fluorophores detected by FLIM 
upon EGF stimulation. The main aim was to establish a FRET method to 
evaluate EGFR phosphorylation in cell lines, which was applicable to paraffin 
sections. The assay was tested in a few cell lines and a series of optimisations 
were done to ensure that the assay was robust. The results presented in this 
chapter illustrate that the FRET associated with the co-incident binding of the 
labelled monoclonals was specific. These established reagents have been 
applied to head and neck tumour arrays using a high throughput automated 
FLIM. Using this highly selective FRET assay in tumour arrays, increased 
FRET efficiency (indicating high levels of EGFR phosphorylation) was shown 
to correlate with disease recurrence and prognosis of the patients. The EGFR
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status determined by IHC or by average fluorescence intensity was also 
correlated with EGFR activation by FRET.
3.2 Results
3.2.1 Establishment of an assay to 
a sse ss  EGFR phosphorylation by FRET in 
cell lines
To develop a phosphorylation state readout with suitable specificity for the 
EGFR, it was hypothesised that following EGFR activation FRET would be 
detectable in fixed cell samples between F4-Cy3b (a monoclonal to the 
cytoplasmic domain of the receptor linked to a donor fluorophore, Cy3b) and 
FB2-Cy5 (an EGFR autophosphorylation site monoclonal linked to an acceptor 
fluorophore, Cy5). A431 cells were chosen as the test cell line to validate the 
assay, because of its high EGF receptor expression and its extensive use for 
nearly 20 years in the analysis of EGFR function. Initially, the specificity of 
the antibodies F4 and FB2 was tested through western blot of A431 cell lysates 
(Figure 3.1 A). The receptor is specifically detected by the F4 monoclonal, 
while FB2 recognises both the phosphorylated receptor and two pairs of faster 
migrating (phospho-) proteins. The degree of immuno-recognition of the 
receptor by FB2 specifically increased in response to EGF as expected for this 
phosphotyrosine site-directed monoclonal. Importantly, this immunoreactivity 
was reduced in a dose-dependent manner by the selective EGFR tyrosine 
kinase inhibitor AG 1478. It should be noted that in these cells there is basal 
EGFR phosphorylation consistent with prior data indicating a degree of 
autocrine receptor activation (Van de Vijver et al., 1991). Moreover, the 
additional recognition of faster migrating protein species by the FB2 
monoclonal does not interfere with the two-site FRET assay reported here, 
since the specificity of the analysis is determined by F4 (this is an important 
feature of the two-site IHC assay) (Figure 3.1 A).
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Fixed A431 cells were employed to test whether in an IHC format, the 
coincident binding of F4-Cy3b and FB2-Cy5 to phosphorylated EGFR 
produced a specific FRET signal. Cells were treated with or without EGF, 
fixed and processed (see Methods Section 2.2.11.4). Employing this assay, it 
was found that following EGF stimulation there is a marked increase in FRET 
as illustrated in Figure 3. IB. This is a specific property of the coincident 
binding of the two fluorescently labelled antibodies, since the lifetime change 
observed for the donor fluorophore following EGF treatment, is not observed if 
the antibody-acceptor conjugate is omitted. In the absence of the EGF stimulus 
there is a reduced degree of FRET, but with lifetimes for the donor in the 
presence of the acceptor below those observed for donor alone (Figure 3. IB).
To determine whether the EGF-induced increase in FRET reflected an 
increase in immuno-recognition of tyrosine phosphorylated receptor by the 
FB2 antibody-acceptor conjugate, cells were pre-treated with AG 1478. At 
effective doses of this EGFR inhibitor (1.5 and 3.0 jiM -  Figure 3.1 A), FRET 
was reduced to the basal unstimulated level. Pre-treating the cells with AG 
1478 did not reverse the basal degree of FRET. An example of donor Cy3b 
intensity images and their corresponding average lifetime maps from the same 
FRET experiment are illustrated in Fig. 3.2A. The average lifetime of F4-Cy3b 
in these studies decreased from 1.63 ns to 1.50 ns when the acceptor FB2-Cy5 
was present and decreased further to 1.38 ns upon EGF stimulation. The 
changes in lifetime induced by EGF are localised mainly at the plasma 
membrane as seen from the pseudocolour changes of the lifetime map. This is 
entirely consistent with the expected increase in tyrosine phosphorylated 
receptor at the cell surface following a ten-minute stimulation with EGF. 
Concentrations of 1.5 |xM and 3 |iM of AG 1478 reversed the donor lifetime to 
1.49 ns. The 2-D histograms representing the phase lifetime and modulation 
can also be represented as average lifetime (the average of phase and 
modulation lifetimes) in the scatter diagram (See Methods Section 2.2.11.5, 
Figure 3.2B, Table 3.1 A). This type of representation although it loses the 
information on the individual components of phase and modulation lifetimes, it 
can be particularly useful in assessing the response of targeted therapy since 
heterogeneity in terms of responses between cells may be seen. Dose
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dependence studies in A431 cells showed that at lower concentrations (0.3 JIM 
and 0.6 pM) FRET was not reversed (Table 3. IB), correlating with the western 
blot results shown in Figure 3.1 A. With higher doses of AG 1478, the lifetimes 
and average FRET efficiency values were reversed to basal levels.
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Figure 3.1: EGF induced phosphorylation of the EGFR is prevented by AG 
1478 and its activation is monitored by FRET. A, A431 cells were stimulated with 
50 ng/ml of EGF for 10 minutes. Cell lysates were probed with F4 (antibody against the 
cytoplasmic domain of EGFR) and FB2 (EGFR autophosphorylation site monoclonal). 
The 170 kDa F4 immunoreactive band (EGFR) co-migrates with the major signal from 
FB2 (arrow). Cells were pre-treated with increasing doses of AG 1478 as indicated and 
then stimulated with EGF. B, The 2-D histogram of phase and modulation lifetimes of 
F4-Cy3b. A431 cells were incubated with either donor alone (F4-Cy3b) or donor and 
acceptor (F4-Cy3b+FB2-Cy5) to assess EGFR phosphorylation after pre-treated with AG 
1478 with or without EGF stimulation as illustrated. The error bars represent the stan­
dard deviations of 5 measurements.
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Figure 3.2: The lifetime maps and 2-D histograms representing data of 
Figure 3.1 B. A, The diagrams show an average lifetime for F4-Cy3b of 1.63 ns.The 
average lifetime remains the same in the presence of EGF but decreases with the 
acceptor (FB2-Cy5).The decrease in average lifetime to 1.38 ns is most noticeable at 
the plasma membrane, as seen from the colour changes of the lifetime map. In the 
presence of AG 1478 (1.5 pM and 3 pM),the average lifetime returns to a higher lifetime 
of 1.49 ns. B, The 2-D histogram representing the phase and modulation lifetimes 
shown in Figure 3.1 B can also be represented as average lifetimes (the average of 
phase and modulation lifetimes) in the scatter diagram.
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A
A431 cells 
Conditions 
(n=5)
Phase (ns) Mod (ns) Ave (ns) Ave FRET 
efficiency %
F4-Cy3b 1.61 ns ± 
0 . 0 1
1.65 ns ± 
0 . 0 1
1.63 ns ± 
0 . 0 1
0 . 0 0  ± 0 . 0 0
EGF + F4-Cy3b 1.59 ns ± 
0 . 0 2
1.65 ns ± 
0 . 0 2
1.62 ns ± 
0 . 0 2
0 . 0 0  ± 2 . 0 0
F4-Cy3b + 
FB2-Cy5
1.47 ns ± 
0.03
1.53 ns ± 
0 . 0 2
1.50 ns ± 
0 . 0 2
7.79 ± 0.51
EGF+F4-
Cy3b+FB2-Cy5
1.30 ns ± 
0.05
1.46 ns ± 
0.04
1.38 ns ± 
0.04
15.11 ±2.10
AG 1.5 \iM 1.45 ns ± 
0.04
1.53 ns ± 
0 . 0 2
1.49 ns ± 
0.04
8.39 ± 2.50
AG 3.0 1.46 ns ± 
0.03
1.53 ns ± 
0.03
1.50 ns ± 
0 . 0 2
7.96 ± 1.96
B
A431 cells 
Conditions (n=3)
Phase (ns) Mod (ns) Ave (ns) Ave FRET 
efficiency %
F4-Cy3b 1.66 ±0.015 1.74 ±0.032 1.70 ±0.02 0 . 0 0  ± 0 . 0 0
EGF+F4-Cy3b 1.67 ±0.015 1.72 ±0.021 1.70 ±0.02 0 . 0 0  ± 0 . 6 8
F4-Cy3b+FB2-Cy5 1.63 ±0.006 1.67 ±0.032 1.65 ±0.02 2.93 ± 1.62
EGF+F4-
Cy3b+FB2-Cy5
1.41 ±0.006 1.54 ±0.036 1.48 ±0.02 12.96 ±0.76
AG 0.3 jiM 2 hours 1.44 ±0.020 1.49 ±0.061 1.47 ±0.04 13.65 ± 1.99
AG 0.6 jaM 2 hours 1.48 ±0.020 1.55 ±0.026 1.52 ±0.01 10.69 ± 1.76
AG 1.5 |*M 2 hours 1.56 ±0.023 1.64 ±0.021 1.60 ± 0 . 0 2 5.87 ±2.44
AG 3 fiM 2 hours 1.55 ±0.010 1.59 ±0.044 1.58 ±0.01 6.48 ±1.55
AG 9 fiM 2 hours 1.59 ±0.006 1.65 ±0.053 1.62 ± 0 . 0 1 4.42 ± 1.32
Table 3.1: A, The phase, modulation and average lifetimes of F4-Cy3b in 
different conditions, same experiment as Figure 3.1B. The values in the table 
represent the average of 5 measurements per condition. B, Lifetimes and FRET 
efficiency values of F4-Cy3b in A431 cells in a dose-dependent study of AG 1478.
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To verify that the signal was indeed due to phospho-tyrosine recognition, the 
protein tyrosine phosphatase from Yersinia enterocolitica (YOP) was 
employed. Pretreatment with YOP abolished both the basal and EGF-induced 
FRET (Figure 3.3A and 3.3B). This suggests that FRET between F4-Cy3b and 
FB2-Cy5 in the basal state is not be due to the direct auto-activation of the 
EGFR receptor (AG 1478 sensitive), but is probably mediated by hetero- 
dimerisation with other activated epidermal growth factor receptors or by other 
receptor-associated proteins, which are not inhibited by AG 1478. The 
observed ligand-induced FRET, the inhibitor dependent reduction of FRET 
and the defined plasma membrane response, coupled with the specificity of the 
F4 monoclonal antibody, establishes the use of the F4-FB2 antibody pair to 
monitor EGFR expression (F4 immuno-reaction) and EGFR activation (F4- 
FB2 co-incident immunorecognition).
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B
A431 cells 
Conditions (n=10)
Phase
lifetime (ns)
Modulation 
lifetime (ns)
Average
lifetime
(ns)
Average
FRET
efficiency
F4-Cy3b 2 . 0 2  ± 0.026 2.06 ± 0 . 0 1 1 2.04 ± 0.02 0 . 0 0  ± 0 . 0 0
EGF+F4-Cy3b 2.06 ±0.031 2.04 ±0.037 2.05 ± 0.01 0 . 0 0  ± 0 . 0 0
F4-Cy3b+FB2-Cy5 1.93 ±0.055 1.95 ±0.062 1.94 ±0.04 5.03 ±2.27
EGF+F4-
Cy3b+FB2-Cy5
1.79 ± 0.047 1.90 ±0.062 1.85 ±0.03 9.64 ± 1.53
Y OP+F4- 
Cy3b+FB2-Cy5
2.08 ± 0.081 2.02 ± 0.052 2.05 ± 0.02 0.00 ±0.74
YOP+EGF+F4-
Cy3b+FB2-Cy5
2.07 ± 0.087 1.99 ±0.069 2.03 ± 0.03 0.00 ±1.64
Figure 3.3: Treatment with protein tyrosine phosphatase from Yersinia 
enterocolitica (YOP) diminishes both the basal and EGF induced EGFR 
phosphorylation in A431 cells. A, The 2-D histogram of phase and modula­
tion lifetimes of F4-Cy3b in A431 cells after the cells were treated with different 
conditions as illustrated. The diagram shows that YOP reverses the lifetime 
changes of F4-Cy3b in the presence of the acceptor FB2-Cy5 (with or without 
EGF stimulation) to that of control F4-Cy3b. B, The changes in EGFR phos­
phorylation indicated by FRET efficiency and lifetimes of F4-Cy3b 
(representing the data in Figure 3.3A are shown in the table.
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3.2.1.1 A ssessm ent of EGFR phosphory-lation
in the  MDMAB-231 b reast cell line
Since A431 cell line over-expresses EGFR it may not be representative of 
other cell lines which have less EGFR receptors. It was decided to assess 
EGFR phosphorylation by FRET in the breast cell line MDAMB-231 cells 
which have around 70000 EGF binding sites per cell (Davidson et al., 1987) 
compared to greater than a million EGF binding sites in that of A431 cells. The 
2-D histogram of phase and modulation lifetimes of F4-Cy3b in MDAMB-231 
cells shows that the lifetimes of F4-Cy3b alone do not change in the presence 
of growth factor EGF (Figure 3.4A). However, the lifetimes decrease (diagonal 
decrease) in the presence of acceptor (FB2-Cy5) even without EGF. The 
lifetimes decrease further in the presence of EGF but with AG 1478 at 1.5 pM 
and 3 |iM the lifetimes of Cy3b return to basal level. The values of the 
lifetimes and FRET efficiency are illustrated in Figure 3.4B. The results are 
similar to those seen in A431 cells although the basal and EGF induced 
phosphorylation as indicated by FRET efficiencies are slightly less than A431 
cells which have higher levels of EGFR. The experiments indicate that FRET 
to assess EGFR phosphorylation state may be applied in various cell lines with 
different amounts of EGFR.
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L ife tim es o f F4-C y3b in MDAMB-231 ce lls
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B
MDAMB 231 
Conditions (n=5)
Phase
lifetime (ns)
Modulation 
lifetime (ns)
Average 
lifetime (ns)
Average
FRET
efficiency
F4-Cy3b 1.48 ± 0 .0 4 1.67 ± 0 .0 2 1.57 ± 0 .03 0.00 ±  0.00
EGF+F4-Cy3b 1.51 ± 0 .0 6 1.69 ± 0 .0 5 1.60 ± 0 .0 4 0.00 ± 2.00
F4-Cy3b+FB2-Cy5 1.46 ± 0 .0 4 1.61 ± 0 .03 1.54 ± 0 .03 2.35 ± 1.75
EG F+F4-
Cy3b+FB2-Cy5
1.39 ± 0 .05 1.54 ± 0 .0 6 1.46 ± 0 .0 5 6.91 ± 3 .3 7
AG 1.5 2 hours 1.46 ± 0 .03 1.61 ± 0 .0 5 1.53 ± 0 .03 2.51 ± 3 .0 5
AG 3 2 hours 1.42 ± 0 .0 7 1.64 ± 0 .0 7 1.53 ± 0 .0 6 2.88 ± 4 .81
Figure 3.4: AG 1478 diminishes EGF induced EGFR phosphorylation in 
MDAMB-231 cells. A, The 2-D histogram of phase and modulation lifetimes of 
F4-Cy3b in MDAMB-231 cells after the cells were treated with different conditions 
as illustrated and incubated with either donor alone F4-Cy3b or donor and accep­
tor (F4-Cy3b+FB2-Cy5) to assess EGFR phosphorylation. B, The changes in 
EGFR phosphorylation indicated by FRET efficiency and lifetimes of F4-Cy3b 
(representing the data in Figure 3.4A) are shown in the table.
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3.2.1.2 Optimising the  use of F4-Cy3b in A431 
cells
A serial dilution of donor F4-Cy3b was performed in A431 cells to assess its 
dynamic range. This control experiment aimed to establish the optimum 
concentration of donor F4-Cy3b relative to the acceptor FB2-Cy5 to assess 
EGFR phosphorylation state by FRET. F4-Cy3b was diluted by factors of 1/5, 
1/10 and 1/50 while the concentration of acceptor FB2-Cy5 remained constant. 
Table 3.2A shows the individual components of lifetimes (phase and 
modulation) as well as average lifetimes of donor F4-Cy3b with or without 
acceptor in a serial dilution. Table 3.2B shows the calculated FRET 
efficiencies based on the average lifetimes of donor alone and donor and 
acceptor (see Methods Section 2.2.11). The results were also represented by 2- 
D diagrams of phase and modulation lifetimes of F4-Cy3b shown in Figure 
3.5A-C.
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A
Dilution factor 
of F4-Cy3b
Conditions Phase
lifetime (ns)
Modulation 
lifetime (ns)
Average 
lifetime (ns)
1/5 F4-Cy3b 1.52 ns ± 
0 . 0 2
1.43 ns ± 
0.08
1.48 ns ± 
0.04
1/5 EGF + F4-Cy3b 1.54 ns ± 
0 . 0 2
1.48 ns ± 
0 . 0 2
1.51 ns ± 
0 . 0 2
1/5 F4-Cy3b + 
FB2-Cy5
1.38 ns ± 
0.04
1.37 ns ± 
0.03
1.38 ns ± 
0.03
1/5 EGF 50 ng/ml 1.16 ns ± 
0.04
1.25 ns ± 
0.04
1 . 2 0  ns ± 
0.04
1 / 1 0 F4-Cy3b 1.59 ns ± 
0.03
1.46 ns ± 
0.06
1.52 ns ± 
0.04
1 / 1 0 EGF+F4-Cy3b 1.41 ns ± 
0.03
1.41 ns ± 
0 . 0 2
1.41 ns ± 
0 . 0 2
1 / 1 0 F4-Cy3b + 
FB2-Cy5
1 . 2 2  ns ± 
0 . 0 2
1.26 ns ± 
0.04
1.24 ns± 
0.03
1 / 1 0 EGF 50 ng/ml 1 . 0 1  ns ± 
0 . 0 2
1.13 ns ± 
0.04
1.07 ns ± 
0.03
1/50 F4-Cy3b 1.42 ns ± 
0.03
1.49 ns ± 
0.03
1.46 ns ± 
0.03
1/50 EGF + F4-Cy3b 1.43 ns ± 
0 . 0 1
1.41 ns ± 
0.08
1.42 ns± 
0.03
1/50 F4-Cy3b + 
FB2-Cy5
1.14 ns ± 
0 . 0 2
1.25 ns ± 
0.04
1.19 ns± 
0.03
1/50 EGF 50 ng/ml 0.95 ns ± 
0.04
1.14 ns ± 
0.08
1.04 ns ± 
0.06
B
F4-Cy3b Dilution Factor Basal EGFR 
phosphorylation (FRET 
efficiency)
EGF-induced EGFR 
phosphorylation (FRET 
efficiency)
1/5 6 .8 % ± 2.03 18.9% ± 2.7
1 / 1 0 18.4% ± 1.97 29.6% ± 1.97
1/50 18.5% ±2.05 28.8% ±4.11
Table 3.2: A, The average lifetimes of F4-Cy3b (± standard deviations from 
three measurements) in A431 cells with different dilution factors of F4-Cy3b. B, 
The changes in EGFR phosphorylation indicated by FRET efficiency (± standard 
deviations from three measurements) with different dilution factors of F4-Cy3b.
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Figure 3.5: The effect of different dilution factors of F4-Cy3b on the 
lifetimes of F4-Cy3b shown by 2-D histogram. A, Dilution factor of F4- 
Cy3b 1/5. B, Dilution factor of F4-Cy3b 1/10. C, Dilution factor of F4-Cy3b
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The intensities of F4-Cy3b were observed to be greater than the arbitrary 
value of 1000 for all dilutions (see Methods Section 2.2.11.2). This meant that 
there was adequate amount of F4-Cy3b binding to EGFR proteins and high 
enough signal-to-noise ratios to calculate the lifetimes of F4-Cy3b in A431 
cells even with a dilution factor of 1/50. The results also showed that EGFR 
phosphorylation induced by EGF may be assessed by FRET in all dilutions up 
to 1/50 (Table 3.2A and Figure 3.5). At a dilution factor of 1/5, the basal FRET 
efficiency was 6 .8 % ± 2.03 and EGF-induced FRET efficiency of 19.8% ± 
2.70 (Table 3.2B), similar to the results of non-diluted donor F4-Cy3b, basal 
FRET efficiency of 7.79% ± 0.51 and EGF-induced FRET efficiency of 
15.11% ± 2.70 (Table 3.1 A). When the donor F4-Cy3b was diluted to 1/10 and 
1/50 concentrations, the basal FRET efficiencies were increased significantly 
compared to the results of dilution factor of 1/5 of donor F4-Cy3b (Table 3.2B 
and Figure 3.5). This is because the dilution of donor F4-Cy3b resulted in 
more acceptors FB2-Cy5 per donor F4-Cy3b and thus increased the quenching 
of the donor F4-Cy3 by the acceptor FB2-Cy5. This caused depopulation of 
the donor excited state and hence lowering the lifetime of F4-Cy3b. The basal 
FRET efficiencies were not due to non-specific FRET since EGF stimulation 
increased FRET efficiencies by about 10% in all dilutions (Table 3.2B and 
Figure 3.5) and previously it was shown that YOP phosphatase was able to 
remove basal FRET.
Altogether the results showed that donor F4-Cy3b may be diluted to a factor 
of 1/50 without affecting the ability for the assay to assess EGF induced 
phosphorylation state. The dilution of donor F4-Cy3b resulted in an increase in 
the basal FRET efficiency due to quenching of the donors by excess acceptors. 
The control experiment emphasises the importance of having internal controls 
for each experiment since the basal FRET values may differ with different 
dilution factors of donor F4-Cy3b. Therefore, in order to compare the 
difference of EGFR phosphorylation by FRET for example between two 
different cell lines, the concentration of donor F4-Cy3b needs to be the same in 
both cases for the results to be valid and comparable.
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3.2.1.3 A serial dilution of acceptor FB2-Cy5
concentration in A431 cells
A serial dilution of acceptor FB2-Cy5 concentration was also performed in 
A431 cells to establish the optimum concentration of acceptor FB2-Cy5 
relative to donor F4-Cy3b to assess EGFR phosphorylation by FRET. Table 
3.3A shows the lifetimes of donor F4-Cy3b and Table 3.3B shows the basal 
and EGF induced FRET efficiencies with different dilution factors of FB2- 
Cy5. The results show that as the concentration of acceptor FB2-Cy5 
decreased, the amount of basal FRET efficiency decreased (Table 3.3B). 
However, EGF stimulation induced further FRET (Table 3.3B) indicating that 
the assay may be used to assess EGF induced EGFR phosphorylation. The 
decrease of basal FRET efficiency was due to less acceptors FB2-Cy5 per 
donor F4-Cy3b, resulting in the decreased quenching of the donor F4-Cy3b 
and increase of donor lifetime. This control experiment again emphasises the 
importance of using internal control for each experiment and the acceptor 
concentration needs to be maintained constant to compare FRET efficiencies 
(e.g. between two cell lines).
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A
Conditions FB2 dilution 
factor
Phase lifetime 
(ns)
Modulation 
lifetime (ns)
Average 
lifetime (ns)
F4-Cy3b NA 2 . 1 2  ns ± 0 . 0 2 2 . 2 2  ns ± 
0.06
2.17 ns ± 
0 . 0 2
EGF + F4-Cy3b NA 2.16 ns ±0.09 2 . 2 2  ns ± 
0 . 0 2
2.19 ns ± 
0.06
F4-Cy3b + 
FB2-Cy5
1 / 1 1.84 ns ± 0.04 2.06 ns ± 
0.08
1.95 ns ± 
0.06
EGF 50 ng/ml 1 / 1 1.57 ns ± 0.02 1.95 ns± 
0 . 0 2
1.76 ns ± 
0 . 0 1
F4-Cy3b + 
FB2-Cy5
1/5 1.87 ns±0.02 2 . 1 2  ns ± 
0.03
2 . 0 0  ns ± 
0 . 0 1
EGF 50 ng/ml 1/5 1.77 ns ±0.02 2.09 ns ± 
0.05
1.93 ns ± 
0.03
F4-Cy3b + 
FB2-Cy5
1 / 1 0 1.92 ns ± 0.01 2.14 ns ± 
0.04
2.03 ns ± 
0 . 0 2
EGF 50 ng/ml 1 / 1 0 1 . 6 8  ns ± 0.06 2.05 ns ± 
0.08
1.87 ns± 
0.07
F4-Cy3b + 
FB2-Cy5
1 / 2 0 1.92 ns ± 0.03 2.13 ns ± 
0.07
2.03 ns ± 
0 . 0 2
EGF 50 ng/ml 1 / 2 0 1.74 ns ±0.04 2.08 ns ± 
0.05
1.91 ns ± 
0.04
F4-Cy3b + 
FB2-Cy5
1/40 1.93 ns ± 0.02 2.14 ns ± 
0.04
2.04 ns ± 
0 . 0 2
EGF 50 ng/ml 1/40 1.85 ns±0.04 2 . 1 2  ns ± 
0 . 1 0
1.98 ns± 
0.07
B
FB2-Cy5 Dilution Factor Basal EGFR 
phosphorylation (FRET 
efficiency)
EGF-induced EGFR 
phosphorylation (FRET 
efficiency)
1 / 1 1 0 .1 % ± 2 . 8 18.9% ±0.5
1/5 7.8% ±0.5 11.1% ±1.4
1 / 1 0 6.5% ±0.9 13.8% ±2.8
1 / 2 0 7.3% ±0.9 1 2 .0 % ± 1 . 8
1/40 6.0% ±0.9 8 . 8  % ± 2 . 8
Table 3.3: A, The average lifetimes of F4-Cy3b (± standard deviations from 
three measurements) in A431 cells with different dilution factors of FB2-Cy5. B, 
The changes in EGFR phosphorylation indicated by FRET efficiency (± stan­
dard deviations from three measurements) with different dilution factors of 
FB2-Cy5
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3.2.1.4 The effect of prolonged Incubation 
periods of acceptor FB2-Cy5 in A431 cells
The effect of incubation periods of acceptor FB2-Cy5 in A431 cells was also 
assessed to obtain an optimum incubation period of acceptor FB2-Cy5 and to 
investigate the effect of prolonged incubation with FB2-Cy5 on FRET 
efficiencies in A431 cells. Table 3.4A shows the lifetimes (phase, modulation 
and average) and Table 3.4B shows the FRET efficiencies of F4-Cy3b when 
the cells were incubated with different periods of acceptor FB2-Cy5. As the 
incubation periods were gradually prolonged, the basal and EGF induced 
FRET efficiencies increased (Table 3.4B). The results showed that for 
incubations between two and four hours the basal and EGF-induced FRET 
efficiencies were relatively constant. The main significant increase of both 
basal and EGF-induced FRET efficiencies occurred after 8 hours of acceptor 
incubation. Prolonged acceptor incubation increases quenching of the donor, 
resulting in a significant decrease of lifetime but non-specific FRET due to 
non-specific binding as a result of prolonged acceptor incubation cannot be 
excluded. The results show that the optimum incubation period of acceptor 
FB2-Cy5 is between 2-4 hours.
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A
Conditions FB2
incubation
period
Phase
lifetime (ns)
Modulation 
lifetime (ns)
Average 
lifetime (ns)
F4-Cy3b NA 2.12 ns ± 
0.02
2.22 ns ± 
0.06
2.17 ns ± 
0.02
EGF + F4- 
Cy3b
NA 2.16 ns ± 
0.09
2.22 ns ± 
0.02
2.19 ns± 
0.06
F4-Cy3b + 
FB2-Cy5
1 hr 1.87 ns ± 
0.01
2.15 ns± 
0.05
2.01 ns ± 
0.03
EGF 50 ng/ml 1 hr 1.54 ns ± 
0.03
2.11 ns ± 
0.06
1.83 ns ± 
0.04
F4-Cy3b + 
FB2-Cy5
2 hrs 1.72 ns ± 
0.05
2.06 ns ± 
0.04
1.89 ns ± 
0.03
EGF 50 ng/ml 2 hrs 1.59 ns ± 
0.01
2.02 ns ± 
0.02
1.80 ns ± 
0.02
F4-Cy3b + 
FB2-Cy5
4 hrs 1.76 ns ± 
0.06
2.09 ns ± 
0.02
1.92 ns ± 
0.01
EGF 50 ng/ml 4 hrs 1.54 ns ± 
0.04
1.95 ns ± 
0.06
1.75 ns ± 
0.05
F4-Cy3b + 
FB2-Cy5
8 hrs 1.75 ns ± 
0.08
2.00 ns ± 
0.01
1.88 ns ± 
0.04
EGF 50 ng/ml 8 hrs 1.35 ns ± 
0.06
1.88 ns ± 
0.06
1.62 ns ± 
0.02
F4-Cy3b + 
FB2-Cy5
18 hrs 1.52 ns ± 
0.04
1.86 ns ± 
0.06
1.69 ns ± 
0.05
EGF 50 ng/ml 18 hrs 1.18 ns ± 
0.07
1.67 ns ± 
0.04
1.43 ns ± 
0.04
F4-Cy3b + 
FB2-Cy5
28 hrs 1.26 ns ± 
0.01
1.79 ns ± 
0.04
1.53 ns ± 
0.02
EGF 50 ng/ml 28 hrs 1.09 ns ± 
0.04
1.58 ns ± 
0.03
1.34 ns ± 
0.02
B
FB2-Cy5
Incubation periods
Basal EGFR 
phosphorylation 
(FRET efficiency)
EGF-induced EGFR 
phosphorylation (FRET 
efficiency)
1 hour 7.4 % ± 1.4 15.7% ± 1.8
2 hours 12.9% ± 1.4 17.1% ±0.9
4 hours 11.5% ±0.5 19.4% ±2.3
8 hours 13.4% ± 1.8 25.3% ±0.9
18 hours 22.1% ±2.3 34.1% ± 1.8
28 hours 29.5% ±0.9 38.2% ±0.9
Table 3.4: A, The average lifetimes of F4-Cy3b (± standard deviations from 
three measurements) in A431 cells with different incubation periods of FB2-Cy5. 
B, The changes in EGFR phosphorylation indicated by FRET efficiency with 
different incubation periods of FB2-Cy5 in A431 cells.
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3.2.1.5 Assessing the minimum exogenous EGF 
concentration in inducing FRET
In the section 3.2.1, it was demonstrated that FRET efficiency was increased 
by exogenous EGF stimulation due to enhanced EGFR phosphorylation, 
indicating that FRET may be used to assess EGFR phosphorylation. It was 
intended to assess whether a decrease in the exogenous EGF dose would result 
in a decrease of FRET efficiency due to inadequate EGFR phosphorylation. 
This control experiment was important as it would prove that EGF-induced 
FRET was specific and indicative of EGFR phosphorylation if a decrease in 
EGF dose also resulted in the loss of EGF-enhanced FRET.
Table 3.5A shows the lifetimes (phase, modulation and average components) 
and Table 3.5B shows the FRET efficiencies with difference doses of 
exogenous EGF stimulation in A431 cells. The results show that as the 
exogenous EGF dose was decreased below 30 ng/ml, the dose became 
ineffective such that EGF did not induce further FRET compared to basal level 
(Table 3.5B). EGF concentration was calculated in nanomolar (nM) unit and 
the relationship between EGF concentration and FRET was plotted in a graph; 
it was shown that EGF induced FRET (EGFR phosphorylation) was saturated 
at an EGF concentration between 2.5 nM and 5nM (Table 3.5B).
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A
Conditions Phase lifetime 
(ns)
Modulation 
lifetime (ns)
Average 
lifetime (ns)
F4-Cy3b 2.12 ns ±0.02 2.22 ns ± 0.06 2.17 ns ±0.02
EGF+F4-Cy3b 2.16 ns ±0.09 2.22 ns ± 0.02 2.19 ns ±0.06
F4-Cy3b
+FB2-Cy5
1.86 ns ± 0.01 2.03 ns ± 0.07 1.95 ns ±0.05
EGF 50 ng/ml 1.57 ns ±0.02 1.95 ns ± 0.02 1.76 ns ± 0.01
EGF 30 ng/ml 1.62 ns ±0.03 2.00 ns ± 0.03 1.81 ns ± 0.02
EGF 10 ng/ml 1.77 ns ± 0.06 2.04 ns ± 0.06 1.91 ns ± 0.06
EGF 1 ng/ml 1.87 ns ± 0.05 2.11 ns ± 0.06 1.99 ns ± 0.05
EGF 0.1 ng/ml 1.80 ns ±0.01 2.08 ns ± 0.04 1.94 ns ± 0.02
B
EGF concentration EGF-induced EGFR phosphorylation 
(FRET efficiency)
No EGF (basal) 8.0% ±2.3
EGF 50 ng/ml 15.5% ±0.5
EGF 30 ng/ml 15.5% ±0.9
EGF 10 ng/ml 8.5% ±2.8
EGF 1 ng/ml 4.5% ±2.3
EGF 0.1 ng/ml 6.7% ± 0.9
>, 20-joc«
& 15' 4>h*
114tru.
10-
0.0 2.5 5.0 7.5 10.0
EGF (nM)
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3.2.2 The activation-state of EGFR in 
head and neck tumours
The series of control experiments established the optimum conditions to 
assess EGFR phosphorylation by FRET. Furthermore, they illustrated the 
importance of strict internal controls and constant conditions of the donor and 
the acceptor for the experiments to obtain meaningful results. The aim was to 
apply the optimised FRET assay in cells to assess EGFR phosphorylation of 
tumour cores in paraffin sections of tumour arrays in a high throughput manner 
by automated FLIM.
The established two-site FRET assay was applied to determine the pattern of 
EGFR phosphorylation in a series of HNSCC. An archive of head and neck 
tumour samples from 130 patients embedded in paraffin blocks were converted 
into three arrays (Figure 3.6). The arrays contained 286 tumour cores (a 
duplicate of a tumour core from each patient) and several cores comprised 
normal tonsil tissue as negative controls. These arrays were prepared for FRET 
experiments using the parameters established in A431 cells.
A duplicate of each array was also prepared. One array was labelled with 
donor alone (F4-Cy3b) and the other with donor and acceptor (F4-Cy3b + 
FB2-Cy5). For each tumour core a pair of average lifetimes was obtained, one 
from the array with donor alone and one from the array that was labelled with 
donor and acceptor (Figure 3.7). Comparing the two arrays, average FRET 
efficiency was calculated for each tumour core (See Methods Section 
2.2.11.6). Therefore average FRET efficiency was utilised as the main 
parameter to correlate with the clinical data (Figure 3.8). The survival data of 
130 head and neck cancer patients were compared with average FRET 
efficiency. The average FRET efficiencies of the normal tonsil tissue samples 
were used as controls, th e  values of the negative controls ranged from 0% to 
8.90% with a median average FRET efficiency of 4.86%. For the tumours, the 
average FRET efficiencies ranged from 0% to 14.70% and the median was 
4.13%. The patients were ranked according to their average FRET efficiency
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and the groups split for comparison into (i) upper median versus lower median, 
(ii) upper tertile versus lower two tertiles, and (iii) upper 10% versus lower 
90% range of average FRET efficiency. The Kaplan Meier method was used to 
compare the survival curves between the groups of patients and log-rank test 
utilised to calculate the hazard ratios (see method). It was found that higher 
FRET efficiency was correlated with worse DFS and it was statistically 
significant in the groups split by upper tertile and upper 10% but not the 
median. Comparing the patients in the lower two tertiles with the upper tertile, 
the log-rank test revealed a hazard ratio of 0.57 (95% Cl 0.29 to 0.99, p=0.05) 
(Figure 3.8A). Patients in the lower 90% range of average FRET efficiency 
had a hazard ratio of 0.43 (95% Cl 0.09 to 0.89, p=0.03) compared with the 
patients in the upper 10% range (Figure 3.8B). However, there was no 
statistical significance in overall survival between the upper tertile and lower 
two tertile groups (hazard ratio for lower two tertile = 0.91, 95% Cl 0.48 to 
1.72, p=0.76) (Figure 3.8C).
To ensure inter-assay validity, the above experiments were repeated in a new 
set of six tumour arrays, which contained tumour cores from the same patients. 
New preparations of conjugated antibodies were used and average FRET 
efficiencies were calculated from each tumour core using automated high 
throughput FLIM. The automated system was programmed to perform 
multiple loops and two loops were performed for each array (See Methods). 
Thus, two measurements were acquired for each process (574 measurements 
were acquired). The Kaplan Meier survival curves were used to compare 
between the patients in the upper 10% FRET efficiency and lower 90% 
efficiency and the log-rank test was used to compare the hazard ratio. The 
results were similar to the initial study in that the patients in the lower 90% 
range of average FRET efficiency had a better DFS compared with the upper 
10% range (hazard ratio for lower 90% range = 0.38, 95% Cl 0.075 to 0.69, 
p=0.001) (Figure 3.8D). From these FRET efficiency studies it was deduced 
that phosphorylation of EGFR assessed by high throughput FLIM correlates 
with DFS. The study illustrated that there was a prominent correlation between 
EGFR activation and DFS.
125
Figure 3.6: Head and neck tissue micro-array (TMA). The left 
panel shows a diagrammatic representation of a standard Oxford 8x15 
TMA. The right panel shows an example of a tumour core with conven­
tional EGFR immunostaining of F4 antibody (monoclonal against EGFR 
cytoplasmic domain, which is the same monoclonal antibody used in 
FRET experiments).
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P atien t 1
Intensity Lifetime map
F4-Cy3b+FB2-Cy5
P atien t 2
F4-Cy3b+FB2-Cy5
FRET efficiency: E(%) 
E = [ 1 - ( ^ L  )] x  100%
Figure 3.7: EGFR phosphorylation can be mapped by variations in FRET 
in Head and Neck tumour cores. The left panels show the intensity images of 
tumour cores from the array. The right panels are lifetime maps of the cores. The 
upper tumour core of patient 1 was from an array labelled with donor alone (F4- 
Cy3b). The average donor lifetime of the tumour core was 2.00 ns.The donor and 
acceptor (F4-Cy3b+FB2-Cy5) core was from a duplicate array. There was no change 
in the lifetime with a FRET efficiency of 0%. The second set of donor and acceptor 
cores from patient 2 indicates a further decrease of the average lifetime (2.20 ns to 
1.90 ns) with a FRET efficiency of 11%. The decrease in donor lifetime induced by 
FRET is used to calculate the FRET efficiency.
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Figure 3.8: Kaplan-Meier curves using average FRET efficiency as a prognostic marker illustrate that FRET effi­
ciency is correlated with disease free survival. A, Pilot study: Disease-free survival (DFS) between patients in upper tertile 
versus the lower two tertiles of average FRET efficiency. B, Pilot study: DFS between patients in upper 10% versus lower 90% of 
average FRET efficiency. C, Pilot study: OS between patients in upper 10% versus lower 90% of average FRET efficiency between 
patients in upper tertile versus the lower two tertiles of average FRET efficiency. D, Validation study: DFS curves comparing the 
upper 10% range with the lower 90% of average FRET efficiency.
3.2.3 Conventional IHC does not reveal a 
correlation of EGFR over-expression with 
disease free survival and overall survival
Previously, IHC analysis of EGFR expression has been shown to correlate 
with survival, particularly disease free survival (DFS) and hence was 
considered useful in predicting disease recurrence (Ang et al., 2002; 
Dassonville et al., 1993). To assess whether in this patient cohort conventional 
IHC revealed a correlation between levels of EGFR expression and survival 
data, the same tumours from the head and neck cancer patients were labelled 
with the F4 antibody using conventional IHC methods although only 122 
patients’ IHC scores were obtainable due to inadequate tumour sample or loss 
of tumour sample from the array slide.
Table 3.6A shows the characteristics of patients according to the subsites of 
head and neck tumours and 3.6B shows the tumour characteristics according to 
IHC EGFR scores. The majority of the tumours were of UICC tumour stage 3 
and 4 and moderate to poor grade. 57 of the 122 patients (47%) have over­
expression of EGFR scored either 2+ or 3+ with only 17 of the 122 patients 
(14%) scored at 3+. As described previously, the same statistical tests were 
used to determine the correlation between DFS, OS and EGFR expression. 
Figures 3.9A and 3.9B show that EGFR over-expression (scores 2+ and 3+) by 
IHC was not correlated with DFS or OS. Kaplan-Meier curves show that there 
was no correlation of EGFR over-expression (2-3+) and DFS [(hazard ratio for 
EGFR (0-1+) = 0.89, 95% Cl 0.5 to 1.6, p=0.67)] or EGFR over-expression (2- 
3+) and OS [(hazard ratio for EGFR (0-1+) =0.64, at 95% Cl 0.35 to 1.05, 
p=0.74)]. The statistical results showed that in this retrospective study, 
conventional IHC did not reveal a correlation with DFS and therefore was not 
informative as a single parameter to predict disease recurrence.
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AAnatomical sites Male Female Median age
Oral cavity (n=38) 19 19 64.5
Oropharynx (n=42) 29 13 53.5
Hypopharynx (n=18) 13 5 64.3
Larynx (n=23) 21 2 62.4
Others (n=l) 1 0 70.1
Total (n=122) 83(68%) 39 (32%) 58.5
B
EGFR Score 0 (n=36) 1+ (n=29) 2+ (n=40) 3+ (n=17) Total =122
Humour Stage
I 3 0 5 1 9 (7%)
II 6 5 5 2 18(15%)
III 11 6 9 0 26 (21%)
IV 16 18 21 14 69 (57%)
Grade
Well 2 4 2 0 8 (7%)
Moderate 17 10 19 8 54(44%)
Poor 17 15 19 9 60 (49%)
Table 3.6: A, T h e ch a rac te ris tic s  o f p a tie n ts  a c c o rd in g  to  s u b s ite s  o f  h e a d  a n d  
n eck  tu m o u rs . B, T h e ch a rac te ris tic s  o f  tu m o u rs  in re la tio n  to  im m u n o h is to c h e m - 
istry  s ta in s.
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Figure 3.9: EGFR concentration does not reveal a correlation with 
disease free survival or overall survival. Kaplan-Meier curves were used to 
compare the disease-free survival (A) and overall survival (B) between EGFR (0-1+) 
and EGFR (2-3+).
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3.2.4 EGFR concentration does not 
correlate with its phosphorylation status
To address whether EGFR expression itself was correlated with its activation, 
average donor fluorescence intensity measurements (i.e. F4 immunoreactivity) 
were compared to average FRET efficiency. It is important to note that average 
fluorescence intensity measurements of F4-Cy3b were related to the amount of 
receptor in each tumour core (see Methods Section 2.2.11.6). To test the 
correlation between EGFR expression and its activation (phosphorylation) the 
linear regression was calculated between the average fluorescence intensity 
and average FRET efficiency. The analysis showed that there was no linear 
relationship between the two parameters [(r2 = 0) (Figure 3.10A)]. These 
studies illustrated that there was minimal correlation between EGFR 
expression and its phosphorylation. To address whether EGFR 
phosphorylation calculated from the average FRET efficiency was correlated 
with EGFR expression by IHC, the Mann-Witney test was utilised. Figures 
3.1 OB illustrates that there was no correlation between IHC EGFR scoring and 
average FRET efficiency (p= 0.24).
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Fig. 3.10: EGFR concentration does not correlate with EGFR phos­
phorylation. A, The linear regression shows no correlation between donor 
intensity Cy3b and average FRET efficiency (r2=0). In these studies expres­
sion of EGFR is not correlated with its phosphorylation state. B, Mann- 
Witney test illustrates that there is no correlation between average FRET 
efficiency and EGFR immunochemistry scoring (log-rank test p=0.24).
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3.2.5 Determination of the prognostic 
value of average FRET efficiency
The results from Section 3.2.2 showed that patients with high FRET 
efficiency specifically those in the top 10% had a poorer DFS. To assess 
whether the top 10% may be used as a prognostic factor, the prognostic value 
of the top 10% FRET efficiency was determined by analysis of the DFS and 
OS using univariate and multivariate analysis (see Methods Section 2.2.11.6). 
Table 3.7A shows the prognostic value of top 10% FRET efficiency in 
comparison with IHC using univariate analysis. In this study, the top 10% 
FRET efficiency was a significant parameter (p= 0.04) for DFS but not OS (p= 
0.35) and over-expression of EGFR (2-3+) by IHC was not a significant 
parameter for either DFS or OS. Table 3.7B shows the prognostic value of the 
top 10% FRET efficiency for DFS and OS with UICC tumour stage and grade 
as covariates. The most significant parameter for DFS was top 10% FRET 
efficiency (p= 0.03) and none of the other parameters were significant for OS 
by multivariate analysis. Further analysis including age and sex as covariates 
in addition to UICC tumour stage and grade showed again that top 10% FRET 
efficiency was the only significant parameter for DFS (p= 0.013) (Table 3.7C). 
To confirm that the FRET efficiency is an independent parameter, Mann- 
Witney tests were used to test the association of average FRET efficiency with 
other known prognostic factors. It was shown that average FRET efficiency 
was not associated with grade or UICC (International Union Against Cancer) 
tumour stage (Figure 3.11A and 3.1 IB).
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A
Univariate analysis Statistical significance value p
Disease-free survival
EGFR (2-3+) by IHC (n= 122) 0.71
Top 10% FRET efficiency (n= 130) 0.04
Overall Survival
EGFR (2-3+) by IHC (n=122) 0.08
Top 10% FRET efficiency (n=130) 0.35
B
M ultivariate analysis Statistical significance value p
Disease-free Survival (n =130)
Top 10% FRET efficiency 0.029
UICC stage 2 0.960
UICC stage 3 0.610
UICC stage 4 0.860
Grade (Linear) 0.190
Grade (Quadratic) 0.970
Overall survival (n=130)
Top 10% FRET efficiency 0.32
UICC stage 2 0.60
UICC stage 3 0.73
UICC stage 4 0.45
Grade (Linear) 0.84
Grade (Quadratic) 0.36
C
Multivariate analysis Statistical significance value p
Disease-free Survival (n =130)
Top 10% FRET efficiency 0.013
UICC stage 2 0.960
UICC stage 3 0.580
UICC stage 4 0.830
Grade (Linear) 0.260
Grade (Quadratic) 0.970
Age 0.240
Sex 0.510
Table 3.7: A, Prognostic value of the top 10% FRET efficiency by univariate 
analysis as compared to conventional IHC. B, Prognostic value of top 10% 
FRET efficiency by multivariate analysis with UICC tumour stage and grade as 
covariates. C, Prognostic Value of Top 10% FRET efficiency for DFS by multi­
variate analysis with UICC stage, grade, age and sex as covariates.
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Figure 3.11: A, Mann-Witney tests show that there is no correlation of 
average FRET efficiency with tumour grade or B, UICC tumour stage.
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3.3 Discussion
In this study a FRET assay was tested and established to report the 
phosphorylation of EGFR in cell lines and paraffin-embedded tumour arrays. 
The assay was first established in cell lines including A431 and MDAMB-231 
cells. A series of control experiments were also performed to obtain optimum 
conditions for the FRET assay as well as to establish the assay to assess EGFR 
phosphorylation. The control experiments illustrated the importance of 
maintaining internal controls, constant donor and acceptor concentrations as 
well as incubation periods of the assay to compare a difference in EGFR 
phosphorylation either between cell lines or tumour cores by FRET. The assay 
is designed to provide a two-site assay for phosphorylation of the EGFR using 
coincidence detection of protein and phospho-site selective monoclonal 
antibodies, which increases the specificity of the assay. This is of particular 
importance in the context of tissue microarrays where there is no opportunity 
to test the validity of the immunoreactions observed. This assay has been 
developed for automated data capture in a format appropriate for tissue 
microarray analysis and was applied to HNSCC tumour arrays to determine the 
relationship between EGFR phosphorylation and prognosis. The study reveals 
10% of patients with a high degree of EGFR autophosphorylation (as 
evidenced by those with the highest FRET efficiency) have a poor DFS. 
Importantly this phosphorylation status does not correlate with EGFR 
concentration per se and this latter variable itself does not correlate with DFS. 
However, this retrospective study had a small sample size of 130 patients and 
10% of the patients represented only 13 patients and thus a type I error cannot 
not be excluded.
Several studies have shown a correlation of EGFR expression with OS and 
DFS (Ang et al., 2002; Dassonville et al., 1993; Gupta et al., 2002; Sheridan et 
al., 1997). In this retrospective study, conventional immunochemistry scores 
failed to show the correlation of EGFR expression (2-3+) with DFS and OS as 
in other prospective studies. This may be due to a small sample size in this 
retrospective study. But using high throughput FLIM, FRET efficiency was
shown to correlate with DFS in the same group of patients. It is proposed that 
future IHC experiments may include only those tumours with 3+ expression 
(i.e. excluding 2+ expression) in the EGFR over-expression group to assess the 
prognostic value.
The pilot study showed a statistically significant result in the upper tertile 
range of average FRET efficiency in its correlation with DFS. However, 
further measurements and validation study only showed statistically significant 
results in the top 10% range. This means that the exact cut-off points for high 
FRET efficiency may vary between studies depend on the design of the study. 
A large prospective trial is needed to determine the cut-off point and to 
validate the FRET methods for wider clinical use (Hayes et al., 1996; Hayes et 
al., 1998).
The results presented in this chapter represent a proof of principle that the 
phosphorylation of EGFR may be assessed by FRET and that such assay may 
be applied to paraffin sections of tumour arrays to assess the prognosis of 
cancer patients. It was shown that the assay can be applied to assess EGFR 
phosphorylation in head and neck tumour arrays in a high throughput manner. 
It was therefore postulated that the assay may also be applied to assess the 
phosphorylation of other HER receptors and other signalling pathways in 
variety of cancers. The ultimate aim is for such assays to be applied to assess 
phosphorylation of HER receptors in relation to targeted therapies against 
HER receptors in patients.
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4  Activation of alternative HER 
receptors m ediates res ista n ce  to  
tyrosine k inase inhibitors (TKIs) in 
breast can cer c e lls
4.1 Introduction
The HER receptors plays a crucial role in breast cancer and many other type 
of cancers (Yarden and Sliwkowski, 2001). Recently, there has been 
accelerated use of drugs targeting EGFR and HER2 receptors in breast cancer, 
including Herceptin (Trastuzumab, a monoclonal antibody for HER2), Iressa 
(Gefitinib or ZD 1839, a tyrosine kinase inhibitor of EGFR) and Lapatinib (a 
tyrosine kinase inhibitor of EGFR and HER2) (Baselga, 2002; Piccart-Gebhart 
et al., 2005; Romond et al., 2005). As discussed in the Introduction, although 
over-expression of HER receptors has been used to select patients for these 
drugs, their expression does not necessarily correlate with the response of 
these drugs (Arteaga, 2006; Chung et al., 2005; Menendez et al., 2006). The 
underlying mechanisms contributing to the resistance as well as predicting the 
success of these drugs in cancer patients are still poorly understood.
The response rate to targeted therapies against HER family therapy depends 
on more than just the receptor concentrations or the mutations of the particular 
HER receptor (Arteaga, 2006; Chung et al., 2005; Menendez et al., 2006). It is 
likely that multiple interacting HER receptors and ligands are involved in 
mediating response to targeted therapy. For example Iressa which targets the 
EGFR receptor also inhibits the PI3K and PKB pathway via HER3 (Engelman 
et al., 2005). Moreover, Iressa is also effective in HER2 over-expressing breast 
cancer cells (Moulder et al., 2001). Therefore, the treatment to reduce the 
tyrosine kinase activity of EGFR receptors may also affect HER2 and HER3 
receptors. Therapy based on receptor concentration, ignoring the activation and
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phosphorylation state of the receptor and its interaction with other HER 
receptors will continue to yield a relatively low response rate (Arteaga, 2002; 
Kong et al., 2006). Activation of alternative HER receptors through their 
ligands may mediate resistance to targeted therapy.
Targeting HER2 has been the main focus in breast cancer although 
increasingly, inhibition of EGFR in combination with HER2 blockage is also 
seen to be important in breast cancer therapy (Baselga, 2002; Piccart-Gebhart 
et al., 2005; Romond et al., 2005). In vitro, Iressa is effective in HER2 over­
expressing breast cancer cells (Moulder et al., 2001). Moreover, EGFR 
expression had also been shown to play a role in hormone resistant breast 
cancer patients (Nicholson et al., 1989) and this has led to the use of Iressa 
with aromatase inhibitors in breast cancer (Polychronis et al., 2005). More 
recently Lapatinib that targets the tyrosine kinase activities of both EGFR and 
HER2 has been successfully used in HER2 positive patients who had 
progressed after Herceptin treatment, confirming the role of EGFR inhibition 
in breast cancer.
The purpose of this study was to assess the change in activation status of all 4 
HER receptors to EGFR tyrosine kinase inhibitors (TKIs) in breast cancer cell 
lines and their relationship to resistance towards these therapies. Firstly, the 
establishment of an assay to assess HER2 phosphorylation was performed in 
A431 cells as a test bed. Secondly, the effect of EGFR TKIs on HER2 
phosphorylation by FRET as well as its effect on the dimerisation pattern of 
other HER receptors with HER2 in breast cancer cells were investigated.
4.2 Results
4.2.1 HER2 phosphorylation sta te  
monitored by FRET
The purpose of this study was to assess the response of HER receptors in 
relation to targeted therapies against EGFR and HER2 in breast cancer cell
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lines since inhibition of EGFR together with HER2 is increasingly thought to 
be important for breast cancer as suggested by the use of the combination 
inhibitor Lapatinib (Geyer et al., 2006; Konecny et al., 2006). Having 
established the assessment of EGFR phosphorylation state by FRET in A431 
cells (Chapter 3), the method was applied to assess HER2 phosphorylation 
state in relation to targeted therapy. HER2 is not known to have its own ligand 
although it is the preferred dimerisation partner for other HER receptors 
(Graus-Porta et al., 1997). To establish an assay for HER2 phosphorylation, it 
was necessary to demonstrate HER2 phosphorylation via other HER receptors. 
A431 cells was chosen as a test bed because of their extensive prior use for the 
analysis of EGFR and other HER receptors.
To assess HER2 phosphorylation, an anti-HER2 antibody was conjugated to a 
Cy3b chromophore (HER2-Cy3b) and an anti-phosphoHER2 antibody to Cy5 
(pHER2-Cy5). It was hypothesized that upon HER2 phosphorylation, there 
would be coincident binding of HER2-Cy3b and pHER2-Cy5 inducing Forster 
resonance energy transfer (FRET). The specific quenching of the donor 
chromophore Cy3b results in the decrease of lifetime of HER2-Cy3b. 
Therefore, a decrease in lifetime of HER2-Cy3b would be indicative of HER2 
phosphorylation.
To show in situ that HER2 could be activated consequent to dimerisation 
with other members of the HER family, A431 cells were stimulated with EGF, 
heregulin P (P3 of NRG1, Materials Section 2.1.5) and heregulin-pi (Pi of 
NRG1, Materials Section 2.1.5). EGF is the ligand for EGF and heregulin p 
and heregulin p-1 are both ligands for HER3 and HER4. The average lifetime 
of the donor HER2-Cy3b alone (detecting HER2 protein) was 2.20 ns and EGF 
stimulation alone did not affect the donor lifetime (Figure 4.1 A). In the 
presence of acceptor pHER2-Cy5 (detecting phosphorylated HER2), the donor 
lifetime HER2-Cy3b decreased to 1.75 ns due to basal HER2 phosphorylation. 
A further decrease of the average lifetime of HER2-Cy3b was measured upon 
EGF, P and P-1 heregulin (Figure 4.1 A). The significant decreases in average 
lifetime compared to the basal levels (p<0.01) indicate an increase in HER2 
tyrosine phosphorylation and therefore activation in A431 cells. To verify the 
measurements were not due to unspecific FRET, the phosphatase YOP was
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used after EGF treatment to dephosphorylate the tyrosine on HER2 in the fixed 
preparations. The average lifetime reverted to the control values (yellow 
triangles) indicating a loss of FRET. Independently, an increase in HER2 
phosphorylation on Tyrl221 and 1222 in a total cell lysate was shown by 
western blot using a phospho-specific antibody (upper panel) (Figure 4. IB).
As expected, heregulin P and P-1 did not cause EGFR phosphorylation in 
A431 cells (Figure 4.1C) since HER2 is the preferred dimerisation partner for 
HER3 and HER4. In this experiment, the cells were incubated with either 
donor EGFR-Cy3b (F4-Cy3b) or donor and acceptor pEGFR-Cy5 (FB2-Cy5) 
to assess EGFR phosphorylation (Since several HER pathways will be 
analysed by FRET in this chapter, F4-Cy3b will be referred to as EGFR-Cy3b 
and FB2-Cy5 will be termed pEGFR-Cy5). Basal phosphorylation was 
indicated by a decrease in the median lifetimes from 2.3 ns to 2.1 ns in the 
presence of the acceptor pEGFR-Cy5. Not surprisingly, EGF caused further 
EGFR phosphorylation as shown by the significant decrease of lifetime to 1.8 
ns (p < 0.01). However, heregulin p and heregulin p-1 did not cause a 
significant decrease in lifetime.
Since A431 cells were used only as a test cell line, three other breast cancer 
cell lines (MCF-7, MDAMB-453 and SKBR3 cells) were also used for this 
study. The amount of EGFR and HER2 receptors of A431 cells in relation to 
the three breast cell lines (MCF-7, MDAMB-453, SKBR3 cells) is illustrated 
in Figure 4.2A. The assay to assess HER2 phosphorylation was also applied in 
MCF-7 cells that have ‘normal’ levels of EGFR and HER2. It was shown that 
EGF and heregulin p-1 activated HER2, indicated by a decrease in the median 
lifetimes from a basal level of 1.93 ns to 1.81 ns and 1.86 ns respectively (p< 
0.001 for both conditions) in MCF-7 cells (Figure 4.2B). Altogether these data 
indicated that HER2 phosphorylation by ligands for other HER receptors 
family members could be monitored in intact cells by FRET.
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Figure 4.1: HER2 is the preferred dimerisation partner for other HER recep­
tors. A, To assess HER2 phosphorylation in A431 cells by FRET, the cells were 
incubated with either donor alone (HER2-Cy3b) or donor and acceptor (HER2- 
Cy3b+pHER2-Cy5) after 10-minute stimulation with either EGF, heregulin beta or 
heregulin beta-1. To remove phosphotyrosine, the phosphatase YOP was used 
following stimulation of the cells with EGF. B, For western blot, near confluent 
A431 cells were stimulated with EGF, heregulin beta and heregulin beta-1 for 10 
minutes and whole cell lysate was obtained after treated with lysis buffer. 10ng of 
proteins were used for each lane for western blot analysis and the phosphorylation 
of HER2 on Tyr 1221/1222 was determined with anti-phosphospecific antibody. C, 
Same experiment as A but A431 cells were incubated with either donor alone 
(EGFR-Cy3b) or donor and acceptor (EGFR-Cy3b+pEGFR-Cy5) after ligand 
stimulation to assess EGFR phosphorylation.
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Figure 4.2. A, A431, MCF-7, MDAMB-453 and SKBR3 were grown to near 
confluency before lysed to assess the total levels of HER2 and EGFR by western blot. 
B, MCF-7 cells were incubated with suitable pair of antibodies to assess HER2 
phosphorylation after ligand stimulation.
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4.2.2 Effect of tyrosine kinase inhibitors 
(TKIs) on HER2 activation state
HER2 phosphorylation induced by other HER receptors via their respective 
ligands was determined in A431 cells and MCF-7 cells while EGFR was 
inhibited or not with tyrosine kinase inhibitor (TKI) AG 1478. Since A431 
cells over-express EGFR, it was expected that AG 1478 would prevent 
phosphorylation of HER2 by EGF stimulation and to exert a possible 
inhibitory effect of the interaction of HER2 with HER3 and HER4. However, 
AG 1478 failed to abolish EGF-induced and heregulin P-induced HER2 
phosphorylation in A431 cells (Figure 4.3A). Moreover, it increased HER2 
phosphorylation with heregulin p-1, indicated by a decrease in average donor 
lifetime compared to those with no AG 1478 pre-treatment (p=0.008) (Figure 
4.3A). In MCF-7 cells, AG 1478 also did not abolish EGF induced HER2 
phosphorylation (Figure 4.3B). Moreover, both heregulin p and heregulin p-1 
enhanced HER2 phosphorylation when cells were pretreated with AG 1478 (p 
< 0.01 for both conditions; Figure 4.3B). Increased doses of AG 1478 up to 
300 pM failed to prevent EGF induced HER2 phosphorylation in A431 cells 
(Figure 4.4A), despite its effect on PKB and ERK1/2 activation (Figure 4.4B). 
In MCF-7 cells higher doses of AG 1478 (up to 300 pM) could inhibit EGF- 
induced HER2 phosphorylation but not the basal HER2 phosphorylation 
(Figure 4.4C).
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Figure 4.3: AG 1478 does not diminish EGF induced HER2 phosphoryla­
tion and enhances heregulin induced HER2 phosphorylation. A, In this 
experiment, A431 cells were pretreated with tyrosine kinase inhibitor 3pM AG 1478 
for two hours before stimulated with either EGF, heregulin beta or heregulin beta-1. 
The average lifetimes of HER2-Cy3b of those pre-treated with AG 1478 were com­
pared with those without treatment and the medians of the average lifetimes were 
compared using Mann-Witney test. B, The same experiment was also done in 
MCF-7 cells.
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Figure 4.4: Inhibition of EGFR with escalating doses of AG 1478 does not 
abolish HER2 phosphorylation. A, Before being treated with increasing doses 
of AG 1478 for two hours, A431 cells were stimulated with EGF 100 ng/ml for 10 min­
utes. The cells were incubated suitable pair of antibodies to assess HER2 phosphory­
lation. B, A431 cells were pretreated with AG 1478 with or without EGF stimulation 
before treated with lysis buffer and loaded in SDS PAGE.The phosphorylation of PKB 
on Ser 473 and p44/42 MAP Kinase (Erk1/Erk2) on Thr202/Tyr 204 was determined 
using phospho-specific antibodies and the total endogenous levels of PKB and 
p44/42 MAP Kinase were assessed by western blot using anti-PKB and anti-MAPK 
antibodies. C, Same experiment as A but MCF-7 cells were used instead.
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To exclude that the inability to inhibit HER2 phosphorylation by AG 1478 
was not due to simultaneous EGF stimulation, the effect of AG 1478 treatment 
alone was assessed in A431 cells and two other breast cell lines, MDAMB-453 
and SKBR3 cells which over-express HER2 since these HER2 over-expressing 
breast cancer cells have been shown to be sensitive to tyrosine kinase 
inhibitors (Anderson et al., 2001; Moulder et al., 2001). However, treatment of 
AG 1478 alone without EGF stimulation also failed to abolish HER2 
phosphorylation in these cells despite its ability to decrease phosphorylation of 
PKB and ERK1/ERK2 during acute treatment of AG 1478 (Figure 4.5A). The 
western blot results are consistent with the FRET data. A two-hour treatment 
with AG 1478 alone failed to reverse basal HER2 phosphorylation in A431, 
MDAMB-453 and SKBR3 cells (Figure 4.5B). There was evidence to suggest 
partial HER2 inhibition indicated by an increase in lifetime in some of the 
MDAMB-453 cells. But overall inhibition of HER2 phosphorylation was not 
prevented after a two-hour treatment with AG 1478.
Since Iressa is more potent than AG 1478 and it is the tyrosine kinase 
inhibitor of EGFR used in clinical settings, it was intended to assess whether 
Iressa had the same effect on HER2 phosphorylation. In addition, inhibition of 
EGFR is increasingly important in breast cancer with the introduction of 
Lapatinib recently (Geyer et al., 2006; Konecny et al., 2006) and the use of 
Iressa in hormone-resistance breast cancer (Gee et al., 2003; Polychronis et al., 
2005). The results showed that in different cell lines pretreatment with 1 pM 
Iressa (physiological dose) had a variable effect on HER2 phosphorylation. At 
a time-point of 2.5 days, Iressa decreased HER2 phosphorylation in A431 cells 
with growth inhibition (Figure 4.6A). On the contrary, MCF-7 cells with 
normal levels of EGFR, had increased HER2 phosphorylation at 2.5 days of 
Iressa treatment and cell viability confirmed that cells were highly proliferative 
at this point; MCF-7 cells were not sensitive to 1 pM Iressa (Figure 4.8B). 
Some SKBR3 and MDAMB-453 (HER2-over-expressing) cells showed partial 
HER2 inhibition but the majority of cells showed no suppression of basal 
HER2 phosphorylation (Figure 4.6A). SKBR3 cells were shown to be sensitive 
to Iressa with prolonged 1 jliM  Iressa treatment (Figure 4.8D). Therefore, the
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results showed that acute 1 pM Iressa (physiological dose) was not able to 
abolish basal HER2 phosphorylation in breast cell lines.
Since TKIs including AG 1478 and Iressa failed to decrease basal HER2 
phosphorylation in breast cell lines like MCF-7 and SKBR3, it suggested that 
the persistence of HER2 phosphorylation in these cells was not be due to 
phosphorylation from EGFR/HER2 dimerisation, but from either HER2/HER3 
or HER2/HER4 dimerisation. The fact that EGFR inhibition enhanced HER2 
phosphorylation by exogenous heregulin stimulation in MCF-7 cells (Figure 
4.3B) suggested that HER2/HER3 and HER2/HER4 dimers occurred to sustain 
HER2 phosphorylation. However, TKIs abolished HER3 phosphorylation with 
a corresponding decrease in phospho-PKB and phospho-ERKl/2 (data on AG 
1478 shown in Figure 4.6B, data on Iressa shown later Figure 4.13B). The 
decrease of HER3 phosphorylation but increased HER2 phosphorylation with 
heregulin (Figure 4.3B) and AG 1478 treatment in MCF-7 cells indicated the 
involvement of HER4 since heregulin activates both HER3 and HER4. It was 
postulated that maintenance of HER2 phosphorylation and the additional 
HER2 phosphorylation by heregulin stimulation following two hour pre­
treatment with AG 1478 may be due to activation of HER4 with subsequent 
HER2 phosphorylation. It was therefore decided to assess HER4 activation and 
its interaction with HER2 following EGFR inhibition by AG 1478 and Iressa 
in breast cell lines like MCF-7 and SKBR3.
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Figure 4.5: The effects of AG 1478 in A431 cells and three breast cell 
lines. A, A431, MDAMB-453 and SKBR3 were grown to near confluency before 
lysed to assess the total levels of HER2 and EGFR by western blot. On the right 
panel, A431 and two breast cell lines were treated with AG 1478 for 2 hours 
before the cells were lysed for western blot analysis. B, A431, MDAMB-453 and 
SKBR3 cells were incubated with either donor alone (HER2-Cy3b) or donor 
and acceptor (HER2-Cy3b+pHER2-Cy5) after pretreated the cells with 3pM 
AG 1478 for 2 hours to assess HER2 phosphorylation by FRET
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Figure 4.6. A, The effect of Iressa on HER2 phosphorylation state by 
FRET. A431 cells and three other breast cancer cell lines MCF-7, MDAMB-453 
and SKBR3 were incubated with suitable pair of antibodies to assess HER2 phos­
phorylation after pre-treated with 1 uM Iressa for 2.5 days. B, The effect of 
Iressa on pHER3 and downstream signalling pathways by western 
blot. On the left panel, A431 cells were pre-treated with AG 1478 with or 
without EGF stimulation as illustrated before western blot analysis. On the 
right panels, A431, MCF-7, MDAMB-453 and SKBR3 were lysed for west­
ern blot after treated with either 3pM AG 1478 for 2 hours or had no treat­
ment.
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4.2.3 TKIs induce proteolytic cleavage 
of HER4 as well as dimerisation between 
HER2 and HER4
As discussed in the Introduction (Section 1.3), proteolytic cleavage of HER4 
occurs in cells at a low basal level and can be increased by heregulin, or other 
growth factors that bind to HER4 (Zhou and Carpenter, 2000). The ectodomain 
cleavage of HER4 is mediated by tumour necrosis factor-°c-converting enzyme 
(TACE), a transmembrane metalloprotease that produces a membrane- 
anchored fragment (80 kD) which consists of the entire cytoplasmic and 
transmembrane domain (Carpenter, 2003; Vecchi and Carpenter, 1997). The 
m80 HER4 fragment from ectodomain cleavage was shown to associate with 
full length HER2 (Cheng et al., 2003). In addition, the transmembrane m80 
was shown to be cleaved by y-secretase and the soluble fraction (S80) was 
shown to be associated with STAT5A as well as translocated to nucleus with 
transcriptional activity (Ni et al., 2001; Williams et al., 2004).
It was postulated from the previous section that EGFR inhibition may activate 
HER4 and increase HER2 and HER4 dimerisation and thus may mediate 
EGFR tyrosine kinase inhibitor resistance. Figure 4.7A illustrates the cleavage 
of HER4 and production of m80 upon heregulin stimulation in SKBR3 and 
MCF-7 cells. Moreover, acute treatment with tyrosine kinase inhibitors (TKIs) 
AG 1478 and Iressa also induced the cleavage of HER4 and production of m80 
in both SKBR3 and MCF-7 cells (Figure 4.7A). Upon tyrosine kinase 
inhibition the m80 fragment accumulation was augmented compared to 
stimulation with exogenous heregulin. Since HER2 may be the preferred 
dimerisation partner of HER4, it was therefore postulated that the activation 
and cleavage of HER4 induced by tyrosine kinase inhibitors may induce 
dimerisation between HER2 and HER4. Figure 4.7B (upper panels) illustrates 
the co-immunoprecipitation with intracellular anti-HER4. A similar response 
to heregulin stimulation was seen with AG 1478 and Iressa which induced 
dimerisation between HER2 and HER4 in SKBR3 and MCF-7 cells (Figure 
4.7B). The co-immunoprecipitation with intracellular anti-HER2 in MCF-7
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cells also demonstrated that AG 1478 and Iressa induced dimerisation between 
HER2 and HER4 (Figure 4.7B, lower panels). In addition, the m80 fragment 
was shown to dimerise with HER2 upon AG 1478 and Iressa treatments.
In summary, acute treatment with AG 1478 and Iressa inhibited downstream 
signalling pathways. The inhibition was due to the prevention of EGFR 
homodimer, EGFR/HER2 and EGFR/HER3 heterodimer formation (Anido et 
al., 2003; Arteaga et al., 1997; Engelman et al., 2005). However, the 
proteolytic cleavage of HER4 and heterodimerisation of HER2/HER4 
sustained HER2 phosphorylation.
153
A CM
00 (Nl
(Uk_O CZ (Z  cdO  X  X  <
250
160
M80
SKBR3
oo
«  CM v Tf TO 
CD 0  $
cz cz o  ox  i  <  —
M80 L U L i  J IP HER4 Blot HER4
MCF-7
B
c
oO
u_ CD 
CD (Z 
lU X
CD
CZ
X
CM
00
3
CM(0
(A c
oO
CM
00h-
3
CMajw
250-
160-
SKBR3
1 3 IP HER4 Blot HER2
MCF-7
c
oO
sz
CM
00r*»M"
3
CMro0)
(A<u
250
160
M80
MCF-7
IP HER2 
Blot HER4
Figure 4.7: AG 1478 and Iressa induce proteolytic cleavage of HER4 as 
well as dimerisation between HER2 and HER4 in breast cancer cell lines 
via the release of the ligands. A, Both MCF-7 and SKBR3 were immunoprecipi- 
tated with intracellular HER4 antibody after being treated in the conditions as illus­
trated Following the immunoprecipitation, the cell lysate without the beads were 
loaded unto a SDS gel and a western blot analysis was performed. The membrane 
was probed with anti-HER4 antibody. B, In the upper panels, both MCF-7 and 
SKBR3 were immunoprecipitated with intracellular HER4 antibody after treated 
with the conditions illustrated before western blot analysis. The membrane was 
probed with anti-HER2 antibody. In the lower panel, MCF-7 cells near confluency 
were lysed and immunoprecipitated with intracellular HER2 antibody after treated 
with either AG 1478 or Iressa.The membrane was probed anti-HER4 antibody.
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4.2.4 TKIs induce the release of ligands
It has been shown in the previous section that acute treatment of AG 1478 
and Iressa caused activation and proteolytic cleavage of HER4 as well as 
dimerisation of HER2/HER4, a similar process to heregulin stimulation. This 
suggested that TKIs which target EGFR may trigger the release of ligands that 
activate HER4. Indeed it was observed that AG 1478 and Iressa induced the 
cleavage of the precursor proheregulin-1 producing a band between 35 and 50 
kDa, which is mature heregulin (Figure 4.8A, left panels). The maximum 
cleavage of proheregulin-1 was seen with acute AG 1478 treatment although 
there was also an increase of cleavage with Iressa treatment. The acute 
treatment of both drugs increased further the production of betacellulin in 
MCF-7 cells. In contrast to heregulin release, the maximum increase of 
betacellulin was seen with acute Iressa treatment rather than AG 1478 (Figure 
4.8A, right panel). The differential effect of these two agents is likely due to 
their different affinities and efficacies in the two cell lines. Therefore, AG 
1478 and Iressa may produce a different ligand response in MCF-7 cells since 
Iressa has a higher affinity than AG 1478. Betacellulin is the ligand for 
EGFR/HER4 and heregulin is the ligand for HER3/HER4 and their release in 
response to drugs may be different. AG 1478 is less potent that Iressa in EGFR 
inhibition and thus produced a minimal betacellulin release. Due to the greater 
potency of Iressa compared to AG 1478, more betacellulin was induced.
MCF-7 cells are generally considered to be resistant to Iressa. Using cell 
viability assays it was confirmed that during acute treatment with Iressa, MCF- 
7 growth was not prevented and furthermore there was an increase in cell 
proliferation compared to control (Figure 4.8B). In MCF-7 cells, the apparent 
resistance may be due to the acute Iressa treatment that resulted in enhanced 
HER2 phosphorylation, with dimerisation between HER2 and HER4. After 
seven days of treatment, MCF-7 cells were only minimally inhibited by ljiM 
Iressa and the cleavage of proheregulin-1 persisted after seven days of Iressa 
treatment. Therefore, the compensatory mechanism from the HER4 activation 
due to ligand release (including heregulin) and its subsequent dimerisation
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with HER2 predicts that Iressa has a minimal cell proliferation inhibitory 
effect in MCF-7 cells.
In SKBR3 cells which are known to be sensitive to Iressa (Anderson et al., 
2001; Moulder et al., 2001), there was also an increase of cleavage of 
precursor pro-heregulin-1 as well as an increase in betacellulin production 
induced by two hours of Iressa treatment (Figure 4.8C). However, the release 
of ligands was not sustained in these sensitive cell lines. Over the seven-day 
treatment of Iressa, the release of these ligands diminished. The cell viability 
experiments confirmed that lpM Iressa decreased the viability of SKBR3 cells 
to 50% of the control in contrast to MCF-7 cells (Figure 4.8D).
The results showed that the activation and cleavage of HER4 during acute 
treatment of TKIs of EGFR correlated with the release of ligands including 
betacellulin and heregulin. The activation of HER4 and dimerisation of 
HER2/HER4 may mediate primary resistance to Iressa in resistant MCF-7 
cells. In sensitive SKBR3 cells, the release of some ligands including 
betacellulin and mature heregulin-1 diminished with prolonged Iressa 
treatment.
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SDS-gel.The membrane was probed with antibodies recognizing HER4 or proheregulin-1 or betacellulin. The anti-beta-actin antibody was used as 
loading control. B, MCF-7 cells were grown in 24-well plate and left to grow for at least 24 hours before treated with either DMSO or 1 pM Iressa for 
different durations as illustrated. The viable cells were counted in cell viability analyzer using Trypan blue to stain the dead cells. C, Near confluent 
SKBR3 cells were pre-treated with Iressa or DMSO as illustrated before the cells were lysed for western blot experiment.The membrane was probe with 
antibodies recognizing proheregulin-1 and betacellulin. D, Same experiment as B but SKBR3 cells were used instead of MCF-7 cells.
4.2.5 Assessm ent of HER4 cleavage by 
FRET
To attribute the sensitivity of SKBR3 to the decrease of ligands for HER4, all 
the ligands activating HER4 needed to be tested in the cell lysate and the 
medium. Since there are multiple ligands for HER4 and multiple isoforms of 
heregulin, it would be more appropriate to assess the effect of long-term 
treatment on HER4 receptors directly instead of their ligands. Although the co- 
immunoprecipitation with anti-HER4 antibody to assess HER4 activation and 
cleavage was appropriate for acute treatment, the effect of long-term treatment 
using the same method would be limited by the effect of long-term Iressa 
treatment which has anti-proliferative effect. Therefore, the effect of long-term 
Iressa treatment on HER4 activation and cleavage in-situ by FRET was 
assessed.
To assess HER4 activation and cleavage, a new assay needed to be 
established. The intracellular anti-HER4 antibody conjugated with Cy3b 
(HER-Cy3b) recognises the residues of the kinase domain near the carboxy- 
terminus of human HER4 and the anti-phosphotyrosine antibody conjugated to 
Cy5 (pTyr-Cy5) binds to sites of tyrosine phosphorylation in the carboxyl- 
terminus. It was hypothesised that upon heregulin stimulation, there would be 
an increase of lifetime due to HER4 cleavage. The loss of FRET was 
postulated to be due to inaccessibility of the anti-phosphotyrosine antibody to 
phosphotyrosine residues as a result of the HER4 cleavage (Ni et al., 2001; 
Williams et al., 2004). The results showed that at the basal state there was 
HER4 phosphorylation resulting in a decrease of average lifetime of HER4- 
Cy3b (Figure 4.9B), consistent with report that HER4 can homodimerise with 
autophosphorylation (Carpenter, 2003). As expected, upon heregulin p-1 
stimulation, there was an increase of the median of average lifetimes of HER4- 
Cy3b (p=0.001 compared to the basal level), indicating the proteolytic 
cleavage of HER4 (Figure 4.9A). However, the cells were not sensitive to 
heregulin p. Although a few cells showed increase of lifetime of HER4-Cy3b,
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overall the median of the average lifetime of HER4-Cy3b upon heregulin p 
stimulation did not change significantly (Figure 4.9A). There are four 
heregulin (or neuregulin) genes, denoted 1, 2, 3 and 4; and they can exist in 
different isoforms due to alternative splicing, with different affinities to HER3 
and HER4 (Bazley and Gullick, 2005). This particular product heregulin P 
from Sigma (recognising p3 of NRG1, Materials Section 2.1.5) had been 
shown to activate mainly HER3 with a crossover ability to activate HER4. 
This would explain the minimal HER4 cleavage compared with heregulin P 
stimulation. Heregulin pi (pi of NRG 1, Materials Section 2.1.5) however, was 
shown to activate both HER3 and HER4 and would explain the results seen in 
Figure 4.9A. As a negative control the cells were also stimulated with EGF. 
An increase of lifetime of HER4-Cy3b was not detected. Unlike the FRET 
experiment assessing HER2 phosphorylation, the increase of lifetime upon 
heregulin P-1 stimulation in HER4-FRET experiments did not mean a loss of 
activation. Instead, it indicated activation of HER4 and cleavage of HER4 
tyrosine kinase cytoplasm domain, resulting in the separation between HER4- 
Cy3b and pTyr-Cy5.
The decrease in lifetime on heregulin P-1 stimulation is due to HER4 
cleavage rather than dephosphorylation, as supported by immunoprecipitation 
results (Figure 4.7) and the literature (Zhou and Carpenter, 2000). 
Furthermore, phosphatase YOP which dephosphorylated the HER4 
phosphorylation could not reverse the change of HER4-Cy3b lifetime 
significantly following the cleavage of HER4 by heregulin p-1 stimulation 
compared to EGF and heregulin P which did not cause significant HER4 
cleavage (Figure 4.9A and Figure 4.9B)
To further establish the assay for HER4 cleavage by FRET, the cells were 
pretreated with 100 pM TAPI-1 (TACE inhibitor). The hypothesis was that if 
the ectodomain cleavage of HER4 is mediated by TACE (Carpenter, 2003; 
Vecchi and Carpenter, 1997) inducing the loss of FRET (increase of lifetime), 
then TAPI-1 should reverse the loss of FRET to prove that the assay is 
specific. MCF-7 and SKBR3 cells were pretreated with 100 pM TAPI-1 or 
DMSO (as control) for 1 hour before the cells were stimulated with either 
heregulin p-1 (MCF-7 cells are more sensitive to heregulin p-1 as shown
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above) or heregulin P (SKBR3). Figure 4.9C and 4.9D show that while 
heregulin induced the loss of FRET (increase of lifetime, p < 0.01 for both 
MCF-7 and SKBR3 cells compared to basal condition) due to HER4 cleavage, 
TAPI-1 reversed the loss of FRET.
The results indicate that activation of HER4 is associated with a decrease in 
FRET with the reagents employed here and that this correlates with cleavage 
of HER4. This effect is blocked if cleavage is blocked. Therefore in the case of 
HER4 and in the context of active TACE, an increase of lifetime can be used 
as a reporter of its activation and cleavage.
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Figure 4.9: Heregulin induces proteolytic cleavage of HER4 in breast cancer cell lines. A, MCF-7 cells were incubated with either 
donor alone (HER4-Cy3b) or donor and acceptor (HER4-Cy3b+pTyr-Cy5) and stimulated with EGF or heregulin beta or heregulin beta-1. B, To 
remove phosphotyrosine, the phosphatase YOP was used following stimulation of the cells with ligands. C,D, FRET experiments to assess 
HER4 cleavage in MCF-7 and SKBR3 cells. The cells were treated with DMSO or TACE inhibitor (TAPI-1) for 1 hour before simulation with 
heregulin beta-1 (MCF-7 cells) or heregulin beta (SKBR3) and the medians of the lifetimes were compared with the basal condition (without drugs 
or heregulin stimulation) using Mann-Witney test and the significance value is denoted as *.
4.2.6 Application of FRET assay to 
a ssess  HER4 cleavage in relation to TKIs
Having established the increase of lifetime of HER4-Cy3b as a reporter of 
HER4 cleavage, the method was applied to assess HER4 activation and 
cleavage in MCF-7 cells to investigate the role of HER4 in mediating 
resistance to TKIs of EGFR as well as to verify the observations from 
immunoprecipitation. The results showed that pretreatment with AG 1478 
treatment with either simultaneous EGF or heregulin (3 stimulation increased 
lifetime of HER4-Cy3b in MCF-7 cells (p < 0.01 for medians between those 
treated with AG 1478 and those without treatment), indicative of the 
proteolytic cleavage of HER4 (Figure 4.10A). The effect of pretreatment with 
AG 1478 on HER4 cleavage with simultaneous heregulin P-1 is additive but 
the difference is not statistically significant (p=0.07) since heregulin P-1 
stimulation already induced cleavage of HER4 (Figure 4.10A). The data of 
Figure 4.10A was represented in Figure 4.1 OB as lifetime maps of HER4-Cy3b 
in MCF-7 cells using a pseudocolour scale (blue colour indicating longer 
lifetime and red indicating shorter lifetime). The average lifetime of HER4- 
Cy3b decreased in the presence of the acceptor (pTyr-Cy5) indicating the basal 
HER4 phosphorylation and FRET. The loss of FRET indicated by blue colour 
was seen with heregulin p-1 stimulation and with two-hour pretreatment of AG 
1478 indicating the proteolytic cleavage of HER4. The two conditions were 
additive on the increase of lifetime of HER4-Cy3b (loss of FRET, indicative of 
HER4 cleavage). Moreover, the effect of Iressa was also assessed on HER4 
cleavage in MCF-7 cells. Following a two-hour treatment with 1 pM Iressa in 
MCF-7 cells, an increase in lifetime of HER4-Cy3b was again observed 
regardless of ligand stimulation (the medians of the average lifetimes of those 
cells treated with 1 pM Iressa are significantly increased compared to basal 
levels, p < 0.01 for all conditions) (Figure 4.11 A). The increase of lifetime of 
HER4-Cy3b persisted after 7 days of treatment with Iressa 1 pM (p < 0.001 
compared to the basal) (Figure 4.1 IB) with minimal inhibition of cell
162
proliferation (Figure 4.11C). However, increasing the dose of Iressa to 10 pM 
inhibited the HER4 cleavage with no increase of lifetime of HER4-Cy3b. 
However, at this dose, DMSO 1:100 concentration was toxic to MCF-7 cells. 
In addition, 1 pM Iressa is the achievable physiological dose, therefore, the 
effect of 10 pM Iressa was not pursued further.
FRET was also applied to assess HER4 cleavage in sensitive SKBR3 cells 
after they were pretreated with Iressa for seven days. Figure 4.12A shows the 
decrease of average lifetime of HER4-Cy3b in the presence of pHER4-Cy5 
from a median of 2.25 ns to a median of 2.1 ns, indicating the basal 
phosphorylation of HER4. After pretreatment with Iressa 1 pM for 2.5 days, 
there was an increase of average lifetime of HER4-Cy3b indicating activation 
and proteolytic cleavage of HER4 (p<0.01 compared to basal), consistent with 
immunoprecipitation results (Figure 4.7). However, the amount of HER4 
cleavage decreased with seven-days of lpM Iressa treatment as indicated by 
the lifetime of HER4-Cy3b returning to basal state (p=0.32 compared to basal) 
(Figure 4.12A). The lifetime map of HER4-Cy3b representing this data is 
illustrated in Figure 4.12B. The diagram shows an average lifetime for HER4- 
Cy3b was decreased with the acceptor (pTyr-Cy5) indicating the basal degree 
of HER4 activation and FRET as illustrated by the change of colour. The 
increase of lifetime of HER4-Cy3b was seen with 2.5 days of pretreatment 
with lpM Iressa. The increase of lifetime of HER4-Cy3b was inhibited when 
the cells were treated for longer durations with 1 pM Iressa. The results 
therefore show that there was activation and proteolytic cleavage of HER4 
during the acute treatment of Iressa in sensitive SKBR3 but this process 
diminished after 7 days of treatment (Figure 4.12A and 4.12B) with the 
decrease in the release of ligands for HER4 including betacellulin and 
heregulin (Figure 4.8C). The diminished HER4 cleavage would explain why 
seven-day treatment with lpM Iressa is able to decrease the proliferation of 
SKBR3 cells to 50% of that DMSO control in contrast to resistant MCF-7 
cells.
In summary, the results showed that the activation and cleavage of HER4 
during acute treatment of tyrosine kinase inhibitors of EGFR correlated with 
the release of ligands including betacellulin and heregulin. The activation of
163
HER4 and dimerisation of HER2/HER4 may mediate primary resistance to 
Iressa in resistant MCF-7 cells. In sensitive SKBR3, there was evidence to 
suggest that the release of some ligands including betacellulin and mature 
heregulin-1 diminished with prolonged Iressa treatment, correlated with 
decrease in HER4 cleavage shown by FRET. Therefore, the induction of 
inactive EGFR homodimers and EGFR/HER2 dimers by Iressa (Arteaga et al., 
1997) and the decrease in HER4 activation may explain Iressa sensitivity of 
SKBR3 cells which over-express HER2 with moderate amount of EGFR. 
However, since assessment of all the ligands or all types of heregulin are 
difficult to achieve, it could not excluded that other ligands may remain 
activated after prolonged Iressa treatment in sensitive SKBR3 cells.
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Figure 4.10: The effect of AG 1478 on HER4 cleavage in MCF-7 cells. A, MCF-7 cells were incubated with either donor 
alone (HER4-Cy3b) or donor and acceptor (HER4-Cy3b+pTyr-Cy5) to assess HER4 cleavage by FRET after stimulated with various ligands 
with or without two hour pre-treatment of 3 uM AG 1478.
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Figure 4.11: Iressa induced cleavage of HER4 in MCF-7 cells. A, MCF-7 cells 
were incubated with either donor alone (HER4-Cy3b) or donor and acceptor (HER4- 
Cy3b+pTyr-Cy5) after pretreated with Iressa 1 pM for 2 hours while being stimulated 
by different ligands B, MCF-7 cells were treated with Iressa either 1 pM or 10 pM for 
7 days to assess HER4 cleavage by FRET C, MCF-7 cells were plated in 24-well plate 
and left to grow for at least 24 hours before treated with either DMSO or Iressa 
(1 uM or 10 uM) as illustrated. The viable cells were counted in cell viability ana­
lyzer using Trypan Blue to stain the dead cells. The proportion of viable cells in 
each condition was compared with DMSO control and the normalised cell viabil­
ity was plotted as bar charts above.
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Figure 4.12: Iressa induces proteolytic cleavage of HER4 only during acute setting in 
SKBR3. A, SKBR3 cells were incubated with either donor alone (HER4-Cy3b) or donor 
and acceptor (HER4-Cy3b+pHER4-Cy5) to assess HER4 proteolytic cleavage by FRET 
after pretreated with different durations of 1 pM Iressa. B, The lifetime maps of 
HER4-Cy3b in SKBR3 cells using pseudocolour to represent data in A.
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4.2.7 Prolonged Iressa treatment caused  
reactivation of phospho-HER3
Iressa has been shown to inhibit the PI3K/PKB pathway via HER3 
(Engelman et al., 2005). Figure 4.6B showed the rapid decrease of phospho- 
HER3 and phospho-PKB (Ser473) upon acute treatment of Iressa through 
inhibition of EGFR/HER3 (Anido et al., 2003; Engelman et al., 2005). 
However, acute treatment of Iressa induced the release of heregulin in both 
MCF-7 and SKBR3 causing dimerisation of HER2 and HER4 (Figure 4.7 and 
4.8). Since heregulin is the ligand for HER3 and HER4, it was thought that 
acute Iressa treatment may have induced dimerisation of HER2/HER3 as well 
as HER2/HER4, causing HER2 phosphorylation. Figure 4.13A shows that 
Iressa was not able to abolish HER2 phosphorylation even in surviving 
sensitive SKBR3 cells. The remaining surviving cells had even more HER2 
phosphorylation compared to basal condition after seven days of Iressa 
treatment (p=0.03) (Figure 4.13A). Since in SKBR3 cells the activation and 
cleavage of HER4 decreased with prolonged Iressa treatment, it was postulated 
that the persistent HER2 phosphorylation after seven days of Iressa treatment 
maybe due to HER2/HER3 dimerisation. Figure 4.13B shows phospho-HER3 
was reactivated with prolonged Iressa treatment. The reactivation occurred 
after the initial decrease in HER3 phosphorylation via EGFR/HER3 
(Engelman et al., 2005) in both SKBR3 and MCF-7 cells. The reactivation was 
not due to the degradation of the drugs since the dose of Iressa was replenished 
after a few days. There was also a recovery of downstream signalling pathways 
phospho-PKB (Ser473) and phospho-ERKl/2 within 48 hours (Figure 4.13 B), 
consistent with activation of alternative HER pathways via the ligands 
including HER2/HER3 and HER2/HER4.
In summary, the results showed that EGFR inhibition by AG 1478 and Iressa 
treatment induced the release of multiple ligands including heregulin and 
betacellulin, which caused cleavage of HER4 and dimerisation of 
HER2/HER4. However the release of heregulin also caused activation of 
HER3 and PKB phosphorylation via the HER2/HER3 dimerisation after the
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initial inhibition of PKB activation via EGFR/HER3 (Engelman et al., 2005). 
The release of these ligands mediates primary resistance in MCF-7 cells. In 
sensitive SKBR3 cells although there is a decrease of HER4 cleavage with 
prolonged Iressa treatment, the reactivation of phospho-HER3 may mediate 
secondary resistance to Iressa.
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Figure 4.13: Reactivation of HER3 causes persistent HER2 phosphoryla­
tion and reactivation of downstream signalling pathways in SKBR3 
cells. A, SKBR3 cells were incubated with suitable antibodies to assess HER2 
phosphorylation after the cells were treated with 1 pM Iressa for different dura­
tions. B, In the upper panel, SKBR3 and MCF-7 cells were lysed after treated with 
either DMSO or Iressa as illustrated for western blot analysis.The phosphorylation 
of HER3 on Tyr 1289 was determined using phosphospecific antibodies. In the 
lower panels,the cells were lysed after treated with either DMSO, AG 1478 or Iressa 
as illustrated. PKB on Ser 473 and MAPK on Thr202/Tyr 204 and the total levels of 
PKB and ERK1/2 were assessed by western blot using appropriate antibodies.
170
4.2.8 HER4 mediates resistance to 
Iressa in sensitive SKBR3 cells via induced 
autocrine ligand release
To test the hypothesis that activation of alternative HER receptors through 
their ligands mediate resistance to Iressa, sensitive SKBR3 cells were 
stimulated with TGF-a, heregulin-p, heregulin P-1 or betacellulin while the 
cells were treated with Iressa for 96 hours. Figure 4.14A shows that all the 
ligands made SKBR3 cells resistant to Iressa but the greatest effect was seen 
with Iressa treatment in combination with either heregulin P or heregulin P-1. 
The results are consistent with previous experiments that EGFR inhibition by 
tyrosine kinase inhibitors sensitises the cells to exogenous heregulin 
stimulation in terms of HER2 activation (Figure 4.2) and hence induced 
enhanced proliferation. The experiment confirms the role of ligands in 
mediating resistance to Iressa, including HER3/HER2 and HER4/HER2 
through heregulin since heregulin activates HER3 and HER4 via HER2 
(Graus-Porta et al., 1997; Lewis et al., 1996).
Since it was shown that Iressa induced the release of ligands including 
betacellulin and heregulin, it was postulated that antibodies neutralising the 
ligands may potentiate an anti-proliferative effect. Therefore, an anti- 
betacellulin antibody (which blocks the effects of betacellulin) was used in 
combination with Iressa and it was determined that it potentiated the effect of 
Iressa in an anti-proliferative manner (Figure 4.14B). In summary, HER4 may 
mediate resistance to Iressa via induced autocrine ligand release.
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Figure 4.14: Ligands mediate resistance in SKBR3 cells. A, SKBR3 cells 
were grown in 24-well plates after seeding approximately 25000 cells per well.The 
cells were left to grow for at least 24 hours before treated with either DMSO 
(1:1000); Iressa 1 pM alone; or stimulated with either 100 ng/ml TGF, 100 ng/ml 
heregulin beta, 100 ng/ml heregulin beta-1 or 20 ng/ml betacelluin while pre­
treated with Iressa 1 pM.The viable cells were counted in cell viability analyzer after 
96 hours using Trypan blue to stain the dead cells. B, SKBR3 cells were left to grow 
in 24 well plate for at least 24 hours before treated with either DMSO or Iressa alone 
or Iressa in combination with 20 pg/ml anti-betacellulin.
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4.2.9 Combined therapy with Iressa and 
Herceptin is additive in SKBR3
It has been shown that the combined treatment with Herceptin and Iressa in 
SKBR3 was either additive (Moasser et al., 2001) or synergistic (Normanno et 
al., 2002) in exerting anti-proliferative effects as well as having enhanced 
antitumour activity in BT-474 xenografts (Britten, 2004; Moulder et al., 2001). 
The cell viability experiments confirmed that the combined treatment was 
more prominent in its anti-proliferative effect than either Iressa or Herceptin 
treatment alone (Figure 4.15A). FRET was used to assess the effect of 
combined therapy on EGFR and HER2 phosphorylation in sensitive cells. 
Figure 4.15B shows the decrease of average lifetime of EGFR-Cy3b with 
pEGFR-Cy5 from 2.45ns to 2.15ns, indicating basal phosphorylation of EGFR 
in these cells. Pre-treatment with lpM Iressa partially suppressed EGFR 
phosphorylation with the increase of the average lifetime of EGFR-Cy3b from 
2.15 ns to 2.3 ns (p < 0.001 compared to basal). The incomplete suppression of 
EGFR phosphorylation by Iressa may be explained by the compensated 
increase in ligand release (including betacellullin production) induced by 
Iressa (Figure 4.8). However, combination of lpM Iressa with 40 pg/ml of 
Herceptin suppressed EGFR phosphorylation (p<0.001 compared to basal) 
(Figure 4.15B). This result depicts the additive effect of combined therapy in 
the cell viability experiments (Figure 4.15A). The assessment of HER2 
phosphorylation by FRET shows that HER2 phosphorylation increased from 
basal levels during the first 2.5 days of treatment. However, after five days of 
treatment we observed a decrease of HER2 phosphorylation (increase in 
average lifetime of donor HER2-Cy3b), in concordance with an enhanced anti­
proliferative effect (Figure 4.15C). And after 7 days of treatment, there are 
very few cells remaining for FRET analysis.
In summary, combined treatment of cells with Herceptin and Iressa exerts a 
greater suppression in EGFR and HER2 phosphorylation and induced an 
enhanced anti-proliferative effect.
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Figure 4.15: Combined therapy of Iressa and Herceptin is additive. A, SKBR3 
cells were grown in 24-well plate and left to grow for at least 24 hours before treated 
with either DMSO or Iressa 1 pM or Iressa 1 pM with Herceptin 40 pg/ml for 7 days.The 
viable cells were counted in Cell viability analyzer using Trypan blue to stain the dead 
cells, after seven days of treatment. B, SKBR3 were pre-treated with either Iressa 1 pM 
or combined treatment of Herceptin 40 pg/ml and Iressa 1 pM different durations to 
assess EGFR phosphorylation by FRET. C, After pre-treated the SKBR3 cells with differ­
ent durations of 40 pg/ml Herceptin and 1 pM Iressa, the cells were incubated with 
suitable pairs of antibodies to assess either HER2 phosphorylation of by FRET.
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Figure 4.16: Model of resistance to TKIs, AG 1478 and Iressa. Quinazoline 
tyrosine kinase inhibitors of EGFR have been shown to induce inactive EGFR 
homodimers, EGFR/HER2 dimer as well as inhibiting EGFR/HER3 dimers, 
resulting in a decrease in PKB and MAPK activities. However, the inhibition of 
EGFR activation by AG 1478 and Iressa caused the release of various ligands 
including heregulin and betacellulin, resulting in HER4 activation and proteo­
lytic cleavage with dimerisation between HER2 and HER4. Moreover, the 
heregulin release also reactivated HER3 via HER2/HER3 dimers and down­
stream signalling pathways after the initial decrease of HER3 activation via 
EGFR/HER3 dimerisation.
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4 .3  D iscu ssion
The EGFR receptor concentration does not predict the response to EGFR 
inhibitors (Arteaga, 2002; Chung et al., 2005); EGFR tyrosine kinase inhibitor 
monotherapy results in a relatively poor response rate and the response is not 
usually sustained for the responders (Cohen et al., 2003). HER receptors are 
highly dynamic and the hierarchy of their activation changes with the 
availability of HER receptors and with drug treatment (Graus-Porta et al., 
1997; Knowlden et al., 2003). For example, MCF-7 cells are not driven by 
HER2 over-expression and have a low level of EGFR. Yet when these cells are 
treated with the anti-oestrogen, tamoxifen, it has been shown that the 
EGFR/HER2 heterodimer levels become elevated and their autocrine loops are 
activated (Knowlden et al., 2003). Iressa has been used to overcome hormone 
resistance in oestrogen deprived MCF-7 cells (Knowlden et al., 2003). Thus, 
the response to these drugs may depend more on the activation and 
phosphorylation status of HER receptors as well as their dimerisation, rather 
than the receptor concentration alone.
Although it has been speculated that alternative HER receptor activation 
mediates resistance to targeted therapies, this is the first time that a molecular 
mechanism is provided to explain drug resistance in breast cancer cell lines. 
Quinazoline tyrosine kinase inhibitors of EGFR have been shown to induce 
inactive EGFR homodimers and EGFR/HER2 dimers in EGFR over­
expressing cancer cells (Arteaga et al., 1997) as well as inhibits EGFR/HER3 
dimers (Engelman et al., 2005). However here, the inhibition of EGFR 
activation by AG 1478 and Iressa caused the release of various ligands 
including heregulin and betacellulin. The release of these ligands resulted in 
dimerisation between HER2 and HER4, and proteolytic cleavage of HER4. 
Moreover, the heregulin release also reactivated HER3 via HER2/HER3 
dimers and downstream signalling pathways after the initial decrease of HER3 
activation via EGFR/HER3 dimerisation. These processes offer an explanation 
for the primary resistance to Iressa in MCF-7 breast cell lines. In Iressa 
sensitive SKBR3 cells, although there is evidence to suggest that HER2 and 
HER4 dimerisation decreases with prolonged Iressa treatment, alternative HER
176
activation including HER2/HER3 dimers may mediate secondary resistance to 
Iressa, despite the initial anti-proliferative effect from the inhibition of EGFR 
homodimers, EGFR/HER2 and EGFR/HER3. The model of resistance to 
Iressa is shown in Figure 4.16.
The current literature seems to suggest that HER2 phosphorylation is 
abolished by TKIs in HER2 over-expressing breast cancer cell lines (Anido et 
al., 2003; Moasser et al., 2001). The study presented here does not contradict 
the current literature, rather the FRET provides a novel insight into the present 
knowledge of HER receptor activation. FRET has the unique ability to 
specifically monitor the phosphorylation status of proteins at the single cell 
level. For example, it can often detect HER2 phosphorylation in individual 
cells even when the HER2 phosphorylation signal is below the detection limits 
of western blot. In cell lines which are sensitive to Iressa, chronic Iressa 
treatment may actually cause down-regulation of EGFR and HER2 levels and 
thus HER2 phosphorylation maybe below detection limit of western analysis 
for the whole cell lysate even though HER2 remains activated in the individual 
cells and may be monitored by FRET. The apparent difference from the 
current literature is also more an issue of different experimental conditions of 
EGFR inhibitor treatments. For example, in Moasser et al (2001), the 
experiments on HER2 phosphorylation were a dose dependent study of Iressa 
on SKBR3 cells (Moasser et al., 2001). HER2 phosphorylation was only 
partially suppressed by 1 pM Iressa and only fully abolished when the dose 
was increased to 10 pM. Similar experiments were performed here but 10 pM 
drug was found to be toxic to cells in part through the vehicle.
In a recent paper by Zhou et al (2006) the authors found that among various 
genes examined in 44 different non-small cell lung cancer cell lines, only the 
expression of heregulin significantly correlated with insensitivity to Iressa 
(Zhou et al., 2006). Although HER3 expression was only very weakly 
correlated with Iressa sensitivity, the authors concluded that it is the heregulin- 
induced HER3 activation rather than the level causing insensitivity to Iressa 
(Zhou et al., 2006). It has been shown in this study that HER3 phosphorylation 
was suppressed by Iressa upon immediate treatment in three breast cancer cell 
lines as well as A431 cells through suppression of EGFR/HER3 dimerisation. 
However, the release of ligands (including heregulin and betacellulin) induced
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by Iressa treatment resulted in dimerisation between HER4 and HER2 as well 
as HER3 and HER2. The effects of these dimerisations were the reactivation of 
phospho-HER3 and phospho-PKB (Ser473).
Sergina et al (2007) also observed the reactivation of phospho-HER3 with 
prolonged Iressa treatment (Sergina et al., 2007). The reactivation of HER3 
may occur within several hours of Iressa treatment after the initial suppression 
of HER3 activation. The group explained that the reactivation of HER3 with 
prolonged Iressa treatment was due to a compensatory shift in the HER3 
phosphorylation-dephosphorylation equilibrium as a result of increased HER3 
expression and reduced phosphatase activity (Sergina et al., 2007) without 
giving consideration to the importance of ligand release. The results on 
activation of the alternative HER receptors have contributed to the gaps in 
understanding the mechanisms of resistance to these targeted therapies.
Although exogenous heregulin enhanced aggregation (Tan et al., 1999) and 
increased invasiveness in breast cell lines (Xu et al., 1997), it has been 
reported to have an anti-proliferative effect (Sartor et al., 2001) and thus may 
challenge the role of HER4 in mediating resistance to Iressa. Aguilar et al 
(1999) reported that some of the disparity on various effects of heregulin is due 
to variations in the cell lines, ligand dosage and the methodologies used 
between different investigators (Aguilar et al., 1999). The group found no 
evidence that heregulin had any growth-inhibitory effects in human epithelial 
cells after using several different in vitro and in vivo assays in nine different 
cell lines. The study presented here has also shown that exogenous heregulin 
induced proliferation rather than exerting an anti-proliferative effect upon 
Iressa treatment, confirming the role of heregulin in mediating resistance to 
tyrosine kinase inhibitors of EGFR. Moreover, the role of HER4 in mediating 
resistance to Iressa was confirmed since anti-betacellulin antibody potentiated 
the anti-proliferative effect in combination with Iressa treatment.
The combined therapy of Herceptin and Iressa is additive in suppression of 
EGFR and HER2 phosphorylation as well as exerting its anti-proliferative 
effect, consistent with the report that a combination of targeted therapies 
against both EGFR and HER2 is more effective that single agents in breast 
cancer (Normanno et al., 2002). There are other signalling pathways such as 
VEGF that are independent but interrelated to EGFR. For instance EGF and
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TGF-a both induce VEGF expression but EGFR inhibition does not block 
VEGF and tumour angiogenesis is maintained (Tabemero, 2007). VEGF 
upregulation may contribute to resistance to EGFR inhibition and both pre- 
clinical and clinical studies have confirmed the additive effects of VEGF and 
EGFR inhibitors. This example also presents a rationale for using combined 
therapies for cancer patients (Ciardiello et al., 2006; Tabemero, 2007). The 
results here indicate how apparent targeted therapies for breast cancer patients 
have complex effects, offering treatment opportunities to overcome resistance 
in patients. It is anticipated that future therapy for breast cancer may involve 
targeting various HER receptors, their ligands (Zhou et al., 2006) as well as 
metalloproteinases that mediate the cleavage of the ligands (Fridman et al., 
2007).
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5 TACE-mediated ligand re lea se  
induces activation of alternative  
HER receptors in resp on se  to  
Trastuzumab (Herceptin) 
treatm ent in breast ca n cer  c e lls
5.1 Introduction
Herceptin, a humanised murine monoclonal antibody against HER2, is now 
used in the adjuvant treatment of breast cancer (Piccart-Gebhart et al., 2005; 
Romond et al., 2005). It binds to the domain IV of the juxtamembrane region 
of HER2 (Cho et al., 2003). As discussed in the Introduction (Section 1.5),o
there have been several proposals of mechanisms of Herceptin to explain its 
clinical benefits. These include HER2 receptor downregulation and inhibition 
of aberrant receptor tyrosine kinase activity (Cuello et al., 2001; Sliwkowski et 
al., 1999); activation of antibody-dependent cellular cytotoxicity (Clynes et al., 
2000; Cooley et al., 1999); activation of pTEN (Nagata et al., 2004); inhibition 
of basal and activated HER2 ectodomain cleavage in breast cancer cells 
(Molina et al., 2001); increased p27Kipl levels and interaction with CDK2, 
resulting in decreased CDK2 activity (Lane et al., 2001). However, the exact 
mechanisms of action are still unknown. Moreover, the reasons why some 
patients are resistant and the responders eventually develop resistance to 
Herceptin have not been explained through experimental procedures.
Here using established FRET methods and western blot to assess 
phosphorylation status of HER receptors, the study assessed the change in 
activation status of all 4 HER receptors in relation to Herceptin treatment in 
breast cancer cell lines.
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5.2 Results
5.2.1 The effects of Herceptin on HER2 
receptors and phosphorylation status in 
SKBR3 cells
In the previous chapter, it was shown that Iressa failed to diminish HER2 
phosphorylation due to activation of alternative HER3 and HER4 receptors via 
various ligands. Since Herceptin targets the HER2 receptor, it was decided to 
investigate whether Herceptin would abolish HER2 phosphorylation in 
SKBR3 cells. Assessing HER2 phosphorylation by FRET, the decrease of 
average lifetime of HER2-Cy3b with pHER2-Cy5 from 2.15 ns to 1.5ns 
indicates the basal phosphorylation of HER2 in SKBR3 (Figure 5.1 A). After 
two days of Herceptin treatment, there was suppression of HER2 
phosphorylation (increase of average lifetime) with an increase in its median 
compared to basal phosphorylation (p=0.03) but the difference was not 
significant after five days. There was however a considerable amount of 
heterogeneity between cells, with suppression of HER2 phosphorylation in 
some cells (yellow box) although the phosphorylation of HER2 was 
maintained in the majority of cells (Figure 5.1 A). After 10 days of Herceptin 
treatment, the remaining treated surviving cells still had persistent HER2 
phosphorylation (Figure 5.1 A). The heterogeneity of responses to Herceptin 
shown in Figure 5.1 A was presented as lifetime maps of HER2-Cy3b in 
SKBR3 cells using pseudocolour; some cells showed reversal of HER2 
phosphorylation (indicated by blue colour) and paradoxically in other cells 
HER2 phosphorylation was increased (indicated by red colour) and two 
examples of each condition are shown in the Figure 5.IB. The inability of 
Herceptin to abolish HER2 phosphorylation after 10 days of Herceptin 
treatment was also confirmed by western blot despite the effect on the viability 
of SKBR3 cells (Figure 5.2A and 5.2B). However, after 10 days treatment of
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SKBR3 cells with Herceptin, the HER2 receptors were downregulated (Figure 
5.2B).
In summary, the results showed that although Herceptin downregulated 
HER2 receptors in HER2 over-expressing SKBR3 breast cancer cells, the 
remaining surviving cells had persistent HER2 phosphorylation. The 
downregulation of HER2 receptors would result in the decrease of HER2 
homodimers which are known to cause ligand independent activation in these 
cells (Worthylake et al., 1999). Therefore, the continued HER2 
phosphorylation in these cells would imply that HER2 phosphorylation may be 
maintained by other HER receptors, e.g. EGFR/HER2, HER3/HER2 and 
HER4/HER2 since Herceptin binds to HER2 receptors without affecting their 
dimerisation with other HER receptors.
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Figure 5.1: Effect of Herceptin on HER2 phosphorylation by FRET. A, SKBR3 cells were incubated with suitable pair of anti­
bodies to assess HER2 phosphorylation by FRET after pretreated with 40 pg/ml Herceptin as illustrated. B, The lifetime maps of 
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Figure 5.2: The effect of Herceptin on HER receptors and downstream 
signalling pathways in sensitive SKBR3. A, SKBR3 cells were grown in 24-well 
plates and left to grow for at least 24 hours before treated with 40 pg/ml Herceptin 
as illustrated. The viable cells were counted in cell viability analyzer using Trypan 
Blue to stain the dead cells. The proportion of viable cells in each condition was 
normalised to DMSO and plotted as bar chart above B, In the parallel experiment 
with the cell viability, SKBR3 cells were lysed for western blot analysis after pre­
treatment with 40 pg/ml Herceptin. 10 ng of protein was loaded in each lane and 
four parallel SDS-PAGE gels were run. Proteins were transferred and different 
molecular weight ranges were probed for different antigens. (Note that at 160 kDa 
is a non-specific band and EGFR molecular weight is 175kDa and HER2 is 185 kDa).
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5.2.2 The effects of Herceptin on EGFR 
and other HER receptors in SKBR3 cells
HER2 amplification has been shown to induce constitutive activation of 
EGFR in addition to HER2 (Worthylake et al., 1999). HER2 over-expressing 
breast cancer cells have also been shown to be sensitive to tyrosine kinase 
inhibitors selective for the EGFR (Anderson et al., 2001; Moulder et al., 2001) 
indicating the importance of EGFR-driven activation in these cells. Since 
SKBR3 over-express HER2 and moderately express EGFR, it was intended to 
assess the effect of Herceptin on EGFR receptors and their phosphorylation 
status. The western blot analysis showed that the cells had increased 
phosphorylation of EGFR receptors upon immediate Herceptin treatment 
(Figure 5.2B). However, since western blot cannot detect the EGFR 
phosphorylation in vivo, the effect of acute Herceptin treatment on EGFR 
activation was assessed in SKBR3 cells by FRET. Using FRET, it was shown 
that there was EGFR basal phosphorylation in SKBR3 cells, indicated by the 
decrease of lifetime of EGFR-Cy3b in the presence of pEGFR-Cy5 from 2.45 
ns to 2.15 ns (Figure 5.3A). Upon the acute treatment with Herceptin 
treatment, there was a group of cells showing increase of lifetime compared to 
basal level (indicative of decrease in EGFR phosphorylation). However, there 
was another group of cells where EGFR activation was not affected. These 
cells in fact had increased EGFR phosphorylation compared to basal level, 
suggesting that these cells were not affected by the inhibitory effect of HER2 
by Herceptin. Long-term treatment of Herceptin downregulated EGFR to an 
undetectable level in western blot and this had occurred in concordance with 
downregulation of HER2 receptors and an effect on the cell viability (Figure 
5.2A and 5.2B).
The western blot analysis also showed that there was increased activation of 
phospho-HER3 and phospho-HER4 (Figure 5.2B). In the previous chapter, it 
was shown that Iressa induced activation and proteolytic cleavage of HER4 as 
well as dimerisation of HER2/HER4. It was intended to assess whether 
Herceptin also induced similar processes in SKBR3. Using
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immunoprecipitation it was demonstrated that there was an increased cleavage 
of HER4 as well as dimerisation between HER2 and HER4 induced by acute 
Herceptin treatment (Figure 5.3B). Using the established method to assess 
HER4 cleavage by FERT, it was shown that Herceptin induced the cleavage of 
HER4 indicated by increase of lifetime of HER4-Cy3b, which persisted over 1 
week treatment with Herceptin (Figure 5.3C).
In summary, the results showed that although Herceptin downregulated 
EGFR and HER2 receptors in SKBR3 which are known to have constitutive 
activation of EGFR and HER2, the phosphorylation of EGFR and HER2 was 
not abolished in the treated surviving cells. In addition, these cells have 
increased HER3 and HER4 levels. Furthermore, Herceptin induced the 
cleavage of HER4 as well as HER2/HER4 dimerisation in these cells.
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Figure 5.3: The effect of Herceptin on EGFR and HER4
activation/cleavage. A, SKBR3 cells were pretreated with different durations of 
40 pg/ml Herceptin to assess EGFR phosphorylation by FRET. B, SKBR3 cells were 
immunoprecipitated with intracellular HER4 antibody. Following the immunopre­
cipitation, the cell lysate without the beads were loaded unto a SDS gel and a west­
ern blot analysis was performed. The membrane was probed with either anti-HER4 
antibody (left panel) or anti-HER2 antibody (right panel). C, SKBR3 cells were 
pretreated with 40 pg/ml Herceptin as illustrated to assess HER4 cleavage by FRET.
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5.2.3 The effects of Herceptin on 
downstream signalling pathways in 
relation to HER receptors in SKBR3 cells
Analysing the downstream signalling pathways by western blot analysis in 
relation to HER receptors’ responses, it was found that the effect of Herceptin 
on phosphorylation of PKB and ERK1/2 was not concordant (Figure 5.2B). In 
the acute treatment of Herceptin there was immediate reduction of PKB 
phosphorylation which did not correspond to activation of HER receptors by 
western blot. Other group had shown that the initial decrease of PKB 
activation upon Herceptin treatment is due to activation of pTEN (Nagata et 
al., 2004). However, FRET data had shown that there was evidence of 
decreased EGFR and HER2 activation in some of the Herceptin treated cells 
during acute Herceptin treatment (Figure 5.1 and Figure 5.3), which may 
explain decrease in PKB activation from decrease activities from HER2 
homodimers and EGFR/HER2 dimers. Discordantly, there was increased 
phosphorylation of ERK1/2 that corresponded to increased phosphorylation of 
EGFR, HER2 and HER4 induced by Herceptin (Figure 5.2B). Subsequent rise 
of phospho-PKB (Ser 473) corresponded to increase of HER3 
phosphorylation. With prolonged treatment, the decrease in the levels and 
phosphorylation of PKB and ERK1/2 was correlated with the downregulation 
of EGFR and HER2.
5.2.4 Control experiments on Herceptin
The results from Section 5.2.1 to 5.2.3 have shown that Herceptin induced 
activation of all HER receptors and such mechanism may mediate its 
resistance in breast cell lines. To conclude such results, several control 
experiments were done to exclude other possibilities.
It was shown that the loss of pTEN predicts Herceptin resistance (Nagata et 
al., 2004). The study however did not find such evidence in SKBR3 and MCF-
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7 cells (Figure 5.4A). Moreover, it was possible that the degradation of 
Herceptin would diminish its effect, resulting in its resistance in breast cell 
lines. To exclude the degradation of Herceptin over the treatment period, a 
western blot analysis was performed on the medium containing SKBR3 cells 
treated with 40 pg/ml Herceptin as well as medium containing 40 pg/ml 
Herceptin that was kept in incubator for up to 10 days. The medium was 
denatured in SDS and was loaded in SDS PAGE. The membrane was probed 
with monoclonal anti-human immunoglobulin antibody that recognizes the Fc 
component of Herceptin. The results showed that degradation of Herceptin did 
not happen for up to 10 days in the experiments (Figure 5.4B). As control, the 
effect of Herceptin on HER2 phosphorylation in normal breast cell line MCF- 
12F was also assessed. Even though Herceptin was unable to abolish HER2 
phosphorylation in SKBR3 cells due to activation of alternative HER 
pathways, it caused almost complete reversal of HER2 phosphorylation 
(shown by increase of lifetime) in MCF-12F (Figure 5.4B).
These control experiments confirmed that the activation of HER receptors in 
SKBR3 cells seen in Section 5.2.1 to 5.2.3 was not due to loss of pTEN or 
degradation of drugs. Moreover, the inability for Herceptin to abolish HER2 
phosphorylation was only seen in SKBR3 cells and not normal breast cells, 
MCF-12F.
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Figure 5.4: Control experiments of Herceptin. A, SKBR3 and MCF-7 cells 
were treated with 40 ug/ml Herceptin for different durations before the cells 
were lysed for western blot analysis and the membrane was blotted with anti- 
pTEN antibody. B, Western blot experiment using the medium from the SKBR3 
cells treated with 40 mg/ml Herceptin as well as medium containing 40 mg/ml 
Herceptin that was kept in incubator for up to 10 days. The medium was denatured 
with SDS-PAGE and boiled for 10 minutes and 40pl was loaded in each lane of SDS- 
PAGE gel.The membrane was probed with monoclonal anti-human immunoglobu­
lin antibody which recognizes the Fc component of Herceptin. C, MCF-12F were 
incubated with suitable pair of antibodies to assess HER2 phosphorylation by FRET 
after pretreated with different durations of 40 pg/ml Herceptin.
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5.2.5 Herceptin treatment induces 
activation of HER receptors via ligands
In the HER2 negative MCF-7 cells as well as A431 cells which are resistant 
to Herceptin, HER2 homodimers do not play a major part. Like SKBR3 cells, 
it was confirmed that Herceptin also induced activation of all HER receptors in 
MCF-7 and A431 cells after seven days of treatment (Figure 5.5A). Therefore, 
the activation of all HER pathways in these cells may mediate primary 
resistance to Herceptin.
In the previous chapter, it was shown that TKIs treatment induce activation of 
alternative HER receptors in breast cancer cells via ligand release. It was 
postulated that the increased activation of HER receptors in response to 
Herceptin treatment could also be due to the release of the ligands, as in the 
case of TKIs. It was therefore decided to investigate the effect of Herceptin 
treatment on ligand release in SKBR3 and MCF-7 cells, using betacellulin as 
an example. In MCF-7 and SKBR3 cells acute Herceptin treatment induced the 
release of betacellulin, as in the case of AG 1478 and Iressa (Figure 5.5B). 
Since betacellulin is the ligand for EGFR and HER4, it would account for the 
enhancement of EGFR and HER4 activation as well as HER2 phosphorylation 
seen in Figure 5.2B. Furthermore, its release induced by acute Herceptin 
treatment also increased cleavage of HER4 and its dimerisation with HER2 
(Figure 5.3B and 5.3C).
Therefore, the results showed that ligand release (including betacellulin) is 
responsible for activation of alternative HER receptors during Herceptin 
treatment in breast cancer cells, a similar process to the treatment with TKIs of 
EGFR. Despite its anti-viability effects, the activation of alternative HER 
receptors may mediate resistance to Herceptin in SKBR3 cells.
5.2.6 The release of ligands induced by 
Herceptin is mediated by TACE
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The release of ligands from their membrane-anchored precursors (ectodomain 
shedding) has been shown to be mediated by TACE (Shirakabe et al., 2001; 
Sunnarborg et al., 2002). Since it was shown that Herceptin induces the 
activation of HER receptors via the release of their respective ligands, it was 
postulated that TACE inhibitors would decrease HER2 phosphorylation by 
inhibiting ligand release. Assessing HER2 phosphorylation by FRET, the 
decrease of average lifetime of HER2-Cy3b with pHER2-Cy5 indicates the 
basal phosphorylation of HER2 in SKBR3 cells and MCF-7 cells (Figure 5.6A 
and B). Acute Herceptin treatment did not reverse lifetime change in SKBR3 
and MCF-7 cells (Figure 5.6A and B). However, with concurrent treatment of 
Herceptin and TAPI-1, there was increased suppression of HER2 
phosphorylation (increase of average lifetime) with an increase in its median 
compared to basal phosphorylation in both SKBR3 and MCF-7 cells (Figure 
5.6A and B).
The results therefore confirmed that the activation of HER receptors in 
response to Herceptin in breast cancer cells is due to TACE-mediated ligand 
release.
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Figure 5.5: The effect of Herceptin on HER receptors and ligand release.
A, A431 cells,MCF-7 and SKBR3 cells were treated with either nothing or 40 ug/ml 
Herceptin for 7 days before western blot analysis. The phosphorylation of EGFR on 
Tyr 845, HER2 on Tyr 1221/1222, HER3 on Tyr 1289 and HER4 on Tyr 1284 were 
assessed using appropriate antibodies. B, MCF-7 cells were pretreated with either 
3 uM AG 1478 or 1 uM Iressa or 40 ug/ml Herceptin as illustrated before the cells 
were lysed for western blot experiment. The membrane was probed with anti- 
betacellulin antibody.
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Figure 5.6 TACE inhibitor decreases HER2 phosphorylation main­
tained by activation of alternative HER receptors induced by Her­
ceptin treatment. A and B, FRET experiments to assess HER2 phospho- 
rytlation in SKBR3 and MCF-7cells. The cells were treated with 40 ug/ml 
Herceptin for 1 hour with or without TACE inhibitor (TAPI-1). The medians of 
the lifetimes were compared with the basal condition using Mann-Witney 
test and the significance value is denoted as *.
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Figure 5.7: Herceptin (Trastuzumab) induces the activation of HER receptors via 
TACE mediated ligand release. Herceptin downregulates EGFR and HER2 recep­
tors in HER2 over-expressing SKBR3 breast cancer cells with decreased EGFR and 
HER2 activation in some cells (most likely through an effect on HER2 homodimers or 
EGFR/HER2 dimers). However, the treated cells have increased total HER3 and 
HER4 protein with increased phosphorylation of all HER receptors, suggesting the 
activation of these receptors via alternative dimers in the surviving cells, e.g. 
EGFR/HER3 and HER3/HER4 as well as HER4 cleavage and HER2/HER4 dimers. 
The increased activation of all HER receptors is due to TACE-mediated ligand release. 
In the acute Herceptin treatment, an immediate reduction of PKB phosphorylation has 
been shown to be due to activation of pTEN by other group. However, it may also be 
due to decreased activation from EGFR/HER2 or HER2/HER2 dimers. Discordantly, 
Herceptin increases ERK1/2 phosphorylation, corresponding to increased phosphory­
lation of EGFR, HER2 and HER4 receptors (and formation of alternative dimers 
including HER2/HER4 dimers) induced by Herceptin treatment. Subsequent rise of 
PKB phosphorylation corresponds to an increase of the HER3 phosphorylation 
induced by Herceptin treatment.
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5.3 Discussion
As discussed in the Introduction (Section 1.1), the present criteria for 
Herceptin treatment based on receptor concentration treatment results in an 
unsatisfactory response rate and the response is not usually sustained for the 
responders for Herceptin monotherapy (Cohen et al., 2003; Vogel et al., 2002). 
The study here has presented evidence from breast cell lines to propose a 
model of how the secondary resistance to Herceptin develops (Figure 5.7). The 
results showed that Herceptin down-regulated HER2 receptors in SKBR3 cells 
consistent with report that Herceptin induces the endocytosis and down 
regulation of HER2 homodimers in HER2 over-expressing breast cancer cells 
(Menard et al., 2003). It was also shown that Herceptin downregulated EGFR 
in HER2 over-expressing SKBR3 breast cancer cells. This is not unpredicted 
since HER2 amplification has been shown to induce constitutive activation of 
EGFR (Worthylake et al., 1999) and HER2 over-expressing breast cancer cells 
have been shown to be sensitive to EGFR TKIs (Anderson et al., 2001; 
Moulder et al., 2001), indicating the importance of EGFR driven activities in 
these cell. On the contrary to current belief that Herceptin reduces tyrosine 
kinase activity of HER2 and other HER receptors, western blot results showed 
that Herceptin treatment increased the activation of all HER receptors in 
SKBR3 cells despite the down-regulation of EGFR and HER2. However, 
analyzing the effects of Herceptin by FRET showed great heterogeneity 
between cells. There is evidence that Herceptin decreased EGFR and HER2 
activation in some of these cells (probably through effect on HER2 
homodimers or EGFR/HER2 dimers), correlated with decreased cell viability 
in Herceptin-treated SKBR3 cells. But overall, there was activation of EGFR 
and HER2 receptors despite the down-regulation of these receptors in the 
treated cells. Furthermore, the treated cells had increased total HER3 and 
HER4 protein with increased phosphorylation of all HER receptors. The 
increased activation of all HER receptors was found to be due to TACE 
mediated ligand release, consistent with report that unlike Pertuzumab, 
Herceptin does not prevent dimerisation of HER2 with other receptors (Agus
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et al., 2002). The activation of downstream signalling pathways (Section 5.2.3) 
in relation to HER receptors is also illustrated in Figure 5.7. This model of 
secondary resistance to Herceptin explain why Herceptin as monotherapy is 
seldom tumouricidal despite a response in HER2 positive tumours since ligand 
mediated activation of other HER receptors through TACE will rescue the 
signalling pathway lost by HER2 homodimers or EGFR/HER2 dimers. The 
model is further supported by the fact that TACE inhibitor diminished 
persistent HER2 phosphorylation in surviving SKBR3 cells. In the HER2 
negative MCF-7 cells which are resistant to Herceptin, HER2 homodimers do 
not play a major part. Herceptin induces activation of all HER pathways 
through TACE-mediated ligand release and may mediate primary resistance to 
Herceptin with no effect on cell viability.
It was shown that Herceptin decreases the viability of treated SKBR3 cells to 
less than 50% of that control. However, the surviving cells continued to have 
HER2 phosphorylation with activation of alternative HER pathways. There are 
two possible explanations. Firstly, breast cancers are a heterogeneous group of 
diseases with different gene expression and protein levels between different 
cell lines as well as within the same cell type (Sorlie et al., 2003). Therefore in 
a pool of SKBR3 cells, there may already be some cells which are resistant to 
Herceptin at the outset and they undergo clonal expansion while the sensitive 
cells undergo apoptosis. The other possibility is that the surviving cells 
represent those that have adapted the environment by shifting the dependence 
of EGFR/HER2 pathway to other pathways. The results suggest that both of 
these two explanations maybe true. Upon Herceptin treatment there were 
immediately two responses on EGFR activation (Figure 5.3A), which 
highlights the possibility of heterogeneous group of cells and the difference in 
their genetic expression, that determine the difference in response to drugs. But 
the results also illustrated here that Herceptin treatment induces the release of 
ligands through TACE and cause activation and dimerisation of alternative 
HER receptors to compensate the drug effect. It seems that Herceptin treatment 
has eliminated the cells that are highly dependent on EGFR activation or 
HER2 homodimers, and the surviving cells have shifted the dependence to 
HER3 and HER4 signalling pathways.
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Lapatinib in combination with Capecitabine was found to be superior in 
women with HER2 positive breast cancer that has progressed after 
chemotherapy and Herceptin (Geyer et al., 2006). The results presented here 
may explain why this is the case. Herceptin treatment in HER2 over­
expressing breast cancer cell may result in activation of all HER receptors 
regardless of response, including activation of EGFR and HER2. This explains 
why Lapatinib which inhibits tyrosine kinase activity of EGFR and HER2, is 
effective in HER2 positive patients who have progressed on Herceptin. 
However, all these patients will invariably progress, implying that other 
pathways like HER3 and HER4 may play a part in the escaping mechanisms.
In this and previous chapters, FRET was applied to assess activation of HER 
receptors in relation to Herceptin and Iressa treatments in breast cancer cells, 
revealing the possible mechanisms of resistance to these drugs. The next 
chapter describes the use of FRET to assess HER2 phosphorylation in 
xenografts and in breast tumour arrays.
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6 A ssessin g  HER2 phosphorylation  
sta te  by FRET in xenograft 
tumours and breast tumour 
arrays
6.1 Introduction
In Chapter 4, an assay to assess HER2 phosphorylation status by FRET was 
established in cell lines. The long-term aim is to apply such an assay in 
stratification of breast cancer patients for targeted therapies in the prospective 
trials. To apply such assay to prospective trials, optimisation of the assays needed 
to be performed in cell lines, xenograft models and archives of paraffin-embedded 
breast tumour arrays. The optimisation will enable problems to be identified 
before applying this novel method to assess HER2 phosphorylation in breast 
cancer patients.
The first objective was to assess the effect of antigen-retrieval in cell lines, in 
particular whether the detection of HER2 phosphorylation by FRET would be 
increased by antigen retrieval through recovery of the epitopes since antigen 
retrieval is routinely applied to paraffin-embedded tumour arrays in IHC. The 
second objective was to assess whether the phosphorylated HER2 epitopes of 
xenograft tumours would be preserved after being removed from Severe 
Combined Immune Deficiency (SCID) mice and being embedded into paraffin 
tissues or whether the phosphorylated epitopes would decay rapidly after removal. 
If the phosphorylated epitopes were to degrade rapidly, FRET would not be useful 
in monitoring the phosphorylation status of HER receptors in tumours. Knowing 
the extent of this decay will also help to develop guidelines for the handling of 
tumours in future prospective trials used for FRET experiments. The differences 
between IHC and FRET in detecting HER2 phosphorylation also were determined 
also. Although formalin is used routinely to preserve human tissues before the
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tumours are paraffin-embedded, it was intended to assess whether liquid nitrogen 
could also be used in preserving the epitopes of phosphorylated HER2. In 
addition, the impact of the delay in fixation on the pHER2 antigen would be 
assessed since it is possible that this delay may occur when the tumours are 
removed surgically. The method of fixation (either by formalin or liquid nitrogen) 
and the effect of delay in fixation as well as the differences between IHC and 
FRET in detecting HER2 phosphorylation will be described in this chapter. The 
third objective was to assess the differences in HER2 phosphorylation between 
different regions of heterogeneous breast tissues (tumour area versus stromal 
area) and between HER2 positive and HER2 negative breast tumour slides. The 
FRET assay was also applied to assess HER2 phosphorylation in a set of breast 
tumour arrays (containing a mixture of HER2 positive and HER2 negative breast 
tumour cores) using automated FLIM. The optimisation of automated FLIM on 
archives of paraffin-embedded breast arrays is essential before its application to 
prospective trials. Lastly the assay was applied to a HER2 positive breast tumour 
array and it was intended to assess whether FRET to assess HER2 
phosphorylation could be used to stratify HER2 positive patients further into 
different prognostic groups. The variation in HER2 phosphorylation between IHC 
and FRET in breast tumour arrays was determined.
6.2 Results
6.2.1 Effect of antigen retrieval on HER2 
phosphorylation in cell lines
Antigen retrieval is routinely performed to recover the epitopes from the 
formalin-fixed, paraffin-embedded tumour arrays during IHC processing. 
However, before FRET could be applied to assess HER2 phosphorylation in 
xenograft tumours and paraffin-embedded tumour arrays, the effect of antigen 
retrieval on HER2 phosphorylation was assessed in cell lines. It was intended to
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assess whether the detection of HER2 phosphorylation by FRET would be 
increased by the recovery of the epitopes through antigen retrieval.
A431 cells and MCF-7 cells were treated with an additional antigen retrieval 
process following fixation with 4% PFA and then incubated with either donor 
HER2-Cy3b with or without acceptor pHER2-Cy5. Figure 6.1 shows the lifetimes 
of HER2-Cy3b with or without prior EGF stimulation to assess HER2 
phosphorylation in A431 cells. The lifetimes and FRET efficiencies obtained 
were compared with the non-antigen retrieval (Figure 4.1) and the results are 
shown in Figure 6. IB. The antigen retrieval increased the detection of basal 
phosphorylation due to recovery of epitopes compared to the non-antigen retrieval 
process (Figure 6. IB). At the basal level, the lifetime of HER2-Cy3b in A431 
cells decreased from 2.2 ns to 1.41 ns in the presence of acceptor (a FRET 
efficiency of 37.1%), in contrast to a decrease of lifetime from 2.19 ns to 1.75 ns 
in the case of non-antigen-retrieval process (a FRET efficiency of 19.8%) (Figure 
6. IB). EGF stimulation induced further phosphorylation, decrease of lifetime 
from 1.4 ns to 1.28 ns (FRET efficiency 42.9%) compared with non-antigen 
retrieval process (lifetime decreased from 1.75 ns to 1.56 ns with EGF 
stimulation, a FRET efficiency of 37.1%) (Figure 6. IB). Similar patterns were 
observed in MCF-7 cells (Figure 6.1C and Figure 4.1C).
In summary the results showed that antigen retrieval increased the detection of 
HER2 phosphorylation by FRET through the recovery of the epitopes.
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50 ng/ml EGF. B, The average lifetimes and FRET efficiencies were com­
pared between the non-antigen retrieval and antigen retrieval conditions. C, 
Same experiment of A done in MCF-7 cells.
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6.2.2 Xenografts
One of the anticipated problems is whether the delay in fixation of the 
tumours after operation may result in degradation of the phosphorylated 
epitopes of HER receptors and whether these antigens are preserved from the 
processes of tumour removal to their fixation and being made into paraffin- 
embedded tumour arrays. The assumption was that phosphorylated antigens 
are preserved after the tumours are made into paraffin sections and thus anti- 
phosphospecific antibodies will be useful in determining the phosphorylation 
status of the tumours. To test this assumption, HER2 over-expressing breast 
cancer cell lines (SKBR3 and MDAMB-453 cells) were inoculated in nude 
mice. Unfortunately, the tumours did not grow successfully in nude mice. The 
same experiment was later repeated in SCID mice but only MDMAB-453 cell 
lines were grown successfully and SKBR3 cells were found to be non 
tumourigenic in SCID mice. It was intended to assess whether the 
phosphorylated HER2 epitopes (pHER2) of the xenograft tumour would 
decrease by delaying the fixation process. Both formalin and the liquid 
nitrogen were used for tumour fixation to compare the phosphorylation status 
of HER2 by IHC and FRET.
6.2.3 Comparison between IHC and 
FRET in assessing HER2 
phosphorylation in formalin-fixed 
xenograft tumours
The largest tumour from one SCID mouse was cut into three parts (see 
Methods): one was fixed immediately with formalin (NBF) and another was 
left at room temperature for 1 hour and the third one was left on ice for 1 hour 
before fixation with formalin. These tumours were processed according to the 
standard protocol and made into paraffin-embedded slides. To perform IHC 
staining, the slides were dewaxed and the antigen-retrieval process was
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performed according to the guidelines from New England Biolabs’ protocols 
on anti-pHER2 IHC staining (see Methods Section 2.2.9). Figure 6.2A shows 
anti-pHER2 IHC staining of the MDAMB-453 xenograft tumour slides. The 
anti-pHER2 staining shown by the brown membranous staining was present in 
all three slides. However, differences in intensity or percentage of cell staining 
between the three slides could not be detected (Figure 6.2A). The control slide 
without primary pHER2 antibody (stained only with rabbit secondary 
antibody) does not show membranous staining (Figure 6.2A). Therefore, the 
results demonstrated that the phosphorylated antigens of HER2 were retained 
up to an hour of delay in fixation with formalin and differences could not be 
detected between the three conditions using IHC method.
To compare IHC and FRET methods, duplicate paraffin slides from the three 
conditions were prepared. The same procedure for dewaxing and antigen- 
retrieval was used. For each condition, a pair of slides were used, one labelled 
with donor HER2-Cy3b alone and the other with donor HER2-Cy3b and 
acceptor pHER2-Cy5 to assess HER2 phosphorylation. The lifetimes of donor 
alone and donor with acceptor were obtained. The FRET efficiency for each 
condition was calculated (see Methods Section 2.2.11). HER2 phosphorylation 
indicated by the FRET efficiency was different in the three conditions. Figure 
6.2B shows a median FRET efficiency of about 15% in a tumour, which was 
fixed immediately by NBF. And in the two tumour samples, which were left 
for 1 hour either at room temperature or on ice, showed a lower FRET 
efficiency, indicative of a decrease in HER2 phosphorylation (Figure 6.2B).
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Figure 6.2: Comparison between assessment of HER2 phosphorylation by 
IHC and FRET in MDAMB-453 Xenograft tumour fixed with formalin (NBF).
A, A MDMAB-453 xenograft tumour was removed and cut into three parts to be 
fixed in three ways: (1) fixed immediately by NBF, (2) left on ice at 4 degree C for 
I hour before NBF fixation, (3) left at 1 hour room temp before NBF fixation. The 
tumours were made into paraffin-embedded tumour slides. The tumour slides 
were subjected to antigen-retrieval as per protocol before anti-pHER2 staining 
was done on all slides. Rabbit seconday antibody was used following primary 
antibody staining. One slide without primary pHER2 antibody was stained with 
only with rabbit secondary antibody as control. B, Duplicate slides were labelled 
with either donor alone (HER2-Cy3b) or donor and acceptor (HER2-Cy3b 
+pHER2-Cy5) to assess HER2 phosphorylation by FRET.
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6.2.4 Comparison between IHC and 
FRET in assessing HER2 
phosphorylation status of the 
xenograft tumours fixed with liquid 
nitrogen
Although formalin is routinely used to fix the tumours in histopathology, it 
was intended also to assess whether liquid nitrogen is useful in preserving 
pHER2 in xenograft tumours. Another MDMAB-453 xenograft tumour was 
removed from the SCID mice and it was sectioned into two parts (see Methods 
Section 2.2.8): one was fixed immediately by liquid nitrogen and another was 
left at 4 °C before fixation with liquid nitrogen. The effect of delay in fixation 
with liquid nitrogen fixation (immediate versus 24 hours) on HER2 
phosphorylation in these xenograft tumours was assessed using IHC and 
FRET. Although the architecture of the tumours was not well preserved 
compared to formalin fixation, the antigenicity of pHER2 was retained even 
after 24 hours at 4 °C before fixation with liquid nitrogen (Figure 6.3A). Using 
IHC, the difference in anti-pHER2 staining could not be detected between 
immediate fixation and 24-hour fixation with liquid nitrogen. FRET however 
revealed that the phosphorylation of HER2 had decreased from immediate 
fixation to 24-hour fixation, indicated by the decrease in the average FRET 
efficiency from a median of 7.5 % to about 5% (Figure 6.3B).
All together the xenograft experiments showed that the variations in HER2 
phosphorylation due to delay in fixation with either formalin or liquid nitrogen 
may be detected by FRET, which would otherwise not be quantified by IHC.
206
m m m m  
illMm
■ I mm fix nitrogen 
* 24h fix nitrogen
Imm N2 
fixation
24h N2 
fixation
^  20-1
MDAMB-453 xenograft tumour
Figure 6.3: Comparison between assessment of HER2 phosphorylation by 
IHC and FRET in MDAMB-453 Xenograft tumour fixed with liquid nitrogen.
A, A MDMAB-453 xenograft tumour was obtained and cut into two parts. They 
were fixed either immediately in liquid nitrogen or left at 4 degree C for 24 hours 
before fixation with liquid nitrogen. The tumours in the two conditions were then 
made into tumour slides and stored in - 80 degree C. On the day of experiment, 
the slides were thawed before being stained with anti-pHER2 antibody. B, The 
tumour slides were prepared in the same manner as A. But after thawing, the 
slides were labelled with either donor alone (HER2-Cy3b) or donor and acceptor 
(HER2-Cy3b + pHER2-Cy5) to assess HER2 phosphorylation.
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6.2.5 Determination of HER2
phosphorylation by FRET in breast 
tumour slides
Before proceeding to breast TMAs, a set of paraffin-embedded formalin-fixed 
breast tumour slides containing both HER2 positive and HER2 negative cases 
were obtained to assess the variation in lifetimes by FRET between different 
regions of the breast tumour tissues and between HER2 positive tumours and 
HER2 negative tumours. The understanding of the variation in lifetimes 
between different regions will be useful for interpretation of TMAs since it is 
not uncommon for tumour cores in the TMAs to differ in the composition of 
tumour and stromal / adipose tissues. It is also essential to assess whether 
FRET may be used to measure HER2 phosphorylation in “HER2 negative” 
breast tumours since breast TMAs may contain a mixture of HER2 positive 
and HER2 negative cases.
The assessment of HER2 positive breast tumour slides was performed first. 
Figure 6.4A shows the Haematoxylin & Eosin (H&E) stain of the HER2 
positive breast tumour slides. For each slide, a pathologist from Oxford 
marked the tumour areas, and the difference between the tumour area and 
stromal / adipose tissues can be visualised by microscopy (Figure 6.4A). The 
variations in the lifetimes of HER2-Cy3b (indicating HER2 phosphorylation) 
between different regions of a HER2 positive breast tumour slide are shown in 
Table 6.1 A. The average lifetimes taken from the tumour areas were below 
1.5ns, whereas the average lifetimes of the stromal areas were in the region of 
2 ns. Figure 6.4B shows examples of these differences represented by lifetime 
maps. The figures show the donor intensity images (left panels), DC images 
(middle panels) and the lifetime maps (right panels) of HER2-Cy3b of a 
tumour region and a stromal region from a HER2 positive tumour slide. In the 
upper panels, the images were acquired from a tumour region and even within 
this region there were differences in donor intensities (indicative of HER2 
expression). As shown (Figure 6.4B, upper panels), only the lifetimes from the
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area with adequate signal-to-noise ratio may be obtained, as represented by the 
pseudo-colour of the lifetime map (red indicates shorter lifetimes). In the lower 
panels, the images were acquired from a stromal region of the tumour slide. 
The average lifetime of the region of interest was higher (i.e. lower HER2 
phosphorylation) as indicated by pseudo-colour of the lifetime map (blue 
indicates higher lifetimes). All together, the data show that the tumour regions 
have a higher HER2 phosphorylation compared to stromal area, as indicated 
by lower lifetimes of HER2-Cy3b.
HER2 phosphorylation by FRET was also assessed in HER2 negative (IHC 0 
or 1+) breast tumour slides. Table 6. IB exemplifies the lifetimes of HER2- 
Cy3b in several tumour areas of a HER2 negative breast tumour slide. In a 
HER2-negative slide the tumour areas had longer lifetimes than the HER2 
positive cases (Table 6.1 A), i.e. lower HER2 phosphorylation. However, in 
some areas, bright spots were noted (an example from tumour area 2 shown in 
Figure 6.5A, upper panels), indicating a high HER2 intensity (concentration). 
If the region of interest included this area, the overall lifetime of HER2-Cy3b 
decreased from 2.1 ns to 1.91 ns (tumour area 2, Table 6. IB). Figure 6.5 shows 
the diagrams of tumour area 2 (representing the data in table 6. IB). It shows 
that there were differences in the maximum intensities of the donor HER2- 
Cy3b within the tumour region. The left upper panel shows a very bright 
region (indicating high HER2 expression) within the tumour area. The lifetime 
map shows that the lifetime of this bright region is below 1.5 ns indicating 
high HER2 phosphorylation. However, average the lifetime of the whole 
region of interest resulted in an average lifetime of 1.91 ns. When the bright 
spot was excluded the average lifetime increased to 2.1 ns.
In summary, the experiments showed that the tumour areas of the HER2 
positive slide had a higher HER2 phosphorylation than the stromal area. The 
tumour areas of HER2 positive slide also had a higher HER2 phosphorylation 
compared to the tumour areas from a HER2 negative slide. In addition it also 
illustrated that the “so-called” HER2 negative breast tumour may be 
heterogeneous and contain areas that have high HER2 concentration with an 
increased HER2 phosphorylation status. Therefore, the results showed the 
importance of selecting an appropriate region for the TMAs since the amount
209
of breast tumour versus stromal tissues may influence the results significantly 
and introduce sample heterogeneity.
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A
HER2 positive 
tumour slide
Phase lifetime 
(ns)
Modulation 
lifetime (ns)
Average lifetime 
(ns)
Tumour area 1 0.85 ±0.35 1.30 ±0.58 1.08
Tumour area 2 1.03 ±0.20 0.79 ± 0.28 0.91
Tumour area 3 0.93 ±0.15 1.35 ±0.25 1.14
Tumour area 4 0.82 ±0.13 1.07 ±0.24 0.95
Stromal area 1 1.68 ±0.30 2.27 ±0.35 1.98
Stromal area 2 1.68 ±0.44 2.83 ±0.50 2.26
B
HER2 negative 
tumour slide
Phase lifetime 
(ns)
Modulation 
lifetime (ns)
Average lifetime 
(ns)
Tumour area 1 1.74 ± 0.60 2.15 ±0.65 1.95
Tumour area 2 
(including bright 
spot)
1.56 ±0.37 2.25 ± 0.49 1.91
Tumour area 2 
(excluding bright 
spot)
1.79 ±0.15 2.40 ± 0.39 2.10
Tumour area 3 
(including bright 
spot)
1.24 ±0.16 1.93 ±0.27 1.59
Tumour area 3 
(excluding bright 
spot)
1.79 ±0.44 2.81 ±0.49 2.3
Table 6.1: A, The average lifetimes of HER2-Cy3b in tumour areas and stromal 
areas of a HER2 positive breast tumour slide. B, The average lifetimes of 
HER2-Cy3b in tumour areas of a HER2 negative breast tumour slide.
211
Tumour area Stromal area Adipose tissue
m m
m&m
‘ji au
; * ’yvC — •''•«•x  ■. •
;  H V  • '• / ' • • >  f s i . .  V.»?4£'v s  *•■•L'T) ,
B  Donor Intensity DC Image Lifetime Map
Tumour
area
H
fff;
Stromal
area
Figure 6.4: Assessment of HER2 phosphorylation by FRET in HER2 positive 
breast tumour slides. Formalin-fixed and paraffin-embedded HER2 positive 
tumour slides were labelled with donor HER2-Cy3b and acceptor pHER2-Cy5 
after antigen retrieval as per protocol. A, The tumour slides were marked for 
tumour regions and stromal regions (stromal and adipose tissue) after H&E stain, 
so that the lifetimes of the different regions within the tumour slide could be 
assessed. B, The diagrams from one tumour slide. The left panels show the 
donor intensity images, the middle panels show DC images and the right panels 
are lifetime maps. In the upper panels, the images were taken from a tumour 
region indicated by H & E stain. In the lower panels, the images were taken from 
a stromal area.
2 1 2
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Figure 6.5: Assessment of HER2 phosphorylation by FRET in HER2 nega­
tive breast tumour slides. A, Formalin-fixed and paraffin-embedded HER2 
negative tumour slides were labelled with donor HER2-Cy3b and acceptor 
pHER2-Cy5 after antigen retrieval as per protocol. The diagrams were taken 
from the tumour region of one tumour slide. The left panels show the donor inten­
sity images of tumour region, the middle panels show DC images and the right 
panels are lifetime maps of the cores. B, Excluding the bright spot in the region 
of interest.
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6.2.6 Assessm ent of the HER2
phosphorylation status in mixed HER2 
breast TMAs
A set of breast tumour arrays (which contained 230 tumour cores with a 
mixture of HER2 positive and HER2 negative breast tumour cores) were 
labelled with either donor HER2-Cy3b alone (as control) or donor and 
acceptor pHER2-Cy5 according to the protocol to assess the HER2 
phosphorylation status by FRET, monitored by high throughput FLIM. The 
tumour cores were mapped in the automated FLIM and lifetimes of individual 
tumours cores were obtained. The results showed great heterogeneity in the 
intensity of donor HER2-Cy3b between the tumour cores due to different 
HER2 expression between them. In the mixed breast TMAs, some tumour 
cores had very low level of HER2 expression and thus very little amounts of 
HER2-Cy3b would have bound to the HER2 receptors. This would result in a 
low signal to noise ratio and the intensity from such sample would be too low 
relative to the background scattering foil to calculate the lifetime (See Methods 
Section 2.2.11). Such problems however did not occur in the tumour cores 
with high HER2 expression. The heterogeneity problem was further 
highlighted when different exposure times of the excitation source were used 
since the tumour cores with high expression of HER2 only required a very 
short exposure time while the tumour cores with low HER2 expression would 
require a longer exposure time to reach an adequate signal to noise ratio. 
Moreover, when exposed to a longer exposure time, the tumour cores with 
high HER2 expression may reach a saturated intensity (> arbitrary threshold 
value of 4900) for the software to calculate the lifetime (See Methods Section 
2 .2 .11).
Due to the heterogeneity problem in the intensity between the tumour cores, 
cores were initially exposed manually to different exposure times to optimise 
and calibrate the automated FLIM instrument. Figure 6.6 shows the diagrams 
from the optimisation in a tumour core. When the exposure time of pulsed 
laser excitation was 2000ms, the intensities of both tumour core and
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background were high and the average lifetime of donor HER2-Cy3b was 2.04 
ns (Figure 6.6A). When the exposure times were decreased to 1500ms and 
1000ms, the contrast of the donor intensity between the tumour core and the 
background was more obvious and the average lifetimes were 2.04 ns and 2.01 
ns respectively (Figure 6.6B and 6.6C). When the exposure time was 
decreased to 500 ms, the maximum intensity of the donor HER2-Cy3b had 
decreased to a threshold of about 1000 (arbitrary value) and the signal-to-noise 
ratio was too low to calculate the lifetime of HER2-Cy3b. In another tumour 
core, the intensity of the donor fluorescence was saturated with 2000 ms 
exposure (> arbitrary value of 4095), resulting in an inability to calculate 
lifetimes (Figure 6.7A). However, when the exposure times were decreased, 
the lifetimes could be calculated (Figure 6.7A). In some of the tumour cores, 
the donor intensities of the tumour core were saturated even with an exposure 
time of 1000 ms and lifetime was only obtained when the exposure was 
decreased to 500 ms (Figure 6.7B).
In summary while processing the mixed breast TMAs, it was found that there 
was a great heterogeneity problem between the intensity of the tumour cores 
making it difficult to process the TMAs in a high throughput manner by the 
FLIM. To optimise the instrument, a calibration curve was plotted so that the 
relationship between exposure times and maximum intensities of donor HER2- 
Cy3b of the breast tumour cores could be determined.
To obtain the calibration curve, several breast tumour cores were manually 
exposed to different exposure times and the intensities of the donor HER2- 
Cy3b were recorded. Figure 6.8 shows examples of four tumour cores 
(TA15DA0001, 0003, 0005 and 0011) and the maximum intensities of the 
donor HER2-Cy3b (y-axis) were plotted against the exposure times (x-axis) of 
the tumour cores. In TA15DA0001 and 0011, the intensities were already 
saturated at an exposure time around 700 ms. Therefore, using an exposure 
time greater than 1000 ms would result in not being able to calculate the 
lifetime of HER2-Cy3b. There was however a linear relationship between 
exposure times and maximum intensities below 700 ms. For tumour cores 
TA15DA0003 and 0005, the maximum intensities relative to the exposure 
times were linear although the intensities decreased below the threshold of 
1000 if the exposure time was less than 500 ms (Figure 6.8). The maximum
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intensity was not saturated even with an exposure time of greater than 2000 ms 
(Figure 6.8).
Therefore, at this stage the lifetimes of the arrays with a mixture of HER2 
positive and HER2 negative breast tumour cores could not be acquired by 
FLIM automatically, due to heterogeneity in the intensities of HER2-Cy3b as a 
result of variable HER2 expression among the tumour cores. The calibration 
curve however provided the relationship between the exposure times and the 
maximum intensities of the tumour cores and this information was used for 
further automation of the instrument which will be discussed in the next 
section.
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Figure 6.6: Optimisation of exposure times for a TMA containing a mix­
ture of HER2 positive and HER2 negative tumour cores. Breast tumour 
cores labelled with donor HER2-Cy3b and acceptor pHER2-Cy5 were 
exposed to different durations of pulsed laser excitation: 2000 ms (A), 1500 
ms (B), 1000 ms (C) and 500 ms (D).
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Figure 6.7: Optimisation of exposure times for an array containing a mixture of HER2 positve and HER2 negative breast 
tumour cores. Breast tumour cores labelled with donor HER2-Cy3b and acceptor pHER2-Cy5 were exposed to different durations 
of pulsed laser excitation. Two examples are illustrated here. A, The intensity of the donor fluoresecence of a tumour core was satu­
rated in the case of 2000 ms exposure and the lifetime of donor HER2-Cy3b was not quantifiable until the exposure times were 
decreased to 1500 ms. B, The donor intensities of another tumour core were saturated when exposed to pulsed laser excitation of 
greater than 1000 ms and lifetimes were not quantifiable until the exposure was reduced to 500 ms.
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Figure 6.8: The calibration curve between the exposure times of the 
pulsed laser excitation and the maximum intensities of donor HER2-Cy3b 
of the breast tumour cores. Breast tumour cores labelled with donor HER2- 
Cy3b and acceptor pHER2-Cy5 were exposed to different durations of pulsed 
laser excitation. The diagram shows examples of four tumour cores 
(TA15DA0001, 0003, 0005 and 0011). The maximum intensities of the donor 
HER2-Cy3b (y-axis) were plotted against the exposure times of the pulsed 
laser excitation (X-axis).of the tumour cores.
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6.2.7 Automation of the exposure tim es 
for high throughput FLIM
To process the breast array with a mixture of HER2 positive and negative 
cores in a high throughput manner, further automation of the instrument was 
required. The aim was to process the array by automatically varying the 
exposure times for tumour cores according to donor intensities of HER2-Cy3b 
(i.e. the amount of HER2 expression) of the tumour cores, so that the tumour 
cores with high HER2 over-expression were not over-exposed with saturated 
intensities and tumour cores with low HER2 expression were not under­
exposed with low signal-to-noise ratios. In collaboration with, Pierre 
Leboucher from College de France (CNRS), re-programming of the FLIM 
software was performed to overcome the problems. During automatic 
acquisition of lifetime, a higher exposure time (e.g. 2000 ms) was first set in 
order to reach a higher signal-to-noise ratio for all the tumour cores. If a 
tumour core was over-exposed with this exposure time, the acquisition of the 
lifetime of that tumour core would be repeated with a lower exposure time 
(e.g. 1900 ms). The cycle (i.e. acquisition with a lower exposure time) would 
continue to eliminate over-exposure of the tumour cores. Before acquisition, 
the operator needed to choose the maximum and minimum acceptable 
intensities (e.g. arbitrary value of 4000 for maximum intensity and 2000 for 
minimum intensity) as well as the interval of decrease in exposure time (e.g. 
100 ms) so that the exposure time would decrease according to a pre-set 
interval during each re-run when the tumour cores were over-exposed. With 
this re-evaluation of the automation software, the tumour arrays with a mixture 
of HER2 positive and negative cases could be processed automatically by 
FLIM. However, out of the 234 tumour cores, only 71 samples could be 
analysed since the lifetimes of most tumour cores were still unobtainable 
despite adequate intensities of the tumour cores. This was because in some 
cases, the tumour and the background had similar intensities and by increasing 
the exposure times, the intensity of the background increased with the tumour
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so that the lifetime could not obtained. The Kaplan-Meier survival curves of 
those 71 were plotted using average FRET efficiency as a prognostic marker 
(split by median). The statistically significant differences the DFS and OS 
between the two groups were not obtained although there was a trend for 
patients with high FRET to have lower DFS (p=0.41) (Figure 6.9).
The automation of the FLIM is an ongoing project in the laboratory and is 
constantly upgraded by Pierre Leboucher and Banafshe Larijani. Since the last 
experiment shown in this section, the automated FLIM is now able to set 
suitable exposure times according to the intensity of HER2-Cy3b of a tumour 
core after the initial run at a low exposure time and the lifetimes of low HER2 
tumour cores can now be obtained. This will enable the arrays to be processed 
in a high throughput manner regardless of HER2 expression of the tumour 
cores.
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Figure 6.9: Kaplan-Meier curves using average FRET efficiency as a 
prognostic marker in a set of breast tumour arrays which contained both 
HER2 positive and HER2 negative cores. A, Disease-free survival (DFS) 
between patients in upper median versus the lower median of average FRET 
efficiency. B, Overall survival (DFS) between patients in upper median versus 
the lower median of average FRET efficiency.
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6.2.8 Assessm ent of the HER2
phosphorylation status by FRET in 
HER2 positive TMAs
The difficulty in achieving an adequate signal-to-noise ratio for HER2 
negative tumour cores in order to calculate their lifetimes was illustrated in 
Section 6.2.6. In Oxford at the IMM, the molecular oncology department had 
recently finished preparing a set of TMAs, which contained exclusively HER2 
positive tumour cores (n=55). This set of TMAs would not have the same 
heterogeneity problem in the intensity since all tumour cores had high 
expression of HER2 (and thus sufficient signal to noise ratio to calculate 
lifetimes).
It was hypothesized that using FRET to assess HER2 phosphorylation status, 
the patients could be stratified into different prognostic groups. The TMAs 
were processed according to the standard protocol (see Methods Section 
2.2.11.6) and were labelled with either donor alone or donor and acceptor to 
assess HER2 phosphorylation in these patients. The lifetimes were obtained for 
individual cores and FRET efficiency indicating HER2 phosphorylation was 
calculated for each patient (only 40 out of 55 patients had enough data to be 
analysed). To assess the prognostic value of FRET, the FRET efficiency was 
correlated with known prognostic factors of breast cancer patients, i.e. lymph 
node status, number of lymph nodes, tumour size, grade of tumour and 
hormone status of the tumour. Figure 6.10 and 6.11 show that increased HER2 
phosphorylation status indicated by high FRET efficiency was associated with 
poor prognostic factors in HER2 positive patients. Amongst the HER2 positive 
patients split by median, patients with high FRET efficiency had poorer 
prognostic factors, with greater proportions of patients having node-positive 
disease, 4 or more lymph nodes positive, tumours greater than 4 cm, high- 
grade tumours and ER negative disease (Figure 6.10 and Figure 6.11). To 
further determine the prognostic value of FRET, the data was also correlated 
with the survival data of these breast cancer patients. Using average FRET 
efficiency as a prognostic marker, Kaplan-Meier curves illustrate that high
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FRET efficiency (indicating high HER2 phosphorylation) had a trend towards 
a poorer disease-free survival (DFS) and overall survival (OS), although the 
number of patients was too low to reach statistical significance (p=0.4 for DFS 
and p=0.38 for OS between low FRET and high FRET) (Figure 6.12).
In summary, the results showed that using FRET to assess HER2 
phosphorylation, HER2 positive breast cancer patients could be stratified 
further into different prognostic groups.
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Figure 6.10 and Figure 6.11: Increased HER2 phosphorylation indicated 
by high FRET efficiency is associated with poor prognostic factors in 
HER2 positive patients. A set of HER2 positive tumour arrays containing 55 
tumour cores were labelled with donor HER2-Cy3b and acceptor pHER2-Cy5 
to assess HER2 phosphorylation by FRET. The FRET efficiency was obtained 
for individual core and the patients were split by median into high FRET 
efficiency group and low FRET efficiency group. The proportion of patients 
having different prognostic factors in the two groups were analysed: A, node 
positive disease, B, 4 or more lymph nodes. C, tumour greater than 4 cm. D, 
high grade tumours. E, ER negative disease
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Figure 6.12: : Kaplan-Meier curves using average FRET efficiency as a 
prognostic marker in a set of HER2 positive breast tumour arrays which 
contained 55 tumour cores. A, Disease-free survival (DFS) between 
patients in upper median versus the lower median of average FRET 
efficiency. B, Overall survival (DFS) between patients in upper median versus 
the lower median of average FRET efficiency.
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6.2.9 Correlation of IHC method with 
FRET to a ssess  HER2 phosphorylation 
status in HER2 positive TMAs
The focus of the study was to assess whether the IHC would correlate with 
FRET efficiency. The HER2 positive breast tumour arrays were stained with 
either anti-HER2 antibody (to confirm the presence of HER2) or anti-pHER2 
antibody (to assess HER2 phosphorylation) using IHC. An example of anti- 
HER2 staining and anti-pHER2 staining from a tumour core is shown in 
Figure 6.13A. All the tumour cores were HER2 positive although differences 
between tumour cores were observed (These tumour cores were all previously 
assigned to be HER2 positive by HercepTest which is based on the intensity of 
HER2 staining). For anti-pHER2 staining, all the tumour cores had a similar 
intensity (2+) using standard IHC scoring and differences could not be 
distinguished between the tumour cores. To further subdivide the tumour 
cores, percentages of cell staining for anti-pHER2 was determined for each 
tumour core (See Methods). The results showed that about half of the tumour 
cores had 4+ scoring (more than 80% cell staining) and the other half of them 
had 1-3+scoring (< 80% cell staining although almost all of them were 2-3+). 
The Kaplan Meier curves were plotted using anti-pHER2 percentage scoring as 
a prognostic marker (4+ versus 2-3+) (Figure 6.13B and 6.13C) and were 
compared to the results with FRET shown in Figure 6.12, Figure 6.13B and 
6.13C. These data show that the differences between the two groups were not 
significant for DFS (p=0.7) although there was a trend for the patients with 4+ 
scoring to have a lower OS (not statistically significant, p=0.1).
To further assess the difference between FRET and IHC, the Mann Witney 
test was used to compare the medians of the average FRET efficiency between 
the two groups (IHC pHER2 scorings 2-3+ versus 4+). Figure 6.14A shows 
that the median of tumour cores with a score of 4+ was higher than with a 
lower score although the difference was not statistically significant probably 
because of low number of tumour cores (p=0.27). The correlation of HER2
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level with FRET efficiency was also explored using the percentage of cell 
staining for anti-HER2 by IHC. The median of the FRET efficiency of tumour 
cores with a score of 4+ was higher than with a lower score (p=0.03, Figure 
6.14B).
In summary, the experiments on HER2 positive breast tumour array showed 
that FRET maybe used to stratify HER2 positive breast cancer patients into 
different prognostic groups. The difference in the intensity of anti-pHER2 
staining between different tumour cores using IHC was not significant. Further 
subdividing these patients by the percentage of cell staining using IHC showed 
that there was a trend for the tumour cores with > 80% cell staining (4+) to 
have a lower OS. These tumour cores also had higher FRET efficiency. 
Moreover, tumour cores with high percentage of anti-HER2 cell staining (> 
80%) had a higher FRET efficiency.
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Figure 6.13: Kaplan-Meier curves using anti-pHER2 staining as a 
pronostic marker in a set of HER2 positive breast tumour arrays 
which contained 55 tumour cores. A, IHC of anti-HER2 staining and 
anti-pHER2 staining of a tumour core. B, Disease-free survival (DFS) 
between patients with 4+ percentage of cell staining versus 1-3+ percent­
age of cell staining. C, Overall survival (OS) between patients with 4+ 
percentage of cell staining versus 1-3+ percentage of cell staining
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Figure 6.14: Correlation betweeen average FRET efficiency and IHC 
scorings of a HER2 positive breast tumour array. Same experiment as 
Figure 6.13. The tumour arrays were stained for either anti-pHER2 antibody 
(A) or anti-HER2 antibody (B) using IHC method. The tumour cores were 
split into two groups: more than 80% percentage staining (4+) or less than 
80% (2-3+). The medians of the average FRET efficiency were compared 
betweem two groups for both anti-pHER2 staining and anti-HER2 staining.
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6.3 Discussion
In this chapter, HER2 phosphorylation status by FRET was established in 
MDAMB-453 xenograft tumours and breast TMAs, to test for the assay to be 
applied for use in the future prospective trials. The assessment of HER2 
phosphorylation by FRET was compared with IHC in MDAMB-453 xenograft 
tumours and in archives of paraffin-embedded and formalin-fixed breast 
tumour arrays. The results showed that the phospho-antigen of HER2 was 
retained for tumours fixed immediately with formalin, after 1 hour on ice and 
at room temperature before fixation. Using IHC, anti-pHER2 staining was 
present in all three conditions and differences between them could not be 
detected. Using FRET to assess HER2 phosphorylation however revealed a 
decrease in FRET efficiency after 1 hour of delay in formalin fixation either on 
ice or at room temperature. The most likely explanation of the difference 
between IHC and FRET is that IHC depends on the subjective interpretation of 
the intensity of the membranous staining and the human eye does not have the 
dynamic range a camera has to enable a distinction. While the variation 
between the HER2 phosphorylation is small, the differences may be difficult to 
detect in a precise manner with the naked eye. Moreover, IHC can be affected 
by background staining which is less of a problem in FRET due to the use of 
two-site assay that increases the specificity of the method. The data therefore 
illustrate that variations in phosphorylation of HER2 can be detected by FRET 
whereas these differences cannot be quantified by IHC. The preservation of 
pHER2 was also assessed in MDAMB-453 xenografts using liquid nitrogen, 
either fixed immediately or left at 4°C for 24 hours before liquid nitrogen 
fixation. It was shown that FRET was more precise in determining HER2 
phosphorylation status since IHC could not detect the difference that was 
shown by FRET. HER2 phosphorylation decreased with delay in liquid 
nitrogen fixation but was retained up to 24 hours at 4° C before fixation. This 
is important considering that there maybe delays in the operating theatre when 
the tumours are removed. It is important to note that the experiments to assess 
HER2 phosphorylation status by IHC and FRET were performed in parallel in
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duplicate sets of tumour arrays. The processes for antigen-retrieval and the 
fixation of the tumour arrays with either formalin (NBF) or liquid nitrogen 
were therefore identical. It is speculated that the phosphotyrosine is retained 
may be in part because activated receptors will recruit SH2 domain 
adaptors/effectors that will help to protect the phosphotyrosine from 
dephosphorylation.
Although IHC staining for phosphorylated HER receptors is possible, the 
two-site FRET assay is more precise than IHC staining. The reason being that 
IHC may be affected by various factors including non-specific staining and 
concentration of the antibodies. HER2 is expressed in normal epithelial cells as 
well as some breast tumour cells. Background staining may be a problem in 
IHC when the concentration of primary antibodies is too high since the anti- 
HER2 or anti-pHER2 antibodies may bind to both normal cells and breast 
tumour cells. In contrast, background staining is not a problem in the two-site 
FRET assay. However, if the concentration of primary antibody is too low this 
may result in a low “signal-to-noise” ratio that in turn results in not being able 
to calculate the lifetime. The calculation of lifetime may also be affected by the 
concentration of the receptors. For example, in breast tumours with low HER2 
concentration, the intensity of HER2-Cy3b was found to be too low for the 
lifetime to be calculated as shown in section 6.2.6. In this case, the “signal-to- 
noise” ratio may be low regardless of the concentration of the primary 
antibody.
Proteins are unstable and one particular study has shown that the variability 
in the type of fixatives, duration of fixation, tissue processing and IHC 
techniques including antigen retrieval processes may all affect the sensitivity 
and specificity of IHC (Vincent-Salomon et al., 2003). The same study 
however showed that a high accuracy of HER2 assessment by IHC maybe 
achieved by using a calibration processes which include antigen retrieval 
procedure, high dilutions of anti-HER2 antibody (to reduce background 
staining) and the use of specific controls. This recommendation can also apply 
to FRET experiments to assess HER2 phosphorylation in tumour arrays since 
the process of tissue processing is essentially similar to IHC. Various antigen 
retrieval processes may be performed to assess whether it affects the detection 
of HER2 phosphorylation status by FRET.
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The quantity of tumour versus stromal components in tumour cores of TMAs 
may vary depend on how the tumour cores are collected and processed. In 
IHC, this variation of the stromal component may affect the IHC results since 
the scorings of IHC depends on the intensity of the staining as well as the 
percentage of staining cancer cells. In this chapter, using FRET, a variation of 
lifetime (indicating HER2 phosphorylation) was observed between the stromal 
component and tumour component of breast tumour slides. When selecting a 
region of interest that includes tumour and stromal areas, the intensity of the 
tumour area is much greater than the stromal area. The lifetime calculation will 
be based mainly on the area with greater intensity (i.e. the tumour area), and 
the stromal contribution may be minimal unless the tumour core contains 
minimal tumour tissue.
As discussed in the Introduction, determining a cut-off point for HER2 status 
by IHC and FISH is problematic and yet extremely important since the 
selection of patients for Herceptin is based on IHC (3+) or FISH (> 6 HER2 
gene copies per nucleus, or ratio > 2.2). Selecting a cut-off point for “high” 
HER2 phosphorylation by FRET is also not straightforward. FRET efficiency 
is a continuous variable and selecting a cut-off point may be based on either 
prognosis of breast cancer patients or prediction for targeted therapy. 
Nevertheless, this needs to be done using the data from a prospective trial to 
have significance. In the small series (n=55) of HER2 positive breast cancer 
cases (n=55) presented in this chapter, the median FRET efficiency was used 
as a cut-off point in the first instance. The results were encouraging in that 
FRET was shown to be able to stratify patients further into different prognostic 
group among HER2 positive cases (IHC 2-3+). However, further validation of 
the cut-off points for FRET need to be performed in a large prospective trial.
Since HER2 has been shown to be the preferred dimerisation partner for other 
HER receptors, it is possible that HER2 may be activated through over­
expression of other HER receptors or one of the ligands. It has been shown that 
Herceptin and Cisplatin were synergistic in MCF-7 cells (non HER2 over­
expressing) engineered to over-express heregulin. One of the reasons for 
Herceptin to be effective in these cells is thought to be due to activation of 
HER2 via HER2/HER3 dimerisation as a result of heregulin over-expression 
(Arteaga, 2006; Menendez et al., 2006). This implies that patients without
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HER2 over-expressing breast tumours may also respond to Herceptin in 
combination with chemotherapy. Using FRET may potentially be useful to 
select patients for Herceptin treatment regardless of the concentration status of 
HER2 by IHC or FISH and may be particularly useful in equivocal cases of 
IHC and FISH cases.
In this chapter, it is shown that FRET may be used to assess HER2 
phosphorylation in paraffin sections as well as liquid-nitrogen frozen sections. 
Moreover, it may be used to stratify HER2 positive breast cancer patients into 
different prognostic groups. However, the results presented in this chapter are 
only a pilot study and further work needs to be performed on another set of 
HER2 positive tumour arrays. More patients will be needed in order to achieve 
enough power to detect statistically significant differences between the high 
FRET group and low FRET group. Further validation may need to be 
performed in large prospective trials. The future aim is that the prognostic and 
predictive values of FRET as well as a cut-off value may eventually be 
determined from the prospective trials.
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7 Final D iscussion
7.1 Overview
As discussed in the Introduction, the HER (ErbB) receptors are implicated in 
the pathogenesis of several cancers, including EGFR in head and neck cancer 
and HER2 in breast cancer (Salomon et al., 1995). Targeted therapies against 
EGFR and HER2 receptors are gaining an increasingly important role in the 
treatment of various cancers. For example, Herceptin was originally 
recommended by NICE to use only for metastatic breast cancer with HER2 
over-expression due to the clinical benefits shown in a randomised trial 
(Slamon et al., 2001). Since the publication of the three trials in 2005 (NSABP 
B-31, NCCTG N9831, HERA) which showed a survival benefit for Herceptin 
to be given as adjuvant treatment during the early course of breast cancer 
(Piccart-Gebhart et al., 2005; Romond et al., 2005), there has been a 
worldwide increased use of Herceptin as adjuvant treatment in early breast 
cancer. The cost of adding this new drug to the management of breast cancer 
can be significant. It has been estimated that the cost of Herceptin is around 
£25 000 per patient per year (Dent and Clemons, 2005) and that treating early 
breast cancer for 75 patients would cost a hospital trust £1.9 millions on drug 
cost alone and £ 2.3 million when including other costs like pathology testing 
and cardiac monitoring for the drugs (Barrett A, 2006). Needless to say that the 
demand for this drug will have a lot of financial as well as ethical issues in the 
UK, with possible diversion of resources from other diseases. This is reflected 
by the constant debate among health care workers (Barrett A, 2006; Editorial, 
2005) as well as in the public domain (in several BBC news’ headlines) about 
the use of this drug since the publication of the three trials. Aside from the 
costs of the drugs and unpredictable response, up to 5-10% patients may have 
worsening cardiac function if given this drug with chemotherapy (Piccart- 
Gebhart et al., 2005). To correctly select cancer patients for these drugs in
order to exclude patients who will not benefit is a challenge for clinicians and 
scientists.
As discussed in the Introduction, over-expression and high levels of HER 
receptors do not necessarily reflect the functional state of their pathways, e.g. 
recent studies indicate that IHC reporting on EGFR expression levels is 
inconsistent in its predictions of disease recurrence and notably response to 
treatment (Arteaga, 2002; Dei Tos AP, 2005). EGFR inhibitors including 
Iressa are now given to patients without assessment of EGFR receptor 
concentration since EGFR has a poor predictive value (Chung et al., 2005). For 
breast cancer patients, despite the selection of patients by HER2 status (using 
either IHC or FISH), only about one third of these patients respond to 
Herceptin monotherapy (Vogel et al., 2002) and non-HER2 over-expressing 
breast tumours may also respond to Herceptin (Arteaga, 2006; Menendez et 
al., 2006). This emphasizes the need to understand at a higher level of detail 
the functional status of candidate markers employed in diagnostic, prognostic 
and therapeutic settings.
Monitoring response to treatment is of increasing importance with respect to 
trials of new molecular-directed therapeutics, as well as in seeking to optimise 
the use of those reaching the clinic. It is well accepted that the use of 
biomarkers in the development of new agents is important and it is implicit 
that these markers reflect the action of the target (whether direct or through a 
validated surrogate) and not simply its presence. The logic applied to the 
targeting and monitoring of inhibition for these targets is no less relevant to the 
question of prognostic indicators in relation to disease. The need to be able to 
determine the functional status of potential therapeutic targets or prognostic 
indicators is essential. Therefore, there is a need for a quantitative and 
objective method for assessing HER receptor phosphorylation to complement 
the current methods of HER receptor concentration testing by IHC.
7.2 Assessing HER receptor 
phosphorylation by FRET
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In this thesis, the assessment of EGFR phosphorylation by FRET was first 
established in cell lines. These established reagents were applied to head and 
neck tumour arrays using a high throughput automated FLIM. It was shown 
that increased FRET (indicative of EGFR phosphorylation) was correlated 
with disease recurrence and prognosis of the patients. Moreover, the results 
showed that EGFR concentration and phosphorylation determined by FRET in 
these patients were not correlated. This is not surprising given that a number of 
mechanisms other than over-expression of EGFR receptors may cause 
increased activation of EGFR, including over-expression of ligands for EGFR 
and other HER receptors, dimerisation with HER2 receptors to induce cellular 
signalling as well as constitutive activated mutant EGFR receptors (Arteaga, 
2002; Dei Tos AP, 2005). Other studies have shown that the response rate for 
EGFR inhibitors in head and neck cancer patients with over-expression of 
EGFR is only around 10% (Baselga et al., 2005; Cohen et al., 2003; Herbst et 
al., 2005) and patients without EGFR over-expression are also found to be 
responsive to Cetuximab in colon cancer (Chung et al., 2005). All these 
emphasise the importance of assessing EGFR phosphorylation rather than just 
concentration in these patients.
Currently the most accurate predictor of disease recurrence for HNSCC is the 
Tumour Node Metastasis (TNM) stage, particularly the lymph node status. 
There have been several studies seeking to find prognostic markers that can 
complement clinico-pathological information to predict survival and 
recurrence in HNSCC, e.g. EGFR over-expression level (Ang et al., 2002), 
TGF-a / EGFR mRNA (Dassonville et al., 1993) and p53 status (Boyle et al., 
1993; Brennan et al., 1995). At present, an elevated level of TGF-°c seems to 
be as important or even more important in classifying prognostic groups than 
EGFR expression level (Chung et al., 2004; Endo et al., 2000; Rubin Grandis 
et al., 1998; Todd et al., 1989; Wen et al., 1996). It is implicit that the ligand is 
engaging and activating its receptor and hence the assessment of activation 
status should be informative and indeed the data in this chapter supports this 
contention. The activation of the receptor measured by FRET gives prognostic 
information that is not available from analysing EGFR in the conventional way 
or even with phospho-antibodies as indicated by Chung et al 2004 (Chung et 
al., 2004).
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FRET to assess HER2 phosphorylation was also established in A431 cells 
and breast cell lines. The assay was applied to assess HER2 phosphorylation in 
MDAMB-453 xenograft tumours. The results showed that variation in HER2 
phosphorylation could be detected by FRET in xenograft tumours whereas 
these differences could not be quantified to the same extent by IHC that relies 
on subjective interpretation of the intensity staining. The FRET assay to assess 
HER2 phosphorylation was also applied to determine HER2 phosphorylation 
in a set of breast tumour arrays that was determined to be HER2 positive by 
IHC method. However, it was shown that FRET maybe used to stratify these 
HER2 positive breast cancer patients further into different prognostic groups, 
demonstrating the superiority of FRET over IHC.
7.3 Resistance to targeted 
therapies in breast cancer
Monotherapy with either EGFR and HER2 inhibitors (e.g. Iressa and 
Herceptin treatment), often results in a relatively poor response rate and the 
response is not usually sustained for the responders (Cohen et al., 2003; Vogel 
et al., 2002) due to primary and secondary resistance to these drugs. The FRET 
assay was used in breast cell lines, to measure the effect of these drugs on 
HER receptor phosphorylation. The method was established in cells prior to 
using it in clinical setting to stratify patients for targeted therapy. It was 
hypothesised that EGFR inhibition should abolish HER2 phosphorylation if 
HER2 is the preferred dimerisation partner for other HER receptors. This was 
however not the case. Using FRET to monitor HER2 phosphorylation, the 
responses of HER receptors in breast cancer cell lines were investigated when 
the cells were treated with targeted therapies. It was shown that the specific 
tyrosine kinase inhibitors of EGFR (HER1), AG1478 and Iressa decreased 
EGFR and HER3 phosphorylation through inhibition of EGFR/HER3 
dimerisation, but induced activation and cleavage of HER4. It is implied that 
the dimerisation between HER2 and HER4 leads to HER2 phosphorylation. 
These drug-induced processes were mediated by the release of ligands
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including heregulin and betacellulin that activate HER3 and HER4 via HER2. 
Whereas anti-betacellulin antibody in combination with Iressa increased the 
anti-proliferative effect, ligands like heregulin and betacellulin rendered 
sensitive SKBR3 resistant to Iressa. These results confirmed the role of ligands 
and activation of alternative HER receptors in mediating resistance to Iressa. It 
was also shown that Herceptin which targets the extra-cellular domain of 
HER2, induced the phosphorylation of HER2 receptors and cleavage of HER4 
in SKBR3 cells through their ligands despite the ability to downregulate EGFR 
and HER2 in the long term. Therefore the results in cell lines provided a 
molecular mechanism for the resistance to Iressa and Herceptin through 
ligands-induced activation of alternative HER pathways. Both of these results 
highlight the complexity of action of targeted therapies and may indicate 
alternative strategies to investigate intervention.
The release of ligands from their membrane-anchored precursors 
(ectodomain shedding) is mediated by different metalloproteinases (including 
the ADAM family). For example, precursors of TGF-a are released by TACE 
(ADAM 17) (Sunnarborg et al., 2002) and precursors of neuregulin (heregulin) 
P~1 and P-4 are mediated by ADAM 19 (Shirakabe et al., 2001). However, 
many questions remain unanswered, including biosynthesis and activation of 
these metalloproteinases like TACE in the secretory pathway, their trafficking 
in different compartments, the regulation/specificity of TACE and other 
metalloproteinases in the processing and shedding of HER ligands and the 
exact cleavage sites of the ligand precursors (Dempsey et al., 2002). The 
specificity of metalloproteinases is particularly important since for example 
TACE has many substrates including the precursors of amphiregulin, TGF-a 
and heparin-binding EGF (Hinkle et al., 2004) as well as the HER 4 receptor 
(Carpenter, 2003; Vecchi and Carpenter, 1997). The complexities associated 
with the regulation of ectodomain shedding of these ligands by the 
metalloproteinases make it difficult to ascertain a definite role for a particular 
metalloproteinase in the processing of a HER ligand. Therefore, understanding 
the cleavage and activation of ligands by the metalloproteinases is key to 
providing further therapeutic intervention. Furthermore, investigating how this 
ectodomain shedding of the ligands is influenced by targeted therapy is also 
crucial. For example to understand the mechanisms of how betacellulin and
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heregulin are released through the inhibition of EGFR may provide a strategy 
to overcome resistance to Iressa via activation of alternative HER receptors. 
The common understanding is that EGFR inhibitors like Iressa must switch off 
all tyrosine kinase activities of EGFR but it was suggested that Iressa may 
inactivate inhibitory kinase like GAK kinase and thus antagonise the inhibitory 
effect of the drug on EGFR signalling (Brehmer et al., 2005). The question of 
whether this inactivation of GAK kinase by Iressa is related to the regulation 
and production of ligands like betacellulin and heregulin remains to be 
answered. INCB3619, a potent inhibitor of ADAM 10 and ADAM 17, is 
effective in preventing the cleavage of heregulin and other ligands mediated by 
these two ADAM family members (Zhou et al., 2006) and it is currently being 
evaluated in the clinic (Fridman et al., 2007). However, INCB3619 being an 
inhibitor of ADAM 10 and ADAM 17, may not be effective in preventing the 
cleavage of ligands by other metalloproteinases, e.g. ADAM 19 which 
mediates heregulin p-1 and P-4 (Shirakabe et al., 2001).
7.4 Future prospects
It has been shown in this thesis that FRET may be used to assess 
phosphorylation of HER receptors quantitatively, in contrast to IHC which is 
semi-quantitative and may be subjective (Dei Tos AP, 2005). FRET uses a 
two-site assay, overcoming the problems of non-specificity of single antibody 
in IHC. The assay has been adapted to assess activation and phosphorylation of 
HER receptors in various cell lines as well as paraffin-embedded formalin- 
fixed tumour slides and arrays. The long-term aim is to exploit the strength of 
the FRET method to assess phosphorylation of HER receptors in relation to 
resistance and sensitivity to targeted therapies. This methodology 
(complementary to current methods, IHC and FISH) may be applied to select 
cancer patients who will respond to targeted therapies like Herceptin, and to 
determine potential resistance mechanisms and develop new treatment 
strategies or rational combinations of therapy. The method can also be used to 
assess HER dimerisation patterns if a suitable pair of antibodies were used, e.g.
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conjugation of Cy3b to anti-HER2 and Cy5 to anti-HER3 to assess 
dimerisation of HER2/HER3. The dimerisation patterns of HER receptors are 
increasingly known to be important for the prognosis of several cancers and 
may predict sensitivity and resistance to targeted therapies. For example it was 
shown that HER2/HER4 and HER2/HER3 dimerisation partners maybe 
important in mediating resistance to EGFR inhibitors. Therefore, FRET may 
be exploited to assess phosphorylation of HER receptors as well as their 
dimerisation patterns to determine mechanisms of sensitivity and resistance to 
targeted therapies in breast cancer.
Since the studies in HNSCC and breast arrays presented in this thesis are 
only retrospective exploratory assessments of patients’ survival, a prospective 
protocol driven assessment for validation and determination of performance 
characteristics needs to be performed using FRET as described by Hayes et al 
(Hayes et al., 1996; Hayes et al., 1998) in order to validate the FRET methods 
for wider clinical use. This strategy will allow the assays to be utilised for 
prospective stratification of patients in randomised trials of EGFR and HER2 
inhibition.
The results from breast tumour arrays showed that FRET may be used to 
stratify patients further among HER2 positive patients, justifying the decision 
to apply this methodology to assess phosphorylation of HER2 and other HER 
receptors in a prospective breast cancer trial including adjuvant Herceptin 
(HERA) trial (Piccart-Gebhart et al., 2005; Smith et al., 2007). HERA trial is 
an international, multicenter, randomised trial compared one or two years of 
Herceptin given in HER2-positive breast cancer patients who had completed 
surgery, radiotherapy and chemotherapy (Piccart-Gebhart et al., 2005; Smith et 
al., 2007). It has been proposed that future work may involve assessing FRET 
as a prognostic tool and a predictive tool for DFS and OS in Herceptin and non 
Herceptin-treated patients of the (HERA) trial. In addition, the trial may also 
be used to validate the methodology as well as to select a cut-off point for 
FRET efficiency. The cut-off point may then be used to separate patients into 
good and bad prognostic groups and early relapse or late/non-relapse patients 
in the HERA trial. The cut-off point may be applied for other future trials once 
it is validated in this trial. This present investigation has shown that 
phosphorylation of alternative HER receptors may mediate resistance to
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targeted therapies in breast cancer cells. Therefore, the hypothesis may be 
tested further in human breast cancer samples from HERA trial by 
investigating whether time to relapse on Herceptin in these patients is related 
to activation of alternative HER receptors and their dimerisation patterns. The 
relapse rate and the onset of relapse may also be correlated with gene 
expression arrays between the control arm and the treated arm in the HERA 
trial to assess the factors that determine who will benefit from Herceptin in 
breast cancer. The overall aim for the proposed works in the HERA trial is to 
assess whether FRET may be used as a diagnostic parameter to assess 
functional status of HER2. The accuracy of this putative diagnostic parameter 
may be exploited to identify breast cancer patients at presentation that may 
benefit from Herceptin and other targeted therapies and exclude non­
responders from the potential side effects of the drugs. Similar strategies may 
also be applied to other prospective trials using the same methodology to 
assess the phosphorylation of HER2 and other HER receptors in breast cancer 
and other types of cancers in relation to targeted therapies.
Future research can also be done to further analyse the mechanisms of 
resistance to targeted therapies like Iressa, Herceptin and Lapatinib in hormone 
sensitive and resistant breast cell lines and in xenograft models. EGFR 
activation has been shown to play a role in hormone resistant breast cancer 
patients (Gee et al., 2003; Knowlden et al., 2003; Polychronis et al., 2005). 
Furthermore, HER receptors have been shown to interact with hormone 
receptors and contribute to resistance to hormone therapies in hormone- 
resistant breast cancer lines (Dowsett et al., 2005; Johnston et al., 2003; Martin 
et al., 2005; Martin et al., 2003). Future work may involve assessing EGFR 
and HER2 activation (as well as the dimerisation patterns of HER receptors) 
by FRET in hormone resistant MCF-7 cell lines with or without Iressa and 
Lapatinib treatment (acute versus long-term) in vitro and investigate their 
interaction with hormone receptors.
It has been shown that reactivation of HER3 occurs in prolonged Iressa 
treatment (Sergina et al., 2007) and heregulin mediated HER3 activation may 
play a role in mediating resistance to Iressa (Zhou et al., 2006). In this thesis it 
was demonstrated that acute treatment with Iressa and Herceptin (acute and up 
to 10 days of treatment) may induce activation of alternative HER receptors
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(including HER3 phosphorylation) in breast cell lines. The goal for future 
investigation may be to assess phosphorylation and dimerisation patterns of 
HER receptors by FRET in relation to targeted therapies, e.g. acute and long­
term treatment with Herceptin, Iressa and Lapatinib in breast cell lines and in 
xenograft models. Particularly HER3 phosphorylation and its dimerisation 
pattern with HER2 should be assessed. These results will be correlated with 
downstream signalling pathways like PKB and ERK1/2 phosphorylation using 
FRET to understand further the mechanisms of resistance to these drugs. These 
experiments can also be performed on human samples by for example 
conducting neoadjuvant Herceptin and Lapatinib trials, in order to understand 
the mechanisms of resistance to these drugs in human patients.
7.5 Concluding remarks
In this investigation, a novel method using FRET to assess HER receptor 
phosphorylation was established in both TMAs and cells. It was shown that the 
two-site assay FRET to assess HER phosphorylation is specific and may be 
applied to paraffin-embedded formalin-fixed head and neck as well as breast 
tissue arrays. Moreover, FRET may be used to stratify HER2 positive breast 
cancer patients into different prognostic groups. Using this method to assess 
HER receptors, it was demonstrated that Iressa and Herceptin treatment in 
breast cancer cells induced activation of alternative HER pathways, providing 
an insight into the mechanisms of resistance to these targeted therapies in 
breast cancer, and hence offering treatment opportunities to overcome 
resistance in patients. It is proposed to utilise this assay for prospective 
stratification of patients in randomised trials of EGFR and HER2 inhibition. 
Since it is applicable to paraffin sections, retrospective analysis of trials of 
EGFR and HER2 inhibitors will also be possible to define those who gain 
most, besides the patients with EGFR and HER2 mutations. In the longer term, 
the identification of these patients at presentation should provide guidance on 
more aggressive treatment or more specifically on appropriate targeted 
therapies. The methodology shows great promise and can also be applied to
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assess the activation of other signalling pathways (e.g. PKB and MAPK) in 
relation to various cancer treatments.
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